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Hematopoiesis; the formation of blood
In our body, billions of red blood cells, white blood cells and platelets are produced daily. 
This process is essential, since most blood cells are short-lived. In addition, increased 
cell production may be temporarily needed, for example in case of infection or excessive 
bleeding. By the enduring activity of hematopoietic stem cells (HSCs), mature blood cells are 
continuously replenished and HSCs can respond upon demand to produce more cells. In this 
way, the total number of cells in the peripheral circulation remains more or less constant 
(homeostasis).
HSCs reside in the bone marrow, which is the spongy, red substance located in the innermost 
part of bones such as the pelvis, vertebrae, ribs, sternum, skull, and limbs. HSCs require spatial 
and temporal input from this microenvironment or ‘niche’, for maturation or self-renewal. 
Specific cell types in the niche, such as vascular endothelial cells, osteoblasts, adipocytes, 
mesenchymal stem cells and neurons provide (gradients of) soluble molecules as well as 
(gradients of) physical factors such as shear stress, oxygen tension and temperature 1. These 
external signals, together with intrinsic mechanisms, induce intracellular signaling cascades 
that determine the behavior of HSCs.
HSCs are typically depicted at the top of a hierarchical ‘lineage tree’, each branch point of 
which indicates a restriction in proliferation and developmental potential. The self-renewal 
ability of HSCs maintains the stem cell pool while their multipotency allows for formation 
of all mature blood cell types through multiple differentiation steps. Although long-term 
(LT) HSCs, short-term (ST) HSCs and multipotent progenitors (MPPs) are all multipotent, 
they differ substantially in their self-renewal capacity. While LT-HSCs possess very extensive 
self-renewal, they progressively lose their self-renewal potential upon entrance into the 
differentiation pathway to form ST-HSCs and MPPs. Multipotency is then lost upon either 
lymphoid or myeloid lineage commitment (Figure 1). Common myeloid progenitors (CMPs) 
can further differentiate into either granulocyte-macrophage progenitors (GMPs) which 
will produce mature leukocytes (white blood cells) such as granulocytes (eosinophils, 
neurophils, basophils) and macrophages, or megakaryocyte-erythroid progenitors (MEPs) 
which will produce erythrocytes (red blood cells) and thrombocytes (platelets) 2. Common 
lymphoid progenitors (CLP) will differentiate into mature B- and T-lymphocytes and NK-cells 
(leukocytes) 3.
Hematopoietic stem cells; their hallmark properties
The nuclear bombing of Hiroshima and Nagasaki in 1945 led to the observation that a 
prolonged period of radiation compromised the hematopoietic system. People in the affected
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area suffered from low blood cell counts and platelets, resulting in bleeding disorders 
and increased sensitivity towards infections 4-6. In addition, increased leukemia incidence 
occurred in persons that were exposed and whose blood counts recovered after the bomb 
fell. These observations led to multiple studies on radiation syndromes. In 1948, Bloom and 
Jacobsen showed that rodents died from hematopoietic failure two weeks after low dose 
whole body x-irradiation 7-8. Soon thereafter, it was shown that injections of bone marrow 
Figure 1: hematopoietic differentiation tree. Abbreviations used: long-term hematopoietic stem cell 
(LT-HSC), short-term hematopoietic stem cell (ST-HSC), common myeloid progenitor (CMP), common 
lymphoid progenitor (CLP), megakaryocyte-erythroid progenitor (MEP), granulocyte-macrophage 
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suspensions from healthy donor mice could rescue irradiated mice from hematopoietic 
failure 9. In 1956, E. D. Thomas performed the first bone marrow transplant in human, 
treating patients with advanced leukemia 10. Although unsuccesfull for a large percentage 
of attempts, in 1975, due to acquired knowledge of the immunesystem and by matching 
donors and recipients based on HLA types, this was shown to be an effective treatment. 
He received the Nobel Prize for Medicine in 1990 11. Nowadays, more than 50.000 bone 
marrow transplants are performed annually. However, at the time E.D. Thomas performed 
transplantations, it was not known which factors were responsible for the reconstitution of 
the entire blood system. It took another ten years before it was acknowledged that specific 
primitive hematopoietic cells were responsible for regeneration of the blood system, and 
not certain soluble blood factors such as hormones 12-16. Pioneering experiments were 
performed by Till and McCulloch. They showed that ten days after transplantation of a 
limited number of bone marrow cells, colonies were formed on the spleen of recipient 
mice 12-13 . These colonies correlated directly in number with the number of bone marrow cells 
originally injected, and were of clonal origin, as assessed by induced chromosomal breaks. 
They proposed the ‘stem cell’ concept which still holds true; only a very small subpopulation 
of bone marrow cells possess two remarkable properties 1) they can self-renew and 2) they 
can from multiple types of mature blood cells, e.g. they are multipotent.
Although Till and McCulloch proposed the existence of adult stem cells in the bone marrow in 
1961, those stem cells were only identified in the late 1980’s after techniques such as multi-
color fluorescence activated cell sorting (FACS) were developed 17. HSCs were phenotypically 
identified after the use of monoclonal antibodies was implemented; murine HSCs lack cell 
surface markers that are generally expressed on mature blood cells (“lineage negative”), 
but are positive for “stem cell antigen-1 (Sca1)” and “c-Kit” 18. These “LSK cells” comprise 
approximately 0.05% of the adult mouse bone marrow cells. Nowadays, several additional 
marker combinations (such as CD34-, Flt3-, CD150+ and EPCR+ 19-22) have been developed 
to more precisely identify the most primitive HSCs within the LSK population. These cells 
are termed “long-term HSCs” since they possess long-term hematopoietic reconstitution 
capacity, and are as infrequent as 1:15.000 bone marrow cells.
HSC assays, combined with the ability to purify HSCs, have provided increasingly detailed 
insight into the unique properties of these cells. The only assay that truly defines the quality 
of HSCs is a reconstitution assay in which the long-term (>16 weeks) presence of donor-
derived cells in a reconstituted host is assessed. It measures both the long-term self-renewal 
and multilineage differentiation capacity of HSCs. Serial transplantation experiments, in 
which the bone marrow from a previously transplanted and reconstituted mouse is the 
new HSC source for a newly irradiated mouse, showed that HSCs can outlive their original 
donor 23-24. This clearly reflects their excessive self-renewal potential. However, it is still 
unclear which key signals are required for self-renewal. This is also the reason why it has 
proven difficult to maintain HSCs in culture, or to expand them. Attempts have been made 
with known stem-cell stimulators such as Stem-Cell Factor (cKit ligand), Interleukins -1, 
-3, -6 and -11 and Flt3-ligand, or with small molecules such as valproic acid 25-26. However, 
although some HSC potential can be maintained, their absolute frequency and self-
renewal potential is quickly lost upon transfer in culture, since they tend to differentiate 
spontaneously. Several in vitro assays have been developed to measure the frequency and 
quality of progenitors and HSCs, such as the colony-forming-unit cell (CFU-C) assay and 
the cobblestone-area forming cell (CAFC) assay 27. The CFU-C makes use of the capacity of 
progenitors to rapidly proliferate and generate many differentiated cells when stimulated 
with growth factors. When cultured in semi-solid media these cells will produce a number of 
countable colonies, which reflects the frequency of progenitors in the initial culture. In the 
CAFC assay, hematopoietic cells are grown on a stromal feeder layer without the addition 
of growth factors. HSCs maintain a specific and easily recognizable way of growing under 
the stromal cells for at least five weeks, while progenitors can only form these so-called 
‘cobblestones’ for shorter periods 27. Although these in vitro assays have been shown to 
correlate with in vivo activity 28, transplantation assays are still the ultimate model to test for 
HSC self-renewal and multipotency.
Leukemia and Leukemic Stem Cells; when HSCs turn bad
By precisely balancing self-renewal and differentiation, HSCs continuously provide 
differentiated progenitors and mature blood cells while simultaneously maintaining a proper 
HSC pool size throughout life. This balance is crucial, since impaired self-renewal can result 
in tissue dysfunction while excessive self-renewal can result in blood cancer (leukemia). In 
addition, the formation of different blood lineages must be tightly controlled. Too many or 
too few cells of any particular type can result in disease 29-31. Erythrocytes are responsible 
for oxygen transport to all tissues. A deficit of erythrocyte production (anemia) can cause 
symptoms such as fatigue, dizziness, and organ failure. Excess erythrocytes (polycythemia) 
increases viscosity of the blood, which can result in microvascular complications as a 
consequence of blood clot formation (thrombosis). Microvascular complications, such as 
infarcts and embolisms, can also occur as a consequence of excessive platelet production 
(thrombocytemia or thrombocytosis). However, since the primary function of platelets is 
to initiate blood clot formation for wound healing, too few platelets (thrombocytopenia) 
can result in bleeding disorders. Leukocytes have their primary function in the innate and 
adaptive immune system, and low white blood cell numbers (leukopenia) can therefore 
result in deficiencies in combatting infections. Excessive production of (immature) white 
blood cells is a sign of chronic or acute leukemia,which is typically characterized by a rapid 
growth and accumulation of immature hematopoietic cells in the bone marrow. A wide 




or the clinical course of the disease. The most common major types are Acute Myeloid 
Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Lymphomas (e.g. Hodgkin and non-
Hodgkin), and Chronic Myeloid Leukemia (CML). Recently, idiopathic thrombocytemia and 
polycythemia are also considered as subtypes of chronic myeloid blood cancers.
Leukemias are clonal proliferative diseases that arise from HSCs or progenitors, which failed 
to obey normal regulatory signals that should restrict their self-renewal. It has been found 
that only a subfraction of cells within the leukemic cell population, termed leukemic stem 
cells (LSCs), possesses the ability to initiate and sustain leukemia. In patients, these LSCs 
often express the same immunophenotypical markers (CD34+,CD38-) as normal human HSCs 
32-34. Although it is still under debate whether LSCs truly originate from normal HSCs, it is 
clear that the leukemic cell population is heterogeneous and comprised of cells that differ 
in their differentiation and self-renewal capacities 35. This suggests that the leukemic cell 
population is composed of a hierarchy that resembles that of the normal HSC compartment. 
Nowadays, therapies focus on eliminating those critical LSCs that propagate the leukemia 
instead of the bulk tumor cell population. Therefore, it is highly important to identify the 
cancer-specific pathways that initiate malignant transformation and that operate in LSCs.
The observation of the age distribution of cancer has been fundamental to the origin of 
the multi-stage theory of cancer 36. This theory implies that most cancers arise from the 
accumulation of multiple mutations, while the probability of acquiring a sufficient number 
of detrimental mutations increases with time 37. Tumors were long thought to evolve in 
a linear fashion, by the sequential acquisition of mutations in tumor suppressor genes or 
oncogenes 36, 38-39. Although it is apparent that mutations in genes that provide a selective 
growth advantage to cells is a hallmark of tumor development, recent studies suggest that 
not all cells in a cancer are linearly related. After a first initial mutation, cells can branch off 
due to different secondary mutations, and cells within these two groups can again acquire 
mutations that makes them distinct from the cells where they originate from. This process 
can result in a heterogeneous cancer, consisting of cells belonging to different ‘clones’ with 
different properties 40-41. Cancer, including leukemias and lymphomas, has long been viewed 
as a purely genetic disease. Many patients with leukemia carry an abnormal karyotype as 
a consequence of chromosomal translocations. These translocations cause in-frame fusion 
of two otherwise separated genes (e.g. t(15;17) PML-RARa, t(8;21) AML1-ETO, t(9;22) 
BCR-ABL). The resulting fusion protein often disturbs proper regulation of proliferation, 
differentiation, growth factor signaling, senescence or apoptosis. However, about a 
decade ago it became apparent that cancer is also associated with profound epigenetic 
changes 42-44. Tumor cells are associated with genome-wide DNA hypomethylation, gene 
specific hypermethylation, as well as aberrant histone modifications 45-47. Whereas DNA 
hypomethylation results in chromosomal instability, both promoter hypermethylation and 
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specific histone modifications represents a mechanism to cause aberrant activity of genes 
involved in cell-cycle regulation.
While in normal hematopoiesis the balance between self-renewal and differentiation is 
tightly controlled, this balance is clearly lost in leukemic cells. Specific pathways that regulate 
normal HSC function often are the same pathways that are deregulated in leukemias. 
Therefore, to fully understand which sequence of events in HSCs can cause leukemic 
transformation, it is highly important to determine the fundamental mechanisms of HSCs. 
Regulation of the chromatin structure of HSCs, establishes, maintains, and/or propagates 
their gene expression programs and thus drives their behavior. Proper regulation of these 
epigenetic processes is therefore essential for balancing HSC self-renewal and differentiation 
and can prevent from leukemic transformation.
Epigenetic regulation of HSCs: keeping DNA in shape
Although adult stem cells and their differentiated progeny contain identical genetic 
information, their gene expression patterns, and consequently their functional behavior, 
differ substantially. This is accomplished by differential accessibility of the DNA for the 
transcriptional machinery, caused by epigenetic modifications. DNA is not found as a 
naked molecule in the nucleus but is wrapped around nucleosomes composed of histone 
octamers, which are the building blocks of chromatin. The manner in which DNA is packed 
around these nucleosomes can be altered, by placing chemical modifications or ‘epigenetic 
marks’ on histone tails or on the DNA itself. These marks can be heritable during mitotic 
divisions but are reversible as well, by the activity of specific enzymes that can remove these 
modifications from the DNA or histones.
DNA methylation
The process of DNA methylation involves the addition of methyl groups to cytosine residues 
in CpG dinucleotides. Most DNA methylation occurs in these so-called CpG islands, which 
are regions in the genome where the frequency of C- and G-nucleotides that occur next to 
each other in sequence is high. In mammalian genomes, CpG island can be 300-3000 base 
pairs in length and most occur in close proximity to promoters of genes 48. Methylation 
of cytosines is executed by the action of the DNA-methyl-transferase (DNMT) family 49. 
DNMT3a and DNMT3b are de novo methyltransferases that actively start DNA methylation 
of unmethylated cytosines on genomic loci that need to be silenced for example during 
differentiation. DNMT1 is thought to be the maintenance methyltransferase, responsible 
for copying DNA methylation to daughter strands during DNA replication. Until recently, 
DNA methylation was long thought as being relatively stable and irreversible and DNA 
demethylation was considered to only passively occur during cell division. However, it is 




5-hydroxymethylcytosines (5hmC) 50-52. 5hmC can act as a substrate for further modications 
(formylcytosine, carbonylcytosine, uracil) after which it will be ultimately replaced with an 
unmethylated cytosine without the need for DNA replication.
Besides important during the process of cellular differentiation, DNA methylation is also 
associated with a number of key processes including genomic imprinting, X-chromosome 
inactivation, and suppression of repetitive elements. Alterations of DNA methylation have 
been recognized as an important component of cancer development. Cancer cells are 
associated with genome-wide DNA hypomethylation, while certain genes show specific 
hypermethylation. In addition, recent genomic studies have identified recurrent somatic 
mutations in TET and DNMT family members in patients with hematopoietic malignancies 53.
Histone modifications
Histone tails that protrude from the histone octamer are subject to several types of 
modifications, including methylation, acetylation, phosphorylation, ubiquitination and 
sumoylation. Histone modifications serve to either loosen or compact the chromatin, 
and thereby influence the accessibility of the DNA. Histone modifications can also serve 
to recruit other proteins such as transcription factors, DNA repair and replication factors, 
and additional chromatin remodelers, which contribute to repression or promotion of 
transcription 54. Locus-specific combinatorial patterns of these modifications define the 
chromatin state which is also referred to as ‘’the histone code” 55-56. Some general histone 
code ‘rules’ are often observed and applied. For example, histone lysine acetylation (for 
example on H3K9) is generally associated with open chromatin and active transcription of 
genes. The overall level of histone acetylation is dictated by opposing activities of histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) enzymes, which add or remove 
acetyl groups on lysine residues, respectively. Methylation of histone tails can occur 
at both lysine and arginine residues and is also mediated by two antagonizing groups of 
enzymes; histone methyl transferases (HMTs), which can actively methylate residues, and 
histone demethylases (HDMs), which can erase these marks. The addition of up to three 
methyl groups at individual lysines produces a total of four methyl states: unmethylated, 
mono, di-, and tri-methylated. According to the specific amino acid residue where these 
methylation marks occur, they are either associated with active expression of genes (for 
example H3K4me3, executed by Thrithorax MLL protein) or with gene silencing (for example 
H3K27me3, executed by Polycomb Ezh2 protein).
In stem cells, lineage-specific genes must remain silenced, yet ready to be activated upon 
differentiation. To accomplish this, both in embryonic and hematopoietic stem cells, active 
H3K4me3 and repressive H3K27me3 histone modifications have been shown to coexist 
on these developmental crucial genes 57-59. Genomic loci where these specific repressive 
17
Introduction and Thesis Outline
1
and active marks co-occur are termed ‘bivalent domains’. Upon differentiation, promoters 
with bivalent domains are resolved into a monovalent state, either active or repressive. 
Although certain rules appear to determine whether specific (combinations of) histone 
modification will result in activation or repression, and thereby specify a certain biological 
outcome (‘acetylation results in gene activation’), prediction of epigenetic regulation is 
actually not straightforward. Histone combinations have the potential to be very complex; 
each of the four histones that compose the nucleosome can be simultaneously modified at 
multiple different sites, with multiple different modifications. In addition, whereas histone 
acetylation and methylation are widely studied, the effect of other histone modifications 
such as phosphorylation, sumoylation and ubiquitination are relatively unknown.
Mis-“writing” and mis-“reading” of histone modifications is strongly associated with cancer 
initiation and progression. MLL rearrangement and deregulation of EZH2 are among the 
most common mutations in leukemia and other cancers 56, 60-61.
Polycomb group proteins
It is well recognized that epigenetic regulators play a prominent role in maintaining daughter 
cells of stem cells in an undifferentiated state by faithfully reproducing the epigenome 
upon self-renewal divisions. However, upon differentiation signals, the chromatin status 
must be changed in such a way that loci that encode differentiation genes can be exposed 
to (transcription-) factors that can promote their expression. Epigenetic regulation can 
therefore be considered a gatekeeper of cellular memory, since it is crucial for establishing, 
maintaining and propagating transcriptional profiles of the cell.
A specific, well-studied, class of epigenetic modifiers are Polycomb group proteins (PcGs). 
They induce transcriptional repression of target genes through catalyzation of specific histone 
modifications 33-34. PcGs reside in two multimeric protein complexes: Polycomb Repressive 
Complex 1 and 2 (PRC1 and PRC2). PRC2 consists of three core subunits; Ezh, Suz12 and 
Eed. The SET-domain containing Ezh proteins catalyze trimethylation of histone 3 lysine 
27(H3K27me3), and to a minor extent lysine 9 of histone 3 (H3K9me3). This modification 
is found to be the initiating step of gene repression. The PRC1 member Cbx can ‘read’ this 
epigenetic mark and recruit PRC1 to the particular locus where this mark is established 62-63. 
PRC1 consists of four core components Cbx, Ring1, Phc, and Pcgf. Ring1 possesses histone 
2A ubiquitination activity 64. This histone modification is thought to be the final step in stable 
gene repression since it blocks the movement of RNA polymerase along the DNA 65-66. 
Several Polycomb group proteins have shown to be key players in determining cellular 
fate decisions in HSCs. In HSCs, they repress the transcription of lineage-specific genes. In 




and be recruited to stem cell specific self-renewal genes to promote differentiation and 
suppress unlimited proliferation. However, during differentiation into either the myeloid or 
lymphoid lineage, PcGs not only repress the transcription of self-renewal genes but also of 
differentiation genes of the alternative lineage. 
Polycomb group genes are often deregulated in various types of cancer, including those of 
the hematopoietic system. Aberrant expression of PcG genes has frequently been detected 
and mutations in PRC2-encoding genes have recently been suggested as a causative factor 
in several types of leukemia 60, 67.
OUTLINE OF THIS THESIS
Whereas in Drosophila each Polycomb component is encoded by a single gene, the number 
of genes encoding for PcG proteins has expanded in mammals which resulted in a large 
combinatorial diversity in PRC1 and PRC2 complex compositions. In this thesis we aim to 
elucidate the relevance of this diversification and to assess whether Polycomb complexes 
with different compositions have different biological functions in murine HSCs.
Chapter 1 provides an introduction into the PcG gene family. We describe how Polycomb 
members have expanded during evolution and comprehensively review recent literature 
on their importance for normal HSC regulation. After focusing on the fact that PcG are 
often aberrantly expressed or mutated in hematopoietic malignancies, we will argue that 
safeguarding the composition of PRC complexes is invaluable for keeping balanced HSCs 
self-renewal and differentiation divisions.
In Chapter 2 we describe the role of PcG proteins in HSC aging. Aging of an organism results 
from tissue dysfunction and degeneration as a consequence of cellular aging. Adult stem 
cells, such as HSCs, are critically important to replenish the age-associated loss of cells. We 
review the literature and hypothesize that stem cells, which have a very extensive lifespan, 
are particularly vulnerable for malignant transformation. We speculate that PcG proteins 
regulate the balance between aging (by limiting stem cell self-renewal) and the risk of 
developing cancer (excessive self-renewal).
In Chapter 3 we studied the biological function of different Cbx-containing PRC1 complexes 
in HSCs. Analysis of PRC1 complex composition previously showed that each complex 
contains a single representative of the Cbx family; either Cbx2, Cbx4, Cbx7 or Cbx8. The 
N-terminal chromodomain of Cbx orthologs can bind H3K9me3 and H3K27me3 14,15, albeit 
with unequal affinities. Therefore, the Cbx proteins are key components for targeting PRC1 
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to specific genomic loci to regulate gene expression. We show that Cbx7-containing PRC1 
complexes induce self-renewal of HSCs by repressing the expression of progenitor-specific 
genes. Other Cbx proteins can compete with Cbx7, resulting in Cbx2-, Cbx4-, or Cbx8-
containing PRC1 complexes that induce entrance into the differentiation pathway.
In Chapter 4 we used a novel barcoding approach that allows tracking the progeny of each 
individually transduced cell in combination with our Cbx7-overexpressing mouse model to 
identify LSC-derived clones and their behavior. We show that within one leukemia different 
LSC clones with different self-renewal and differentiation properties can co-exist. Thus, 
leukemias can be heterogeneous, containing quiescent cells with very delayed latencies, 
which can be activated upon proliferative stress.
In Chapter 5 we summarize the findings of this thesis and discuss future perspectives for 
example how our findings can contribute to the development of novel leukemia therapies.
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ABSTRACT
The equilibrium between self-renewal and differentiation of hematopoietic stem cells 
is regulated by epigenetic mechanisms. In particular, Polycomb-group (PcG) proteins 
have been shown to be involved in this process by repressing genes involved in cell-cycle 
regulation and differentiation. PcGs are histone modifiers that reside in two multi-protein 
complexes: Polycomb Repressive Complex 1 and 2 (PRC1 and PRC2). The existence of 
multiple orthologs for each Polycomb gene allows the formation of a multitude of distinct 
PRC1 and PRC2 sub-complexes. Changes in the expression of individual PcG genes are likely 
to cause perturbations in the composition of the PRC, which affect PRC enzymatic activity 
and target selectivity. An interesting recent development is that aberrant expression of, and 
mutations in, PcG genes have been shown to occur in hematopoietic neoplasms, where they 
display both tumor-suppressor and oncogenic activities. We therefore comprehensively 
reviewed the latest research on the role of PcG genes in normal and malignant blood cell 
development. We conclude that future research to elucidate the compositional changes of 
the PRCs and methods to intervene in PRC assembly will be of great therapeutic relevance 
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INTRODUCTION
The genome of every organism contains a developmental program that results in expression 
of various collections of genes in various cell types. In most adult tissues and organs, stem cells 
have been identified that maintain tissue homeostasis, and the quest to identify novel adult 
stem cell types is ongoing. Adult stem cells have the capacity to self-renew and the ability 
to differentiate into the mature cell types of the tissue in which they reside. Although adult 
stem cells and their differentiated progeny contain identical genetic information, their gene 
expression patterns differ substantially. This is predominantly accomplished by differential 
accessibility of the DNA for the transcriptional machinery. Along with this, alterations in 
the epigenetic landscape of the genome affect the transcriptome, the functioning and the 
behavior of each cell. However, we are only beginning to understand how collections of 
genes are turned ‘on’ or ‘off’ simultaneously, thereby controlling stem cell self-renewal and 
differentiation.
The hematopoietic system is a particularly well-studied example of a homeostatic tissue. 
It generates massive numbers of new blood cells during our entire lifespan by means of 
hematopoietic stem cells (HSCs), which normally reside in the bone marrow. Recent studies 
of HSCs have advanced our understanding of the epigenetic mechanisms that maintain the 
balance between self-renewal and differentiation.
One of the main classes of such epigenetic regulators is provided by the Polycomb-group 
(PcG) proteins. These proteins are histone modifiers, and their activity results in repression 
of genes involved in cell-cycle regulation and differentiation. Aberrant PcG expression 
and mutations in PcG genes have been shown to occur frequently in various types of 
hematopoietic neoplasms. Emerging evidence indicates that leukemic stem cells (LSCs) 
evolve from hematopoietic stem cells or progenitor cells, which have acquired abnormal 
expression of genes involved in cell survival and proliferation. This suggests a vital role for 
PcG-induced epigenetic modifications in malignant transformation.
In our review, we first describe the PcG gene family and how its members have expanded 
during evolution. We then focus on their molecular function and their importance for 
normal HSC regulation. Finally, we describe how aberrant Polycomb functions can result in 
neoplastic transformation of hematopoietic cells.
POLYCOMB-GROUP GENES (PCG GENES)
PcG genes were first discovered in Drosophila melanogaster as key regulators of homeotic 
(Hox) gene expression 1. The PcG proteins reside in two main complexes: Polycomb Repressive 
Complex 1 and 2 (PRC1 and PRC2). In addition, a Pleiohomeotic Repressive Complex (PhoRC) 
has been identified to be involved in recruitment of PRCs to chromatin 2-4.
PRC2 consists of three core subunits corresponding to Drosophila PcG genes: Enhancer of 
zeste (E(z)), Suppressor of zeste 12 (Suz12) and Extra sex combs (Esc). In mammals, the PRC2 
complex consists of one of the two Ezh orthologs (Ezh1 or Ezh2), Suz12 and one isoform 
of Eed (Eed1-4) 5-8. The classical model by which PRC2 induces transcriptional repression 
involves the activities of Suz12 and Eed, which together contribute to binding the complex 
to nucleosomes 9 and to the histone methyltransferase (HMTase) activity of SET domain-
containing Ezh proteins 5-9. The capacity of Ezh to transfer methyl groups to lysine 9 and 27 
of histone 3 (H3K9me3, H3K27me3) is stimulated by Eed 10-12. Furthermore, PRC2 can recruit 
co-factors such as Aebp2, Mtf2, Pcl3, Jarid2 and Phf1, which can modulate its enzymatic 
activity and recruitment to target genes 13-19. The well-documented trimethyl modification 
of H3K27 (H3K27me3) serves as a docking site for PRC1 assembly and subsequent induction 
of higher chromatin organization (Figure 1) 5.
PRC1 consists of four core subunits, which are homologous to Drosophila Polycomb (Pc), 
Polyhomeotic (Ph), Posterior sex combs (Psc), and Sex combs extra (Ring/Sce). Each of these 
four core components has several orthologs in the mammalian genome 2, 20, which compete 
for incorporation into PRC121. These orthologs are sorted into families of Cbx, Phc, Pcgf 
and Ring1 genes. The H3K27me3 repressive mark, established by PRC2, induces binding of 
PRC1 through the chromodomain-containing Cbx subunit 22,23. Binding of PRC1 to chromatin 
allows mono-ubiquitination of histone 2A on lysine 119 (H2AK119ub1), which is stimulated 
by Pcgf and executed by Ring1 proteins 24. H2A ubiquitination is believed to be the final step 
in stable gene silencing, as it blocks Pol II transcriptional elongation 3, 25-27.
Polycomb complex evolution
The emergence of multiple Polycomb-encoding genes during evolution coincided with 
the requirement for compaction of genetic information as genomes and multicellular 
organisms became more complex 28-29. PcG genes expanded by multiple gene duplications 
and subsequent diversification of the ancestral gene 28-29. In addition, an accumulation of 
single-nucleotide polymorphisms and the advent of new regulatory elements resulted in 
small changes in the DNA sequence and the emergence of alternative splice variants 28-29. For 
example, in mammals four alternative splice-variants exist for the PcG gene Eed 8, and recently 
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expansion and divergence of different PcG genes ultimately resulted in large Polycomb gene 
families in mammals, such as the Pcgf and Cbx gene families. This resulted in multiple PRC 
sub-complexes, which can consist of various PcG orthologs.
PRC2 first emerged during early eukaryotic specification. It is possible that this occurred 
in the last common unicellular ancestor of eukaryotes, since several important protein 
domains of PRC2 members are conserved between plants and animals. RNAi-mediated 
silencing of the E(z) homolog in unicellular algae Chlamydomonas reinhardtii suggested that 
one of the primary roles of PRC2 in early eukaryotes was to maintain genome stability by 
suppressing transposable elements 31. This suppression might have protected cells against 
adverse horizontal gene transfer. In multicellular organisms, their function might have been 
A
B
Figure 1. The canonical Polycomb-mediated gene silencing model. A PRC2 initiates gene repression 
by methylation of H3 on lysine 9 and 27 (H3K9/H3K27) catalyzed by the histone methyltransferase 
activity of the SET domain-containing E(z) subunit using the S-adenosyl methionine (SAM) co-factor as 
a donor for methyl groups. B The H3K9/27me3 histone marks are specifically recognized and bound 
by chromodomain-containing Pc subunits of PRC1 complexes. Binding of PRC1 to chromatin can drive 
further gene repression by mono-ubiquitination of H2A on lysine 119 (H2AK119ub1) by the Sce/Ring 
subunit.
adapted to regulate cell identity. The largest expansion of the PRC2 gene family occurred 
during plant evolution. Plants have up to 8 PcG members, which can form an array of PRC2 
sub-complexes 32-33. In contrast to plants, PRC2 members underwent little duplication in 
animals, with only four genes encoding for the core subunits (Eed, Ezh1, Ezh2, and Suz12) 31,34.
PRC1 homologs have not been identified in plants. However PRC1-like complexes (LHP1-
AtRING1/LHP1-AtRING2) were shown to be involved in gene repression by binding to 
H3K27me3. This suggests that PRC1 function might have been conserved as a result of 
convergent evolution 32-33. In contrast to PRC2 genes, expansion of PRC1 genes did occur in 
the animal kingdom, mainly at the invertebrate-vertebrate transition 28,35. Although teleost 
radiation is accompanied by divergence of PRC1 members, further evolutionary events 
resulted in both expansion and loss of individual members. A combination of specific PcG 
genes might have increased the fitness of its carriers under certain environmental conditions 
and contributed to the evolution of tetrapods. (see Figure 2, Whitcomb et al. 28; and Table 
1, Le Faou et al. 35) 29.
PcG diversification and functional complexity of PRC1 and PRC2
Functional complexity of PRC1
Due to this evolutionary diversification of PcG genes and proteins, a wide array of 
combinatorially distinct PRC complexes can occur in any cell. For example, five Cbx family 
members exist in mammals. Cbx2, Cbx4, Cbx7 and Cbx8, but not Cbx6, are known to function 
within the PRC1 complex 21. Although the N-terminal chromodomain and C-terminal 
polycomb repressor box of Cbx proteins are highly conserved (typically >75% amino acid 
similarity), their affinity towards histone repressive marks (H3K27me3/H3K9me3) and PRC1 
interacting partners varies substantially 21,23. This distinct affinity might be attributed to 
high divergence in additional domains and motifs that have been acquired during evolution 
28,29. PRC1 can induce opposing activities, depending on which Cbx protein is present in the 
complex. For example, Cbx7 sustains pluripotency of embryonic stem cells (ESC), whereas 
other Cbx orthologs induce ESC differentiation and are directly repressed by Cbx7 36-37.
 
A recent study identified six distinct PRC1 sub-complexes, each containing different Pcgf 
family members, and showed that these Pcgf sub-complexes bind differentially throughout 
the genome with little overlap in target genes 38. This clearly suggests that different PRC1 
sub-complexes have different molecular functions. Indeed, two Pcgf family members, Bmi1 
and Mel-18, have been shown to have non-redundant functions at the molecular level, even 
though they share 70% of their protein sequence. Although integration of Bmi1 in PRC1 
complexes enhances Ring1b E3 ligase activity, Mel-18 integration does not 24, indicating 









Figure 2. Schematic overview of PRC1 (A) and PRC2 (B) complex compositions and aberrations of 
various PRC members found in human hematological neoplasms. Diseases in the gray fields are 
caused by mutations, whereas diseases in the yellow fields are caused by overexpression of the 
corresponding Polycomb gene. Green fields represent single nucleotide polymorphisms (SNPs) in 
the corresponding Polycomb gene that correlated with a higher incidence of that particular disease. 
Black fields with the question mark indicate that no alteration in that particular PcG gene sequence or 
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opposite effect of Bmi1 and Mel-18 on the cell cycle has also been demonstrated. Using a 
retroviral insertional mutagenesis approach in predisposed Eμ-Myc transgenic mice, Bmi1 
was characterized as a proto-oncogene that collaborates with c-Myc 39. It induces S-phase 
entry by inhibiting the function of retinoblastoma protein (Rb) through repression of the 
Ink4a/Arf locus 40. In contrast, its ortholog Mel-18 arrests the cell cycle before entry to 
the S-phase by repressing c-Myc, resulting in downregulation of several cyclin-dependent 
kinases 41,42. Moreover, Mel-18 could function as a cell-cycle inhibitor by downregulating 
Bmi1 expression 42,43. Accumulating evidence thus indicates that the activity of PRC1 is highly 
dependent on its exact molecular composition 4,37,38,44-46.
Functional complexity of PRC2
Ample evidence also indicates that PRC2 has different functions depending on whether Ezh1 
or Ezh2 is present in the complex. The catalytic SET domain of both Ezh proteins is highly 
conserved 28, and both possess catalytic activity to mono-, di- and tri- methylate H3K27. 
Ezh1 and Ezh2 compete for binding to Suz12 and Eed 11,47 and are part of distinct PRC2 
complexes. These Ezh2- and Ezh1-containing PRC2 complexes appear to have complementary 
transcriptional repressive functions in ESCs 11,47. Depletion of Ezh2 or Ezh1 shows differential 
effects on the level of methylated H3K27 in ESCs. H3K27 methylation was severely impaired 
upon Ezh2 depletion, whereas knockdown of Ezh1 did not result in global change of 
H3K27 methylation levels 11. However, depletion of Ezh1 in Ezh2-/- ESCs abrogated residual 
methylation on H3K27, resulting in derepression of H3K27me3 target genes 47. Thus, both 
Ezh1- and Ezh2-containing PRC2 complexes are necessary for proper H3K27me3-mediated 
silencing of target genes in ESCs. Functional complementation of Ezh1 and Ezh2 has also 
been observed in skin stem cells and in adult, but not in fetal liver, hematopoietic stem cells. 
In skin, ablation of both Ezh1 and Ezh2 resulted in reduction of H3K27me3 levels, arrested 
skin development and degeneration of hair follicles, while ablation of a single Ezh ortholog 
had no effect 48. In fetal liver HSCs, conditional deletion of Ezh2 strongly compromised their 
function. However, in adult HSCs, Ezh1 is highly expressed and can compensate for the loss 
of Ezh2 and restore H3K27me3 levels 49.
Very recently, a novel role of Ezh1 became apparent in the regulation of transcriptional 
activation. In primitive skeletal muscle cells, Ezh1 can promote RNA polymerase elongation 
at gene bodies. In these cells, Ezh1-containing PRC2 complexes preferably associate with 
the active histone mark H3K4me3, while Ezh2-containing PRC2 complexes show canonical 
H3K27me3 association. Consequently, the overlap between target genes for Ezh2 and Ezh1 
is very limited, and Ezh1- and Ezh2-containing PRC2 complexes show highly opposing roles 
in myoblast regulation 45.
A non-canonical model of PRC1 function
The canonical Polycomb-mediated model of gene silencing implies the hierarchical 
recruitment of PRC2 and PRC1 complexes at target sites. PRC2 initiates gene repression by 
methylation of H3K9 or H3K27, after which PRC1 is recruited by binding of the Cbx protein 
to this histone modification. PRC1 then drives further gene repression by ubiquitination of 
H2AK119. However, this model has recently been challenged on two grounds. First, PRC1 
and PRC2 gene targets are not completely overlapping 50,51. Non-overlapping genes targeted 
by PRC2 therefore lack ubiquitination of H2AK119. Second, disruption of PRC2 (partial or 
otherwise) does not prevent binding of PRC1 and ubiquitination of H2A on target genes, 
although the methylated histone mark is lacking 44,46,52.
A non-canonical PRC1 complex apparently exists, which could explain, at least partially, 
the functional independence of PRC1 from PRC2 and the H3K27me3 mark. Whereas the 
canonical PRC1 complex contains a Cbx protein, the non-canonical PRC1 complex contains 
either Rybp or Yaf2 38,46. Cbx proteins (Cbx2, Cbx4, Cbx7 or Cbx8) are mutually exclusive for 
PRC1, 21 and they specifically assemble in PRC1 complexes containing either Bmi1 or Mel-
18, but not in PRC1 complexes containing other Pcgf orthologs 38. These canonical PRC1 
complexes bind H3K9me3 and/or H3K27me3 repressive marks set by PRC2 complexes. 
Strikingly, both canonical and non-canonical complexes have similar H2A ubiquitinating 
activity 46.
Polycomb PhoRC complex and recruitment of Polycomb complexes to chromatin
The diversity of PRC sub-complexes most likely results in targeting different collections 
of genes. In Drosophila, the PRC complex is recruited to DNA elements called Polycomb 
Response Elements (PREs) through interaction with the DNA-binding protein Pho 34,53. 
Pho forms a stable two-subunit complex with the protein Sfmbt1 (Scm-like with four MbT 
domain-containing protein 1), which is referred to as the Pho-RC 3,14,54.
In Drosophila PhoRC plays an essential role in PRC recruitment, but no central recruitment 
mechanism or specific DNA elements have been identified in mammals. A first attempt 
by Ku et al. 51 using ChIP sequencing of PRC1 and PRC2 binding sites in ES cells did not 
result in the detection of specific sequence motifs, although PRC2-targeted sequences 
were found to be highly enriched in CpG islands. More recently, two studies reported the 
identification of mammalian PRE-like elements based on PcG recruitment. These PRE-like 
elements were found only at very specific sites (between the human Hoxd11 and Hoxd12 
genes and upstream of the mouse MafB gene), and not throughout the genome 55. These 
regions apparently do not qualify as consensus mammalian PRE elements. Both studies also 
suggested an important role for the mammalian transcription factor Yy1, the mammalian 
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hypothesis 53,56. However, since Yy1 and Polycomb target genes do not show a high degree 
of overlap 56, and Yy1 also has many PcG-independent functions in the cell 57, Yy1-mediated 
PRC recruitment is most probably not general, and additional mechanisms in mammalian 
cells are likely to exist. Solid evidence of the interaction of Polycomb complexes with other 
transcription factors has been lacking, but recent studies have shown that the transcription 
factors Gata1 58, Hic1 59, Rest 60, and the Runx1/CBFβ transcription factor complex 61 can also 
recruit Polycomb complexes to specific target genes. Besides transcription factors, long non-
coding RNAs have also been recognized as important Polycomb recruiters 3,34
More work is needed to address several remaining issues of PRC recruitment. For example, 
distinct Polycomb sub-complexes might utilize different recruiting mechanisms, thus binding 
different collections of genes; the non-canonical PRC1 complex, but not the canonical Cbx-
containing PRC1 complex, may utilize Yy1-mediated recruitment since it contains the Rybp 
protein that has been shown to physically interact with Yy1 62.
POLYCOMB PROTEINS AND HSC REGULATION
Although we found no studies on the effects of distinct PRC compositions in the 
hematopoietic system, hematopoietic phenotypes based on the ablation or overexpression 
of single PcG genes have been reported frequently (Table 1). Modulating PcG expression, 
thereby changing its protein abundance, is likely to alter the composition of PRCs, since 
PcG orthologs compete for incorporation. Therefore, these studies provide insight into the 
function of distinct PRC complexes in HSCs.
PRC1 members and HSCs
Bmi1 and Mel-18
Although highly similar in protein structure, the Pcgf family members Bmi1 and Mel-18 
have very different effects on the maintenance of self-renewal of HSCs 63. Despite normal 
embryonic hematopoiesis, Bmi1-null mutant mice displayed postnatal pancytopenia and 
died within 2 months after birth 63-65. Park et al. 64 showed that the number of HSCs in Bmi1-/- 
fetal liver was not affected, whereas the number of HSCs in adult bone marrow was severely 
reduced. However, transplantation of Bmi1-/- fetal liver cells resulted in only transient 
hematopoietic reconstitution. This is compatible with the notion that Bmi1-/- HSCs cannot 
maintain long-term hematopoiesis, which causes hematopoietic failure soon after birth 63-64. 
Indeed, it is now well established that Bmi1 is required for HSC self-renewal, both in mice 
and humans (Table 1) 66.
Although Bmi1-/- fetal liver cells are functionally defective 64, Mel-18-/- fetal liver cells show 
almost normal repopulating capacity of the hematopoietic compartment 63, but a defect in 
B-cells might indicate its potential role in more differentiated cells (Table 1) 41,67. Another 
study even reported a slight increase in HSC self-renewal capacity of adult Mel-18-deficient 
BM cells 68. It seems likely that upon depletion of Mel-18 in HSCs, PRC1 complexes exclusively 
incorporate Bmi1, which then establishes the self-renewal phenotype. The specific 
function of Bmi1 in stem cells and of Mel-18 in more differentiated cells coincides with 
their endogenous expression patterns. Whereas Bmi1 is found to be specifically expressed 
in immature hematopoietic cells, its ortholog Mel-18 becomes upregulated along with 
differentiation 69.
Bmi1 is one of the best studied PcG members and many attempts have been made to clarify 
how Bmi1 sustains HSC self-renewal. In Bmi1-/- mice, the Ink4a-Arf locus was shown to be 
partially responsible for the hematopoietic defects; a double deletion of Bmi1 and Ink4a-
Arf largely rescued the phenotype 40. This locus encodes two proteins, p16Ink4a and p19Arf. 
p16 functions as a cyclin-dependent-kinase-inhibitor and hampers cell cycle progression by 
activating the Rb pathway, while p19 is important for p21/p53-mediated cell cycle arrest and 
apoptosis 70. Ineffective self-renewal in Bmi1-deficient HSCs has been widely attributed to 
the derepression of the Ink4a-Arf locus and subsequent induction of premature senescence 
63-64, 66.
More recently, it was shown that Bmi1 not only protects HSCs against premature cellular 
senescence, but also safeguards their multipotency. In HSCs, Bmi1 represses lineage 
specification through reinforcement of bivalent domains (overlapping repressive H3K27me3 
and activating H3K4me3 histone marks) at the lymphoid regulator genes Ebf1 and Pax5. 
Bmi1-deficient HSCs showed loss of H3K27me3 and H2Aub1 repressive marks, resulting in a 
monovalent active state (H3K4me3) of these key lymphoid loci. Therefore, downregulation 
of Bmi1 might have promoted early expression of lymphoid genes and accelerated lymphoid 
specification 71.
Another mechanism by which Bmi1 can manifest its self-renewal function is its protective 
effect against oxidative stress and DNA damage. In the absence of Bmi1, reactive oxygen 
species levels were found to be elevated, resulting in increased apoptosis and reduced 
HSC numbers and activity 72-73. Bmi1 also affects DNA repair, which is crucial to maintain 
genetically stable HSCs. Not only Bmi1, but also other PcG members, were found to be 
recruited to sites with double stranded breaks (DSB) and contributed to the initial steps 
of DSB repair 74. Whereas overexpression of Bmi1 protects against the effect of radiation 
75, Bmi1 knockdown increases radiosensitivity and resulted in a severe accumulation of 





Polycomb-group proteins in hematopoietic stem cell regulation and hematopoietic neoplasms
2
reviewed by Gieni RS et al. 76
Future research should clarify how all these Bmi1-mediated effects on senescence, apoptosis, 
lineage specification, reactive oxygen species levels and DNA damage are integrated and 
collectively regulate HSCs functioning.
Other PRC1 members in HSCs
Besides Bmi1, other PRC1 components have also been studied for their role in HSCs, although 
less intensively (Table 1). Most understanding of the role of various orthologs from the Cbx 
family originates from knockout mice. Studies of Cbx2 and Cbx8-deficient mice showed that 
neither gene is required for normal hematopoietic stem and progenitor function, although 
in vitro data suggested a role for Cbx2 in lymphopoiesis (Table 1) 63,77-79. Also, in mice deficient 
for Cbx7, no effect on hematopoiesis was reported 80. In contrast, overexpression of Cbx7 
in the lymphoid compartment showed enhanced lymphomagenesis, which appeared to be 
dependent on c-Myc 81. To our knowledge, Cbx4-deficient mice have not yet been generated. 
Although Cbx-deficient animals do not show overt hematopoietic abnormalities, caution is 
warranted with respect to the interpretation of these studies. It is likely that the absence 
of a single Cbx protein can be compensated by incorporation of another Cbx ortholog into 
PRC1 complexes during development. Functional redundancy between Cbx orthologs may 
therefore obscure the interpretation of PcG function in these studies.
Rae28-deficient mice exhibited perinatal lethality 82, and heterozygous Rae28+/- mice 
showed a severe delay in B-cell development 83. In addition, fetal liver Rae28-/- HSCs were 
unable to functionally reconstitute the hematopoietic compartment of lethally irradiated 
mice 84-85. Together this indicates that Rae28-/- HSCs are unable to sustain hematopoiesis 
during embryonic development. However, the function of Rae28 in adult HSCs has not been 
investigated. Ring1b exhibited a dual function in hematopoietic cells depending on their 
stage of differentiation. It restricted progenitor cell proliferation and stimulated maturation 
of their progeny via regulation of p16Ink4a and cyclin D2 expression 86.
Since Yy1 is the only—non-canonical—PcG member with DNA binding capacity, it can target 
PRC1 and PRC2 complexes directly to chromatin. Majewski et al. 87 included this protein in 
a sensitized in vivo screen in which they systematically tested whether individual PcG genes 
are required for HSCs and progenitor activity. They showed that defects in canonical PcG 
genes (Bmi1, Mel-18, Ring1a, Ring1b, Phc1/Rae28, Phc2, or Cbx2), and a defect in the non-
canonical Yy1 were both associated with HSC/progenitor cell defects. Therefore, it appears 
that all core PRC1 components and Yy1 enhance HSC activity. The positive effect of Yy1 on 
HSCs was confirmed in a recent study, which showed that overexpression of Yy1 resulted in 
accumulation of HSCs 88.
PRC2 members in HSCs
Orthologous components of PRC2 have different expression patterns and functions in HSCs. 
While Ezh2 was found to be ubiquitously expressed in human and mouse bone marrow and 
fetal liver cells 49,69, its ortholog Ezh1 showed specific expression in adult mouse HSCs (Lin- 
Sca+ cKit+) and was decreased upon differentiation 49.
Although only few studies have explored the role of Ezh1, Ezh2 has been widely studied 
in HSCs using both gain- and loss-of-function approaches. Using a “genetical genomics” 
approach 89 followed by functional studies, Ezh2 was identified as an important HSC regulator 
90. Repeated serial transplantations greatly impair the potential of HSCs to reconstitute the 
hematopoietic system of recipient mice, but overexpression of Ezh2 completely prevents 
the exhaustion of HSCs during serial transplantations (Table 1). An inducible Ezh2 knock-
in mouse was recently generated, which confirmed that elevated Ezh2 expression indeed 
increases the self-renewal capacity of HSCs 91.
However, loss-of-function studies did not support a positive role for Ezh2 in HSCs, but instead 
suggested an effect in early lymphoid development. Ezh2-deficient mice had no obvious HSC 
phenotype 92, although B and T cell development and VDJ rearrangement was affected 93. Ezh2-/- 
LSK fetal liver cells transplanted into irradiated recipient mice showed high engraftment ability, 
and a severe impairment of lymphoid lineage differentiation, but the myeloid lineage was not 
affected 49. In experiments that tested the effect of Ezh2 in a sensitized Mpl-/- background, not 
only Ezh2, but also Eed and Suz12 were found to restrict HSC activity. Although other studies 
also documented inhibitory effects of Eed and Suz12 on HSCs and progenitors 94,95, this is 
difficult to reconcile with the studies of Kamminga et al. and Herrera-Merchan et al. 90,91 We 
hypothesized that Ezh2 gene dosage and/or the balance between PRC2 complexes, including 
either Ezh2 or its homolog Ezh1, are important for proper HSC functioning. In addition, upon 
Ezh2 depletion, Ezh1 might complement Ezh2 in PRC2 integration and contribute to the 
functional activity of adult HSCs. Indeed, a recent study by Iwama et al. showed that Ezh1 can 
compensate Ezh2 loss in adult HSCs, but not in fetal liver HSCs 49.
Abundant evidence now shows that PcG genes must be correctly expressed in HSCs. We 
hypothesized that this correct expression ensures the multipotency of HSCs. A seemingly 
moderate imbalance, for example caused by gain or loss of function of individual PcG 
components, results in pronounced HSC phenotypes.
The diversity of PRC sub-complexes may regulate the dynamic equilibrium between HSC 
self-renewal and differentiation, but it is unclear how PRC complexes composed of different 
subunits actually affect HSCs. Ideally, proteomic analysis of PRC complex compositions 
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POLYCOMB PROTEINS IN HEMATOPOIETIC NEOPLASMS
Paradigmatically, leukemia is considered to be the consequence of a multistep process 
ultimately leading to unrestrained cell proliferation. Aberrant activity of genes involved 
in cell-cycle regulation is one of the prerequisites for malignant transformation of cells; 
many malignant cells have lost their cell cycle checkpoint control mechanisms. Both proto-
oncogenes and tumor-suppressor genes (for example Ink4a-Arf) are often deregulated in 
cancer cells, and both classes of genes have been found to be under the control of PcG 
proteins 63, 96-97. Interestingly, the aberrant expression of PcG genes has frequently been 
detected in various types of cancer, including hematological neoplasms (Figure 2) 98-99. In 
addition, mutations in PRC2-encoding genes have recently been suggested as a causative 
factor in several types of leukemia. So far, PRC1 mutations have not been described in 
patients with leukemia. Strikingly, some PcG components, such as Bmi1 and Ezh2, have 
been reported to have both oncogenic and tumor-suppressor activity. Below we describe 
the functional involvement of PcG proteins in various types of hematological neoplasms.
PRC1 members in hematopoietic neoplasms
Bmi1
Bmi1 has been linked to leukemogenesis ever since it was identified as a cooperating partner 
of c-Myc in the induction of B-cell lymphomas 100.
Overexpression of Bmi1 is commonly found in patients with myelodysplastic syndromes 
(MDS) 101-102, acute myeloid leukemia (AML) 103, chronic myeloid leukemia (CML) 104-105, and 
various types of lymphoma 106-107. In addition, the expression of Bmi1 has been shown to 
correlate with disease progression (Table 2) 106-107. No evidence has been reported indicating 
that overexpression of Bmi1 is sufficient to induce leukemia. However, studies in various 
leukemic mouse models suggested that Bmi1 might be an important collaborating factor 
in leukemic transformation. For example, Sall4, an oncogene implicated in AML 108, was 
found to bind directly to the Bmi1 promoter and induce its expression 109. Moreover, mice 
that constitutively overexpress Sall4 developed leukemia and displayed upregulated Bmi1 
expression, particularly after disease progression to AML 109. In a HoxA9-Meis1 leukemia 
mouse model, Bmi1 was shown to be essential for maintenance of leukemic stem cells 
(LSCs). Hoxa9 and Meis1 are oncogenes that were shown to induce transformation of 
murine BM cells 110. Bmi1-/- fetal liver cells transduced with Hoxa9-Meis1 were able to induce 
AML when transplanted into irradiated recipient mice, but failed to sustain leukemia in 
secondary recipients 111. In a MLL-AF9 mouse model, Bmi1 was shown to play an essential 
role in malignant transformation of myeloid progenitors into LSCs 112. The fusion gene MLL-
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and development of AML upon transplantation into irradiated recipient mice 113. However, 
granulocyte macrophage progenitors derived from Bmi1-deficient mice and transduced 
with MLL-AF9 displayed reduced proliferative and clonogenic capacity in vitro and absence 
of leukemia development in vivo.
Several studies have shown that Bmi1 can play a role in the progression of CML towards 
acute blast crisis. The BCR-ABL oncoprotein is necessary and sufficient to initiate CML 114, but 
overexpression of Bmi1 was required to provoke the progression to a more advanced stage 
of the disease 104. CD34+ cells from CML patients transduced with Bmi1 showed enhanced 
proliferative capacity and self-renewal properties in vitro, and resulted in a transplantable 
leukemia in vivo 115. Synergistic effects of Bmi1 and BCR-ABL have also been shown to trigger 
acute B-cell lymphoid leukemia (B-ALL) development in mouse models 116.
The above results indicate that Bmi1 cooperates with oncogenic fusion proteins in leukemic 
transformation. In human leukemias, Bmi1 protects LSCs from senescence and apoptosis by 
inhibiting p16 and p19 expression 96,111, but enhanced expression of Bmi1 may also result 
in protection of LSCs from oxidative stress66. Pharmacological downregulation of Bmi1 
was therefore predicted to reduce the proliferative capacity of AML cells. This hypothesis 
was supported in an experimental study where downregulation of Bmi1 in AML CD34+ cells 
reduced their proliferative capacity and stem/progenitor cell frequency by inducing ROS 
accumulation and apoptosis 66.
In contrast to the role of Bmi1 in promoting self-renewal of normal BM cells and its oncogenic 
role in several types of leukemia, a recent study by Oguro et al. 97 demonstrated a potential 
tumor-suppressor function of Bmi1 (Table 2). Irradiated recipient mice, repopulated by 
Bmi1-/- Ink4a-Arf-/- BM cells, developed lethal myelofibrosis (MF). These mice showed an 
expansion of LSK and myeloid progenitor cells, along with abnormal megakaryocytopoiesis 
in the bone marrow.
Other PRC1 members
Although a role for Bmi1 in leukemogenesis appears to be well established, less is known 
about other Pcgf family members. Several studies, based on immunohistochemical analyses 
of leukemic tissues, proposed that aberrant expression of PcG genes results in abnormal 
formation of PRC1 complexes and suggested that this might have contributed to the 
development of hematological neoplasms 117-118. In a study where the expression of multiple 
Polycomb family members was assessed in 126 AML patients by real-time qPCR, Bmi1 was 
found to be overexpressed, whereas Mel-18 was one of the few tested PcG genes that 
showed no overexpression 119.
Little is known about the contribution of Cbx family members to the development 
of hematopoietic malignancies. Cbx8 was shown to be essential in MLL-AF9 induced 
leukemogenesis, even though this function was found to be PRC1-independent (Table 2) 
120. Cbx8 was also shown to be required for leukemic transformation of other MLL fusion 
proteins121. One study showed that Cbx7 is often overexpressed in human follicular 
lymphomas (FLs) 81 and that Cbx7 overexpression in the mouse lymphoid compartment 
results in T-cell and B-cell lymphomas upon transplantation (Table 2) 81. Cbx2 and Cbx4 have 
not been associated with leukemia development.
The PRC1 member Ring1a is commonly overexpressed in MDS and AML and correlates with 
poor prognosis 102. In addition, single nucleotide polymorphisms (SNPs) in Ring1a were 
found to be associated with non-Hodgkin lymphoma 122. Enhanced expression of its ortholog 
Ring1b has been detected in lymphomas such as diffuse large B-cell lymphoma (DLBCL), 
Burkitt’s lymphoma and Hodgkin’s lymphomas (Table 2) 123.
The Rae28 locus was found to be disrupted in patients with hematological malignancies 
83,124–126. Furthermore, it was demonstrated that inactivation of Rae28 is implicated in severe 
B-cell maturation arrest (Table 2) 83.
PRC2 members in hematopoietic neoplasms
Similar to PRC1 components, aberrant expression of PRC2 genes, most notably Ezh2, has 
been associated with the development of hematopoietic neoplasms (Table 2). In 2000, it 
was first reported that increased Ezh2 expression might promote lymphoma development. 
106,107,117 More recently, recurrent heterozygous Tyr641 mutations that occur in the catalytic 
SET domain of Ezh2 were discovered in two types of lymphomas that arise from germinal 
center B-cells. These mutations were found in approximately 20% of the patients with a 
germinal center B (GCB) subtype of DLBCL and in 7% of follicular lymphoma FLpatients 
127,128. While the recurrent heterozygous Tyr641 mutation of the Ezh2 allele resulted in a 
reduced ability to trimethylate H3K27 127, co-occurrence with the wild type Ezh2 allele 
induced increased H3K27me3 levels. Heterozygous Tyr641 mutations therefore effectively 
represent a gain-of-function mutation 129. This supports the hypotheses that Ezh2, which 
is often overexpressed in lymphomas, can contribute to the disease 107. Very recently, 
pharmacological inhibition of the methyltransferase activity of Ezh2 by GSK126 was shown 
to effectively inhibit the proliferation of Ezh2 Tyr641 cell lines and DLBCL xenografts in 
mice 130. This drug might therefore be a promising treatment for patients with activating 
mutations in Ezh2. However, caution is warranted when administering such inhibitory drugs 
to patients, since inactivating mutations and deletions of Ezh2 and other PRC2 components 
have also been discovered recently. In a study of 68 adult T-ALL cases, loss-of-function 
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the incidence of inactivating PRC2 mutations was found to be even higher in a pediatric 
subtype of T-ALL; 40% of ETP ALL patients showed a deletion or sequence mutation in Eed, 
Ezh2 or Suz12 132. Various inactivating homozygous and heterozygous Ezh2 mutations were 
also discovered in patients with myelodysplastic and myeloproliferative neoplasms 133,134. 
Ezh2 mutations, which are associated with poor prognosis, were shown to coexist with 
the well-known Jak2V617F mutation in primary myelofibrosis 135. Mutations in other PRC2 
components (Eed and Suz12) have also been detected in MDS/MPN patients, albeit with 
lower frequencies (Table 2) 136.
The above findings indicate that loss or gain of Ezh2 activity (either by altered expression 
or by mutations) can both contribute to leukemogenesis in patients. These “two faces of 
Ezh2 in cancer” have been well described in a recent review by Hock et al. 137 The function 
of Ezh2 as both a tumor-suppressor and an oncogene has also been described in various 
mouse models 138,139. We suggest that a single PcG can display either tumor-suppressor or 
oncogenic functions depending on the cell context and its interaction partners. Prescreening 
to determine whether mutations cause either a loss or gain of function is therefore crucial 
before starting PRC2-targeted therapy in patients.
CONCLUDING REMARKS
It has now become evident that PcG proteins play an important role in both normal 
hematopoiesis and in various hematological malignancies. Depending on the stage of 
hematopoietic cell differentiation when neoplastic transformation first occurs and which 
PcG gene is involved, different types of leukemia may arise. In addition, depending on the cell 
context and interacting partners, individual PcG genes may display either tumor-suppressor 
or oncogenic functions. Compositional rearrangements of PRCs may provide true oncogenic 
events, instead of aberrant PcG functions caused by mutations or misexpression. However, 
the fact that leukemic cells are genetically unstable, and are susceptible to additional 
genetic abnormalities, make it difficult to determine whether PcG aberrations are a cause or 
a consequence of malignant transformation.
It should be noted that besides PcG proteins, other epigenetic mechanisms, such as DNA 
methylation and ncRNA interference, are also employed in regulation of gene expression 
140. Understanding the interplay between these distinct epigenetic mechanisms in the 
maintenance of a cell-type specific epigenome will be important for leukemia research.
The assessment of the epigenetic signatures of normal and leukemic stem cells is of great 
importance for future cancer research since compositional changes of PRC complexes may 
present useful prognostic markers. Pharmacological targeting of PRC compositions may 
therefore be an effective anti-leukemia strategy.
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ABSTRACT
Protection of the transcriptional “stemness” network is important to maintain a healthy HSCs 
compartment during the lifetime of the organism. Recent evidence shows that fundamental 
changes in the epigenetic status of HSCs might be one of the driving forces behind many 
age-related HSC changes and might pave the way for HSC malignant transformation and 
subsequent leukemia development, the incidence of which increases exponentially with 
age. Polycomb group (PcG) proteins are key epigenetic regulators of HSC cellular fate 
decisions and are often found to be misregulated in human hematopoietic malignancies. In 
this review, we speculate that PcG proteins balance HSC aging against the risk of developing 
cancer, since a disturbance in PcG genes and proteins affects several important cellular 
processes such as cell fate decisions, senescence, apoptosis, and DNA damage repair.
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INTRODUCTION
The appearance of an aged individual is often typical; skin wrinkles, hair loss, and fragility often 
accompany loss of visual and auditory abilities and cognitive decline. These consequences 
of aging are associated with an increased risk for developing age-related diseases, such as 
cancer, neurodegenerative diseases and diabetes. Although the phenotypic characteristics 
of aging are evident, their molecular causes are not well understood. In general, aging of 
an organism must result, to a great extent, from tissue dysfunction and degeneration as a 
consequence of cellular aging. Mature cells of most tissue types are short-lived and need 
to be continuously replenished throughout life. This process is preserved by the enduring 
activity of tissue-specific adult stem cells. Hematopoietic stem cells (HSCs), which reside 
within the bone marrow, are the best studied category of adult stem cells 1-3. These cells 
are able to undergo both symmetric and asymmetric divisions, leading to their self-renewal 
or differentiation. A precise coordination of these cell fate decisions is essential to sustain 
proper blood cell production throughout the entire lifespan of the organism.
In HSCs, multiple age-dependent changes have been identified. Successively serially 
transplanted HSCs from several strains of mice remained able to repopulate the 
hematopoietic system of recipient mice 4-6. However, these cells were less functional than 
their young counterparts and eventually exhausted 6-10. Likewise, studies in which HSCs 
isolated from old mice were directly compared to HSCs obtained from young mice clearly 
showed that HSC function declines with age. Old HSCs possessed impaired homing potential 
and self-renewal activity and, in addition, showed a propensity toward a myeloid-lineage-
skewing of differentiation potential 11-12.
Dysfunction at the level of the stem cell compartment might underlie the decline of 
several age-related parameters in hematopoietic tissue function. For example, numerous 
impairments in the functioning of an aged immune system are found 13-14. These might 
either be attributable to an impaired activity and specificity of mature T cells, B cells, 
macrophages and NK cells, or more directly related to bone marrow failure. The changes in 
the functional properties of HSCs might also have more severe pathological consequences. 
For example, it has been shown that with advanced age the incidence of hematological 
malignancies increases substantially. Myelodysplastic syndromes (MDS) are the most 
prevalent hematologic disorders in the elderly population. These syndromes are defined as 
clonal stem cell disorders characterized by ineffective differentiation. In patients this results 
into peripheral blood cytopenias in combination with a hypercellularity of the bone marrow. 
Ultimately, MDS often progresses into acute myelogenous leukemia (AML).
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Although many theories have been put forward to explain the phenomenon of aging, 
studies in the mouse hematopoietic system have made it increasingly evident that there 
is a clear stem cell basis for age-associated changes. However, the molecular mechanisms 
driving functional changes in HSCs during aging remain elusive. First of all it is still a matter 
of debate whether aging is a programmed or stochastic process that occurs in all individual 
HSCs equally 11, or whether the clonal composition of the HSC compartment changes 12, 
15-18. Theoretically, the latter might ultimately result in a monoclonal dysfunctional HSC 
population. Second, oxidative and metabolic stress, telomere attrition and defects in DNA 
repair mechanisms all contribute to severe DNA damage which may result in an instable 
genome and the formation of toxic mutant proteins. Yet, neither of these processes in 
isolation can account for all age-related changes observed in HSCs. Thus, aging appears to 
be a multifactorial process.
There is emerging consensus that safeguarding the transcriptional “stemness” network is 
important to maintain a healthy HSC compartment. Gene profiling studies, for example, 
demonstrate that gene expression programs of aged hematopoietic stem cells are different 
from those in their young counterparts 12, 19-22. Whether these changes are caused by genetic 
or epigenetic dysregulation of gene expression programs is still unclear. An accumulation of 
mutations in the DNA sequence and a dysfunctional DNA repair machinery may result in the 
observed changes in gene expression. However, changes in the chromatin status of the cell 
are also expected to have a strong causative effect in altering gene expression.
Factors that control chromatin organization, the manner in which the DNA is packed around 
histones, are important for safeguarding the genomic integrity as well as transcriptional 
activity of the cell. Several chromatin modifiers have shown to be essential in the regulation 
of HSC cell fate decisions 23-24. Dysregulation of these epigenetic factors that control the 
balance between self-renewal and differentiation might account for many age-related 
impairments in HSC function. In this review we will discuss recent evidence that supports 
the concept that fundamental changes in the epigenetic status of HSCs might be one of the 
driving forces behind many age-related HSC changes.
AGE-ASSOCIATED EPIGENOMIC CHANGES IN HSCs
Epigenetic regulation of chromatin structure can be considered a gatekeeper of cellular 
memory, since it is crucial for establishing, maintaining and propagating transcriptional 
profiles of the cell 25-26. Epigenetic modulation involves DNA methylation of cytosine residues 
in CpG islands 27 and modifications of histone tails, mostly by acetylation, methylation and 





epigenetic status as the parental pluripotent cell to maintain the unique HSC cell fate. Thus, 
for a proper self-renewing cell division, besides the DNA sequence the chromatin structure 
also needs to be copied. In contrast, during asymmetrical divisions, chromatin modifications 
need not to be faithfully copied, leading to differential gene expression profiles and a distinct 
identity of both daughter cells.
Throughout life, cellular memory needs to be maintained, and proteins that control 
chromatin organization are therefore likely to be important for the maintenance of cell-
type specific gene expression patterns during HSC aging as well 30-31. This interpretation is 
supported by a study of Chambers and coworkers 19 in which gene expression profiles of HSC 
isolated from young (2 months), intermediate (6 and 12 months) and old mice (21 months) 
were compared. Genes involved in transcriptional silencing via chromatin regulation were 
specifically downregulated with age. These included histone modifying genes from the SWI/
SNF-complex (Smarca4 and Smarcb1), the polycomb (Ring1) and Trithorax complexes (Mll3, 
Mllt10), histone deacetylases (Sirt2, Sirt3, Sirt7, Hdac1, Hdac5, Hdac6) and histone acetyl 
transferases (Myst2). Genes involved in DNA methylation were also found to be repressed 
during aging. These included DNA methyltransferase (Dnmt3b) and the methyl-CpG-binding 
protein encoding genes (Mbd1). In a related gene expression study by Rossi and colleagues, 
the PcG gene Ezh2, which possesses histone-methyl-transferase activity, was found to be 
downregulated in old HSCs, while Smarca2 and polycomb-interacting protein Jarid1a were 
found to be significantly upregulated 21.
In a recent study conducted with human cells, genes involved in chromatin remodeling 
were also overrepresented in being differentially expressed in old human hematopoietic 
stem/progenitor cells (HSPCs), compared to their young counterparts. Using micro-arrays, 
gene expression profiles from old HSPCs isolated from mobilized blood from individuals 
between 27 and 73 years were compared to gene expression profiles from young HSPCs 
isolated from cord blood 22. The polycomb genes Ezh1 and Cbx7 and polycomb-associated 
gene Jarid2 were upregulated in old human HSPCs. Upregulation was also observed for 
other chromatin-modifying genes such as Rnf20, Jmjd1a, Mllt4 and Sirt2. Other chromatin 
regulators such as Hdac6, Ezh2, Hmgn2, Myst4, Smarca5, Cbx1 and Cbx5 were found to be 
significantly downregulated with age.
Together, these studies imply that genes involved in chromatin organization are frequently 
dysregulated upon HSC aging. In addition, both in old murine HSCs and human HSPCs, large 
gene clusters were identified that were coordinately up or down-regulated. This may reflect 
the impact of dysregulated epigenetic factors on genome-wide expression profiles 19, 22. In 
agreement with this hypothesis, in thirteen different tissues it has been shown that genes 
that were normally coordinately expressed in young to intermediate-aged tissues (from 16 
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month mice), failed to do so in older tissue (24 months) 32. Moreover, aberrantly expressed 
genes tended to be clustered in close proximity to each other. Together, these observations 
support the concept of a deterioration of chromatin integrity with age (Figure 2).
Due to the difficulty of collecting adequate cell numbers for analysis, genome-wide studies 
on chromatin modification in aged HSCs are so far lacking. However, studies in other cell 
types have shown that several epigenomic changes indeed accumulate over time 33-35. 
Although overall genomic DNA methylation has been found to decrease with age, a number 
of specific promoters become hypermethylated. Intriguingly, both genome-wide DNA 
hypomethylation and aberrant promoter hypermethylation are also epigenetic hallmarks 
of cancer 36-37, which will be discussed further in this review. An age-associated decrease in 
histone acetylation and alterations in histone methylation patterns have also been reported 33.
In concert, chromatin dysregulation might present a plausible explanation for the numerous 
and broad genome-wide changes in gene expression levels observed in aged HSCs.
POLYCOMB GROUP PROTEINS AND HSC REGULATION
PcG proteins
Polycomb group (PcG) proteins form an explicit class of epigenetic modulators. They assemble 
within multimeric protein complexes and induce transcriptional repression of target genes 
through catalyzation of specific histone modifications. PcGs were originally identified in 
Drosophila as repressors of homeotic (Hox) genes 38. Together with the counteracting Trithorax 
group (TrxG) proteins, PcGs showed to be crucial for maintenance of appropriate patterns 
of Hox gene expression for correct axial patterning of body segments. The function of PcG 
proteins seemed to be highly conserved during evolution since they also showed to be 
important for proper development in mammals. For example, several mutant mice models 
that were generated displayed skeletal malformations 39-42.
Biochemical analyses have revealed that PcG proteins assemble within at least two multimeric 
protein complexes, termed Polycomb Repressive Complex 1 and 2 (PRC1 and PRC2) (Figure 1) 
26, 43-44. PRC2 contains three core subunits homologous to Drosophila; Enhancer of zeste (E(z)), 
Suppressor of zeste 12 (Suz12) and Extra sex combs (Esc). The currently identified mammalian 
orthologs that have shown to function within PRC2 are Ezh1/Ezh2, Suz12 and Eed 45-48. In 
addition, three different isoforms exist for Eed (Eed1, Eed2 and Eed3/4 49-50. The SET-domain 
containing Ezh proteins catalyze trimethylation of histone 3 lysine 27(H3K27me3) and to a 
minor extent lysine 9 of histone 3 (H3K9me3). This modification is found to be the initiating 





PRC1 complexes consist of four core components; Drosophila polycomb (Pc), Sex combs extra 
(Ring/Sce), Polyhomeotic (Ph), and Posterior sex combs (Psc) proteins (Figure 1). Each of these 
proteins have several orthologs in mammals, classified respectively as the Cbx, Ring1, Phc, and 
Bmi1/Mel18 families. Cbx proteins recognize and catalyze PRC1 binding to the H3K9/27me3 
mark which has been established by PRC2 51-52. Subsequently, Ring1 possesses histone 2A 
ubiquitination activity 52-54. Data indicate that this histone modification is the final step in gene 
repression since it blocks the movement of RNA polymerase along the DNA 55-56. However, 
several studies challenge this strict hierarchical recruitment model, since PRC1 and PRC2 can 
also function independently 57-60.
The number of genes encoding PcG family members has expanded tremendously in mammals, 
which resulted in a great combinatorial diversity in PRC1 and PRC2 complex compositions 
(Figure 1) and molecular functions. For example, the Cbx family consists of Cbx2, Cbx4, Cbx6, 
Cbx7 and Cbx8. The chromodomains of different Cbx proteins were found to have different 
affinities toward mono-, di-, and tri-methylated H3K9 and H3K27 51. Likewise, whereas 
Bmi1 can stimulate the E3 ubiquitin ligase activity of Ring1b, its homologue Mel18 does not 
possess this ability 53. Distinct functional roles for Ezh1- and Ezh2-containing PRC2 complexes 
in gene repression were found as well 61. Taken together, stoichiometric perturbation of one 
component of the PRC complex might be sufficient to modify its molecular function.
As discussed before, expression levels of several PcG genes showed to be affected during HSC 
aging 19, 21-22. One can imagine that changes in gene expression levels of PcG genes during HSC 
aging results in modifications of the compositions and diversity of PRC1 and PRC2 complexes. 
The observed age-related changes in HSCs, such as the myeloid-skewage of differentiation and 
reduced self-renewal abilities, might be the result of a misbalance in HSC cell fate decisions by 
PcG misregulation and/or altered ratios in terms of PcG homologs (Figure 2).
PcG proteins in HSC regulation
Polycomb group proteins have shown to be key players in HSCs by determining cellular fate 
decisions (Figure 1). In HSCs, they repress the transcription of lineage-specific genes. In 
response to extrinsic or intrinsic signals, PcG proteins can be displaced from these promoters 
and be recruited to stem cell-specific self-renewal genes to promote differentiation and 
suppress unlimited proliferation. However, during differentiation into either the myeloid or 
lymphoid lineage, PcGs not only repress the transcription of self-renewal genes but also of 
differentiation genes of the alternative lineage.
The precise mechanism whereby PcGs are recruited to their target loci remains elusive, 
although evidence accumulated that several transcription factors and long non-coding RNAs 
are involved in this process 62. Interestingly, one recent report showed that long non-coding





Figure 1. Schematic representation of the two Polycomb Repressive Complexes and their role in 
Hematopoietic Stem Cell regulation. The PRC1 complex consists of four core subunits homologous to 
Drosophila Polycomb (Pc), Sex combs extra (Ring), Polyhomeotic (Ph), and Posterior sex combs (Psc). 
The PRC2 complex comprises three core subunits, Enhancer of zeste (E(z)), Suppressor of zeste 12 
(Suz12), and Extra sex combs (Esc). In mammals, several different homologs exist for every distinct PRC 
core subunit, resulting in PRC complex composition diversity. Expression pertubation studies showed 
that distinct PcG genes have different functions in Hematopoietic Stem Cell regulation. Several PcG 
genes stimulate HSC or progenitor self-renewal divisions (dark and light green balloons, respectively), 
whereas others negatively affect HSC self-renewal (red balloons). Several PcG genes have not yet been 
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RNAs (lncRNA) are able to physically connect polycomb complexes with another histone 
modifying complex (LSD1/coREST/REST) to coordinately specify histone modifications 
on target genes 63. LSD1 specifically catalyzes H3K4 demethylation. Whereas polycomb-
mediated H3K27me3 is generally associated with repressive chromatin, methylated H3K4 
is considered to be an active histone mark. Only recently, the existence of bivalent marks 
(the appearance of both “active” methylated H3K4 and “repressive” methylated H3K27 
marks on the same locus) has been reported in murine CD150+ LSK HSCs and human CD34+ 
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Figure 2. Model in which Polycomb Group proteins balance HSC aging and cancer development. 
External factors, genetic or epigenetic lesions or stoichiometric changes in expression or activity 
can alter the function of Polycomb Group proteins and the composition of the Polycomb Repressive 
Complexes. Polycomb group proteins are known to safeguard the epigenetic integrity of the cell. 
However, misregulation of Polycomb Group proteins can affect several important cellular processes 
such as cell-fate decisions, the p16/p19 senescence and apoptosis pathway, and the DNA damage 
repair machinery. Impaired self-renewal activity, a differentiation skewage and derepression of the 
INK4a-ARF locus which results in HSC senescence, are common hallmarks of aging. However, malignant 
transformation of HSCs is generally associated with the acquisition of excessive self-renewal properties 
by, for example, stable repression of the INK4-ARF locus by Polycomb Group proteins and improper 
functioning of the DNA damage response machinery. This might subsequently promote accumulation 




developmental genes poised for activation. Oguro et al. 66 recently discovered that Bmi1 is 
involved in transcriptional repression of lymphoid loci (Pax5 and Ebf1) by bivalent domains 
in hematopoietic stem cells. The physical interaction of polycomb complexes with an H3K4 
demethylase complex mediated by lncRNA might be important for the removal of bivalent 
domains in HSCs upon differentiation. However, this concept needs further experimental 
support.
Many PcG genes show stage-specific expression patterns along hematopoietic differentiation. 
For example, Bmi1 is preferentially expressed in HSCs and its transcript levels decrease upon 
lineage specification, whereas Eed shows ubiquitous expression in all hematopoietic stages 
67-69. By analysis of the subcellular localization of PcG proteins in different hematopoietic 
cell populations, LT-HSCs (CD34- LSK), multipotent progenitors (CD34+ LSK) and B cell 
progenitors (B220+ CD43+), Kato et al. 70 showed that PRC1 complexes in primitive HSCs 
showed a unique composition different from progenitor cells.
HSC regulation by PRC1 members
Bmi1 is the first discovered and best studied polycomb member involved in HSC regulation 
(Figure 1). By a retroviral insertional mutagenesis approach in predisposed Eμ-myc transgenic 
mice, Bmi1 was originally discovered as a proto-oncogene that cooperates with MYC in the 
generation of B and T cell lymphomas 71. The importance of Bmi1 in adult hematopoiesis 
became particularly apparent in Bmi1-null mutant mice 42. Despite normal embryonic 
development, these mice showed hypoplastic bone marrow and reduced white blood cell 
counts due to impaired bone marrow hematopoiesis after birth. Park et al. showed that the 
number of HSCs in Bmi1-/- fetal liver was not affected but the number of HSCs in postnatal 
Bmi1-/- mice was severely reduced 72. Bmi1-deficient mice died within two months of birth. 
Functional analysis of Bmi1-/- HSCs in a transplantation setting showed that these cells were 
incapable of self-renewal since they did not sustain long-term hematopoietic repopulating 
ability 67, 72. In turn, forced expression of Bmi1 in CD34- LSK sorted HSCs promoted self-
renewal 67. This effect was restricted to HSCs, since overexpression of Bmi1 in multipotent 
progenitors (CD34- LSK) gave no such effects 67. Recently, the important role of Bmi1 in 
human HSCs (CD34+ cord blood cells) was confirmed 67, 73-74.
The PRC1 component Mel18, a homologue of Bmi1 with 70% identity at the amino-acid 
level, showed negative effects on the self-renewal activity of HSCs (Figure 1) 75-76. Recently, 
some evidence has emerged showing that the balance between Bmi1 and Mel18 regulates 
HSC functioning 76. However, this concept needs further support, for example by studying 
whether Bmi1 and Mel18 indeed compete for incorporation in the PRC1 complex in HSCs.
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Other PcG PRC1 components are also studied for their role in adult HSC regulation, although 
less intensively (Figure 1). Inactivation of Ring1a and Ring1b in mice showed distinct 
phenotypes. Ring1a -/- mice are fertile but show a number of minor skeletal abnormalities 
along the anterior-posterior axis 41, whereas Ring1b -/- mice showed defective gastrulation 
and were embryonic lethal 77. In the hematopoietic system, conditional deletion of Ring1b 
resulted in hypocellularity of the bone marrow. Ring1b was found to specifically restrict the 
proliferation of progenitors and it paradoxically promoted proliferation of their maturing 
progeny. Thus, Ring1b showed to have dual functions in the regulation of hematopoietic cell 
turnover depending on the maturational stage of cell differentiation by both targeting cell 
cycle activators (cyclin D2 and cdc6) and inhibitors (p16 Ink4a) 78. PRC1 member Rae28 (a.k.a. 
Phc1, Edr1, Mph1) is the only member of the Phc family that has been studied for its role in 
hematopoietic stem cells. During embryonic development, the number of HSCs in fetal liver 
progressively declines in Rae28-deficient mice 79. Rae28 showed to be essential for effective 
HSC self-renewal and Rae28-/- stem cells were unable to reconstitute the hematopoietic 
compartment upon serial transplantation experiments 79-80.
At present, the Cbx family has been the least studied PcG PRC1 member with respect to 
their role in HSCs (Figure 1). The Cbx family of proteins comprises Cbx2, Cbx4, Cbx6, Cbx7 
and Cbx8, and all can bind to H3K27me3 marks through their N-terminal chromodomain. 
Cbx -/- mice showed normal numbers of HSCs in fetal liver and these HSCs were fully 
functional even after successive serial transplantations 67. Although no gross abnormalities 
on fetal liver HSCs number and function was observed, 4-week-old Cbx2-/- mice showed 
several lymphocyte abnormalities 40. By means of in vitro proliferation assay using thymidine 
incorporation, Cbx2 appeared to be required for T cell precursor proliferation 40. This is 
further supported by the observation that Cbx2 is specifically present in PRC1 complexes 
in lymphocytes but not in HSCs 70. This suggests that the PRC1 complexes in HSCs have 
a unique composition that includes another Cbx member that can compensate for Cbx2. 
However, this particular Cbx protein has not yet been identified since studies on the role of 
Cbx4, Cbx6, Cbx7 and Cbx8 in HSC regulation are so far lacking.
HSC regulation by PRC2 members
In a ‘genetical genomics’ approach 81-82 followed by functional studies, the PRC2 member 
Ezh2 has been identified as being important in HSC regulation and aging (Figure 1). More 
than a decade ago, age-related properties of HSCs were found to be highly strain-dependent 
83-84. For example, HSCs from of DBA/2 mice (D2) mice are more abundant in number and 
have a higher turnover rate than C57BL/6 (B6) HSCs. Stem cell turnover rate was shown 
to be correlated with mean lifespan, and has therefore been considered as being one of 
the most important factors that underlies the aging process 85-86. To uncover genes that are 




of recombinant inbred strains from DBA/2 and C57Bl/6 was conducted 87-90. Since 30 BXD 
strains were fully genotyped, the genetic basis of these differences in gene expression 
could be determined by quantitative trait loci (QTL) analysis 91. Two genetic regions, one 
on chromosome 11 and one on chromosome 18, showed to be highly deterministic for the 
variation in cycling activity and HSC frequency, respectively 91.
Ezh2 was found to be transcriptionally controlled by the chromosome 18 locus 7 and HSCs 
of BXD mice that had inherited the B6 allele at the chromosome 18 locus showed significant 
higher expression levels of Ezh2 than mice that carried the D2 allele. Along hematopoietic 
differentiation, Ezh2 expression levels significantly decreased 7, 68 and enforced expression 
of Ezh2 prevented HSC exhaustion, as shown by repeated serial transplantations 7. Whereas 
control HSCs cease to show long-term repopulating ability after three serial transplantations, 
the function of Ezh2 overexpressing stem cells was not impaired. Ezh2-deficient mice have 
no clear HSC phenotype, although B and T cell development and VDJ rearrangement showed 
to be affected 92, 93. Likewise, inactivation of its homolog Ezh1 did not affect HSC function 92 
93. In a recent study 94, the function of Ezh1 and Ezh2 was shown to be partially redundant 
with respect to self-renewal in embryonic stem cells. Upon loss of Ezh2, Ezh1 incorporated 
into PRC2 and compensated for its loss. This might also hold true for HSCs and might explain 
the lack of HSC phenotypes in knockout mice. However, several differences between Ezh1 
and Ezh2 molecular functions have also been reported and these do not fully comply with 
functional redundancy 61.
In contrast to the effect of Ezh2 on HSCs, its binding partners Eed and Suz12 were shown 
to have negative effects on HSC and progenitors (Figure 1) 69, 95-96. Eed loss of function 
using hypomorphic mice resulted in hyperproliferation of both primitive and more mature 
lymphoid and myeloid progenitors 69. With age, the defects in proliferation capacity of 
progenitor cells in Eed mutant mice deteriorated and ultimately developed into leukemia 69. 
Mutations in Suz12, which resulted in a truncated inactive form, enhanced HSC activity 95. 
In another study, a sensitized Mpl-/- background was used to detect subtle changes in HSC 
function in mice heterozygous for individual PRC2 components (Ezh2+/-, Eed +/- or Suz12+/-). 
Ezh2, Eed and Suz12 were all found to restrict HSC activity 96. The results for Ezh2 obtained in 
this study were not consistent with reports by Kamminga et al. 7, that were discussed above. 
Since both studies were performed in C57Bl/6 mice, the genetic background cannot account 
for this discrepancy. Yet, Ezh2 gene dosage and/or the balance between PRC2 complexes 
including either Ezh2 or its homolog Ezh1 might be important. Since we hypothesize that 
a strict balance in PRC complex compositions is central for HSC fate, we speculate that 
downregulation or overexpression of a PcG member does not necessarily have to result in 
strict opposite phenotypes. For example, upon overexpression of one particular PcG member 
(Cbx2), its family members (Cbx4, Cbx6, Cbx7 and Cbx8) will most likely be outcompeted 
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from the complex. In this case, the function of PRC complexes exclusively containing the 
overexpressed PcG member (Cbx2) will be studied. However, upon downregulation, the 
stoichiometry of PcG family members becomes disturbed and it will be difficult to foresee 
which homologs will take its position in the PRC complex and thus what exactly will be 
studied. Unfortunately, proteomic analysis regarding PRC complex compositions after PcG 
gene expression modification is generally lacking.
PcG target genes in HSC
In HSCs, the most important target identified for PcG genes thus far has been the tumor 
suppressor locus INK4a-ARF. This locus encodes two proteins, p16Ink4a and p19Arf. p16 is a 
key regulator of cellular senescence since it functions as a cyclin-dependent-kinase-inhibitor 
and hampers cell cycle progression by activating the retinoblastoma (RB) pathway. p19 is 
important for p21/p53-mediated cell cycle arrest and apoptosis 97-98. In Bmi1-/- mice, the 
INK4a-ARF locus showed to be responsible for the lymphoid and neurological defects, as 
a double deletion of Bmi1 and INK4a-ARF partially rescued the phenotype 99. In mouse 
and human Bmi1-deficient HSCs, ineffective self-renewal has also been attributed to 
derepression of the INK4a-ARF locus and subsequent premature senescence 67, 72, 74. p16, 
but not p19, was found to be a key-target of Ring1b in hematopoietic cells as well 78. p16 was 
found to be upregulated in response to Ring1b deletion and INK4a-deficiency rescued the 
expansion defects of Ring1b-deficient lymphoid and myeloid precursor cells.
Chromatin immunoprecipitation experiments in mouse embryonic fibroblasts showed that 
INK4a-Arf is a critical target of many other PcG proteins as well 57, 100-102. They repress its 
transcriptional activity by direct binding and catalyzation of H3K27 trimethylation. Ectopic 
expression of different PcG members in primary fibroblasts was shown to result in bypass of 
senescence and cellular immortalization 7, 57, 100-102.
Interestingly, several studies showed that p16 expression markedly increased with age in the 
hematopoietic and neuronal system and in the pancreas 103-105. In the hematopoietic system, 
this increase was found to be restricted to the stem cell compartment (Lin-, Sca1+,cKit+, 
CD34low, Flk2low) , because other bone marrow cells did not express p16 in an age-dependent 
fashion 103. Using both p16-deficient and overexpression mice models, p16 was shown to 
promote aging by restricting stem cell self-renewal potential 103-105. For instance, whereas 
normally the reconstitution ability of HSC declines with age, Janzen et al. 103 showed that 
this impairment could partially be mitigated by repressing p16. Thus, deficiency of a critical 
polycomb target gene, p16, showed to delay the age-associated decline of several adult 
stem cell types and therefore strongly argues for the involvement of PcG proteins in the 




Nonetheless, critical INK4A-ARF-independent PcG targets in HSC also must exist, as the 
effect of both Eed and Suz12 downregulation showed to be INK4a-ARF independent 69, 95. 
Hox genes such as HoxB4 and HoxA9, cell cycle-related genes such as p21, p27, cyclin D2, 
Geminin, and cdc6, C/EBPα target genes, and lineage developmental regulator genes (Pax5 
and Ebf1) have all been suggested as being direct PcG targets in HSCs 66, 75, 78, 95, 96.
POLYCOMB GROUP PROTEINS AND THE DNA-DAMAGE RESPONSE
During each division of HSCs, either symmetrical or asymmetrical, replication of the genome 
results in copy errors. During evolution, several different DNA damage response mechanisms 
have developed that function as an initial step to repair these errors. However, during aging 
deficiencies in the DNA damage repair system have shown to limit the function of HSCs 
106, 107. Appropriate regulation of DNA repair mechanisms is therefore crucial to maintain 
a proper HSC pool size with age, since extensive DNA damage is likely to trigger cellular 
senescence and apoptosis.
Very recently, several PcG proteins were identified to be involved in DNA damage responses in 
multiple cell types, including neural stem cells 108-111. In an attempt to identify factors that 
are specifically enriched in the chromatin-associated proteome after DNA damage, Chou et 
al. combined stable isotope labeling of cells in culture (SILAC), chromatin fractionation, and 
quantitative mass spectrometry and compared protein abundance of normal cells with cells 
damaged by UV-irradiation. Three polycomb group proteins, Suz12, Cbx8 and Ezh2, were 
found to be recruited to sites of damaged DNA. Depletion of these proteins caused cells 
to become more sensitive to ionizing radiation 108. In a different study, Bmi1 and Ring1b 
were found to be recruited to sites with double stranded breaks (DSB) 111 and contributed 
to the ubiquitinilation of γ-H2AX, an initial step in DSB repair. Bmi1 knockdown resulted in 
increased sensitivity to ionizing radiation and simultaneous depletion of Bmi1 and Ring1b 
resulted in an even severe accumulation of DNA damage after insult 111. Bmi1 also has 
shown to be involved in DSB repair in neuronal stem cells (NSC) 109. Overexpression of Bmi1 
in these cells resulted in enhanced recruitment of ataxia-telangiectasia-mutated (ATM) 
kinase (ATM) to DSBs. ATM constitutes a crucial component of the DNA double-strand break 
(DSB) response machinery. Overexpression of Bmi1 subsequently resulted in resistance of 
NSC to radiation. Together, these results show a clear link between polycomb group proteins 
and the DNA damage response, and suggest yet another mechanism whereby PcG might 
safeguard genomic stability and cellular integrity during aging (Figure 2).
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POLYCOMB GROUP PROTEINS, AGING, AND HEMATOLOGICAL 
MALIGNANCIES
The incidence of developing cancer increases exponentially with age 112. The median age 
of diagnosis of acute myelogenous leukemia (AML) is 65 years 113 and fewer than 10% of 
the patients are children 114. The observation of the age-distribution of cancer has been 
fundamental to the origin of the multi-stage theory of cancer 115. This theory implies that 
most cancers arise from the accumulation of several mutations, and the probability of 
acquiring a sufficient number of detrimental mutations increases with time 112. Because 
the lifespan of HSCs can surpass that of the organism 4, 116 and because of their potentially 
extensive replicative history, primitive hematopoietic cells are thought to be particularly 
subject to the accumulation of errors. However, according to the clonal succession theory, 
most cells in the HSC compartment are quiescent and only a few are activated at any given 
time 117. In theory, dormancy lowers the risk of replication errors. This has recently been 
supported by advanced label-retaining studies 118.
Nevertheless, substantial evidence suggests that aging HSCs are likely targets for leukemic 
transformation. For example, it has been found that only a subfraction of cells, termed leukemic 
stem cells (LSC), possess the ability to initiate and sustain leukemia. Intriguingly, these LSCs express 
the same immunophenotypical markers (CD34+, CD38-) as normal human HSCs 119-121, which 
suggests that these rare LSCs originally derived from healthy HSCs. Second, the unique intrinsic 
property of stem cells to self-renew indefinitely is the foremost important criteria for malignant 
transformation, besides growth factor independency, differentiation blockage and escape from 
apoptosis. However, it has also been suggested that leukemias can arise from more committed 
progenitors that have acquired ‘stemness’ properties that allows them to self-renew infinitely. Yet, 
theoretically, malignant transformation of an HSC that already possesses self-renewal capacities 
requires fewer reprogramming events than transformation of a more differentiated cell without 
such self-renewal ability, and this is therefore more likely to occur in HSCs.
Cancer, including leukemias and lymphomas, has long been viewed purely as a genetic 
disease. Many patients with leukemia carry an abnormal karyotype as a consequence of 
chromosomal translocations. These translocations cause in-frame fusion of two otherwise 
separated genes. The resulting fusion product often disturbs proper regulation of proliferation, 
differentiation, growth factor signaling, senescence or apoptosis. Traditionally, these genetic 
abnormalities were considered to be the sole cause of malignant transformation of the 
cells. Typical examples of translocations frequently observed in AML patients are t(15;17) 
PML-RARa, t(8;21) AML1-ETO, Inv(16), CBFb-MYH11, t(7;11) NUP98-Hoxa9, and several 
varieties of 11q23 MLL rearrangements 122. The ‘Philadelphia Chromosome’, the result of 




(CML) which often used to progress into AML 123 but also in a subset of patients with acute 
lymphoblastic leukemia (ALL) 124. However, it has been shown that some chromosomal 
translocations associated with hematopoietic malignancies can be present in healthy (aged) 
individuals, and do not seem to cause leukemia per se 125-128, arguing for cooperating events. 
An additional argument for the requirement of cooperating mutations for full malignant 
transformation is the observation that some oncogenic fusion proteins do not cause 
leukemia with 100% penetrance after cloning and expressing in murine hematopoietic cells, 
and leukemia develops only after many months 129, 130. Together, these observations resulted 
in the (at least) two-hit model of leukemogenesis, stating that malignant transformation 
depends on both the activation of proto-oncogenes and deactivation of tumor-suppressor 
genes by genetic alterations 131. Hence, cancer has been viewed as a disease driven by 
progressive genetic abnormalities, including chromosomal translocations and mutations in 
tumor suppressor genes (e.g. INK4a-ARF) and oncogenes.
However, about a decade ago it became apparent that cancer is also associated with 
profound epigenetic changes 132-134. Tumor cells are associated with genome-wide DNA 
hypomethylation, gene specific hypermethylation, as well as genome-wide histone 
modifications 37, 135-138. Whereas DNA hypomethylation results in chromosomal instability, 
both promoter hypermethylation and specific histone modifications represents an efficient 
mechanism for inactivation of tumor suppressor genes such as INK4a-ARF. Although it is 
now widely accepted that epigenetic alterations are common hallmarks of human cancer, 
epigenetic alterations are still viewed largely as a consequence of genetic lesions.
Yet, recently a critical role for polycomb (dys)regulation in the initial stages of tumorigenesis 
became apparent. First, it has been demonstrated that genes that are normally suppressed 
by polycomb complexes in stem cells are far more likely to undergo cancer-specific promoter 
DNA-hypermethylation than non-PcG target genes 139-141. Half of the genes frequently 
hypermethylated were found to be premarked with Ezh2-containing PRC1 complexes that 
catalyzed the recruitment of DNA-methyl transferases (DNMT) in prostate and colon cancer, 
but not in healthy cells 140. In a different study, Cbx7-containing PRC1 complexes were shown 
to be able to recruit DNMT to genes frequently found to be hypermethylated in cancer 142. 
Next, in a study by Teschendorff et al., it was shown that aging contributes to this process. In 
aged blood cells and bone marrow-derived mesenchymal stem cells, silencing of PcG targets 
by promoter hypermethylation predisposed cells to become malignant 143.
Polycomb group genes are often deregulated in various types of cancer, including those 
of the hematopoietic system 144-145. For example, Bmi1 overexpression is associated with 
both myeloid and lymphoid malignancies 146-149 and Cbx7 was expressed at elevated levels 
in human follicular lymphomas 150. In turn, Ezh2 is overexpressed in several different 
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types of lymphomas 149, 151-153. Very recently, a number Ezh2 mutations that inactivate its 
methyltransferase SET domain have been identified in different types of hematological 
malignancies, including in follicular and diffuse large B cell lymphomas 154 and in 
myeloproliferative syndromes 155, 156.
Taken together, we hypothesize that epigenetic dysregulation, for example by PcG 
misexpression, may precede genetic changes in premalignant progenitor or stem cells and 
set the stage for accumulation of additional genetic and epigenetic errors such as mutations, 
promoter hypermethylation and chromosomal instability that, together, may further drive 
tumor progression (Figure 2).
ADDITIONAL REMARKS AND FUTURE PROSPECTS 
Polycomb group proteins are key factors in HSCs by regulating the transcriptional ‘stemness’ 
profile of the cell. Epigenetic changes imposed by PcG proteins can result in extensive 
effects on cell fate as they orchestrate DNA compaction and thereby affect expression of 
numerous genes. Traditionally, cellular aging and cancer, of which the incidence increases 
with age, have been viewed as genetic syndromes driven by the sequential accumulation 
of mutations. However, it is now clear that both hematopoietic stem cell aging and 
hematopoietic malignancies are accompanied by many epigenetic changes, including 
changes in PcG expression and function. This dysregulation can be held accountable for 
the disturbance of a variety of cellular processes, including senescence, DNA repair and 
cell fate decisions (self-renewal vs. differentiation), and it may contribute to aging as well 
as facilitating malignant transformation of hematopoietic cells. We therefore speculate that 
PcG proteins regulate the balance between aging (by limiting stem cell self-renewal) and the 
risk of developing cancer (excessive self-renewal) (Figure 2).
Whether dysregulation of PcG proteins in aged and malignant hematopoietic cells truly 
comprise the initial step of cellular aging and/or malignancy remains largely unknown, since 
at present there is no mechanistic evidence of a direct causal relationship. However, an 
intrinsic property in biology constitutes “epigenetic gambling” or “epigenetic drift”. Subtle 
changes, that alter the epigenetic landscape of cells, constitute a mechanism to provide 
random changes and sufficient variation in cellular gene expression programs to ensure 
survival of the population (of cells or species) (Figure 2) 157. Changes in PcG expression and 
its activity that occur during normal aging, are unlikely to uniformly affect all individuals. In 
addition, epigenetic modifications are thought to mediate, at least in part, the relationship 
between the environment and the genome. They could therefore provide a direct link 




been associated with healthy aging, and the risk of developing cancer (Figure 2). Further 
elucidation of the epigenetic background of hematopoietic stem cell aging and aging of 
other adult stem cell types could lead to strategies that stimulate healthy aging and prevent 
cancer development.
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ABSTRACT
The balance between self-renewal and differentiation of adult stem cells is essential for 
tissue homeostasis. Here we show that in the hematopoietic system this process is governed 
by Polycomb Chromobox (Cbx) proteins. Cbx7 is specifically expressed in hematopoietic 
stem cells (HSCs), and its overexpression enhances self-renewal and induces leukemia. 
This effect is dependent on integration into Polycomb Repressive Complex-1 (PRC1) and 
requires H3K27me3 binding. In contrast, overexpression of Cbx2, Cbx4 or Cbx8 results in 
differentiation and exhaustion of HSCs. ChIP-sequencing analysis shows that Cbx7 and Cbx8 
share most of their targets; we identified approximately 200 differential targets. Whereas 
genes targeted by Cbx8 are highly expressed in HSCs and become repressed in progenitors, 
Cbx7 targets show the opposite expression pattern. Thus, Cbx7 preserves HSC self-renewal 
by repressing progenitor-specific genes. Taken together, the presence of distinct Cbx proteins 
confers target selectivity to PRC1 and provides a molecular balance between self-renewal 
and differentiation of HSCs.
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INTRODUCTION
Mature blood cells have a limited lifespan and are continuously replenished by HSCs, 
which have the potential to undergo both self-renewal and differentiation. Identifying the 
molecular basis of this process will be of great value for a fundamental understanding of 
normal and malignant hematopoiesis and holds promise for stem cell-based therapies in 
the future.
Proteins that maintain or modify the transcriptional profile of stem cells by organizing 
chromatin structure can be considered as key epigenetic candidates. Polycomb group 
(PcG) proteins were first discovered as important developmental regulators in Drosophila 1. 
According to the classical PcG model, they assemble into at least two complexes, PRC1 and 
PRC2, which collaborate to repress gene transcription by catalysing histone modifications 
2-3. PRC2 is comprised of three core components (Ezh, Suz12, and Eed), of which the SET-
domain containing Ezh protein contributes to gene repression by tri-methylating histone H3 
on Lys 9 and 27 (H3K9me3, H3K27me3). PRC1 contains Pcgf (for example, Bmi1 and Mel18), 
Phc, Ring1 and Cbx, and catalyses mono-ubiquitylation of H2AK119.
Whereas in Drosophila each Polycomb component is encoded by a single gene, the number 
of genes encoding for PcG proteins has increased in mammals. However, the relevance of 
this diversification is unclear. Yet, expression patterns of PcG family members vary between 
distinct tissues and between various cell types within the same tissue 4-7. For example, in 
the hematopoietic system, Bmi1 is specifically expressed in immature hematopoietic cells, 
while the expression of Bmi1 paralogue Mel18, is increased during differentiation 6. This 
argues for the existence of cell-type and differentiation-stage specific PRC1 and PRC2 sub-
complexes with unique molecular functions 8-11.
Analysis of the composition of the PRC1 complex showed that it contains a single 
representative of the Cbx family; either Cbx2, Cbx4, Cbx7 or Cbx8 12-13. The amino-terminal 
chromodomain of Cbx orthologs can bind H3K9me3 and H3K27me3 14-15, albeit with unequal 
affinities 16-17. Therefore, the Cbx proteins are key components for targeting PRC1 to specific 
genomic loci to regulate gene expression. Whereas several PcG proteins, such as Ezh2 and 
Bmi1, have shown to be important for HSC self-renewal 6, 18-22, no data are available for how 
different Cbx subunits contribute to HSC regulation.
By overexpressing individual Cbx family members in HSCs, we have interrogated the 
biological function of different Cbx-containing PRC1 complexes. We show that the decision 
of HSCs to self-renew or differentiate critically depends on the molecular composition of the 
PRC1 complex.






10-16 week female C57BL/6 CD45.2 (Harlan, The Netherlands) or CD45.1 (bred at the 
Central Animal Facility) mice were used. All experiments are approved by the Animal Care 
Committee.
Cell purification
Long-term HSCs (Lin-, Sca1+, c-Kit+, CD48-, CD34- (BD) CD150+ EPCR+), short-term HSCs (Lin-
, Sca1+, c-Kit+, CD48-, CD34+, CD150-) and multipotent progenitor cells (Lin-, Sca1+, c-Kit+, 
CD150-, CD34+) were sorted from pooled BM cells as described previously 23.
Common lymphoid progenitors (Lin-, CD127+, c-Kitmid, Scamid), common myeloid progenitors 
(Lin-, CD127-, c-Kit+, Sca1-, CD16/32mid, CD34mid) , granulocyte-macrophage progenitors 
(Lin-, CD127-, c-Kit+, Sca1-, CD16/32high, CD34high) and megakaryocyte-erythroid progenitors 
(Lin-, CD127-, c-Kit+, Sca1-, CD16/32low, CD34low) were isolated by staining with Alexa-Fluor-
conjugated lineage antibodies (B220 clone RA3-6B2, Biolegend 135010, 1:500, Gr1 clone 
RB6-8C5, Biolegend 108422, 1:75, Mac1 clone M1/70, Biolegend 101222, 1:100, Ter119 
clone TER119, Biolegend 116220, 1:100, CD3 clone 17A2, Biolegend 100216, 1:150), CD127-
PE (clone A7R34, Biolegend 135010, 1:250), Sca1-Pacific Blue (clone D7, Biolegend 108120, 
1:150), cKit-APC (clone 2B8, BD Biosciences 561074, 1:75), CD16/32-PeCy7 (clone 93, 
eBioscience 25-0161-82, 1:75) and CD34-FITC (clone RAM34, BD BD Biosciences, 1:100). 
Sorting gates were set according to Challen et al. 24. Granulocytes (Gr1+), T-cells (CD3ε+) 
and B-cells (B220+) were isolated using B220-Pacific blue (clone RA3-6B2, Biolegend 
103227, 1:1000), CD3ε-APC (clone 145-2C11, eBiosciences 17-0031, 1:100) and Ly-6G(Gr1)-
AlexaFluor700 (1:100).
Retroviral vectors
Retroviral SF91-IRES-GFP vector (gift of C. Baum, Hannover Medical School, Germany) was 
used as backbone for cloning cDNAs upstream of IRES. Cbx2, Cbx4, and Cbx7 cDNA clones 
were ordered from OpenBiosystems (accession numbers: Cbx2 BC035199, Cbx4 BC117801, 
Cbx7 BC021398). myc-flag-Cbx8 was cloned from PINCO 42 into SF91.
N-terminal flag-tagged Cbx7 was generated by PCR using forward primer containing flag-se-
quence F:5’GCAGCGGCCGCATGGACTACAAGGACGACGATGACAAGATGGAGCTGTCAGCCATAG
GCGAGCAGGTG-3’ and reverse R:5’-GGTCGACAGGGGAAGCCGCTATTCACAG-3’, and cloned 
into TOPO-blunt. Cbx7 chromodomain mutant (Cbx7AA: K31W32 to A31A32) was cloned 
via PCR on TOPO-flag-Cbx7 using F:5’-CAAAGTTGAATATCTGGTGGCGGCGAAGGATGGCCCCC-
CA-3’ and R:5’-CTTGGGGGGCCACCTTTCGCCGCCACCAGATATTCAACTT-3’. 
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Cbx7ΔPc (ΔTVTFREAQAAEGF) was cloned by insertion of Xba1 restriction sites flanking the 
Pc-box using F:5’-GCTCTAGATTCCGAGACCGCAACGAGAAG-3’ and R:5’-GCTCTAGAGACG-
GAGTTGGCGGTGATG-3’. The Pc-box was then deleted by Xba1 digestion and self-ligation. 
Subcloning from TOPO into SF91 was performed by Not1-Sal1 digestion and ligation. All 
constructs were verified by Sanger sequencing.
Retroviral overexpression in primary BM
Post-5FU primary BM cells from female C57BL/6 (CD45.2) were isolated from tibia, femora 
and pelvic bones and transduced with indicated vectors as described 43. EGFP+ cells were 
sorted using a MoFlo flowcytometer (BeckmanCoulter).
Downregulation of Cbx7 in primary BM
Lentiviral construct containing a short hairpin against Cbx7 
(CCGGCCTCAAGTGAAGTTACCGTGACTCGAGTCACGGTAACTTCACTTGAGGTTTTTG 45) was 
generated by cloning annealed oligos into the AgeI and EcoRI cloning sites of pLKO.1 
(Addgene plasmid 10878 44). As a control, a pLKO.1 vector containing a scrambled RNAi 
(CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG 46) was used (Addgene 
plasmid 1864).
20% confluent 293T cells (T75) were transfected with 3μg of pLKO1-shRNA (Cbx7 or 
scrambled), 0.7μg of pCMV-VSV-G, and 0.3μg of pCMV-8.91 plasmids in DMEM . After 18h 
medium was changed to StemSpan. Virus supernatant was added to HSPCs 18h later. Cells 
were selected with 3μg/mL puromycin 48h after infection. 72h later cells were plated in 
assays. Liquid cultures were maintained under selective antibiotics.
In-vitro assays
Post-5FU GFP+ HSPCs cells were collected in StemSpan (StemCell Technologies) 
supplemented with 10% FBS, 300 ng/mL rSCF (Amgen), 20 ng/mL rmIL11 (R&D Systems), 
1 ng/mL Flt3 ligand (Amgen), and penicillin and streptomycin. Cytospots were generated 
by spinning at 800rpm in 200μL FCS (Shandon Cytospin3) 10-days after culturing. 10-day 
cultured cells were lysed, fixed and permeabilized according to manufacturer’s protocol 
(BD™ Phosflow, BD Biosciences) and stained with 1.2 μg/mL DAPI. Apoptosis was assessed 
by staining 10-day cultured cells with 10μg/mL 7AAD (Sigma) and 50μL/mL Annexin-V (IQ-
Products) in calciumbuffer. Cells were analyzed by flowcytometry (LSRII, BD Biosciences).
Post-5FU transduced 7-day cultured GFP+ cells were plated in methylcellulose supplemented 
with 100ng/mL mSCF and 20ng/mL rmGM-CSF (R&D systems). After a 6-day incubation 
period, CFU-GM colonies were scored. Cells were collected by scraping and washed 3x in 
PBS. All cells were collected in fresh methylcellulose medium, vortexed and replated. For 




single colony replating, 50 single colonies were picked, made single-cell by vortexing in new 
methylcellulose and plated in a 35mm-dish. Colonies were scored 7 days later.
Cobblestone-area forming cell (CAFC) assays were performed as previously described 47. 
Directly after transduction, GFP+ cells were plated in limiting dilution on a FBMD stromal cell 
layer and CAFCs were scored weekly.
BM transplantation
4.5-7.5x10^6 freshly transduced HSPCs (CD45.1) were transplanted into lethally irradiated 
(9.0Gy) CD45.2 mice, without prior GFP sorting. Transduction percentages were 20%-
40%. The relative contribution of transduced cells (GFP+) compared to identical treated 
non-transduced cells (GFP-) was determined by blood withdrawal from the retro-orbital 
plexus. Red cells were subjected to lysis and white blood cells were stained with CD45.1-
PE (Clone A20, Biolegend 110708, 1:200), B220-Pacific blue (clone RA3-6B2, Biolegend 
103227, 1:1000), CD3ε-APC (clone 145-2C11, eBiosciences 17-0031, 1:100) , Ter119-Pe/Cy7 
(Clone TER-119, Biolegend 116222, 1:200), CD11b-AlexaFluor®700 (Clone M1/70, Biolegend 
101222, 1:100), and Ly-6G(Gr1)-AlexaFluor®700 (clone RB6-8C5, Biolegend 108422, 1:100).
At clear signs of morbidity, blood was taken from the orbital plexus. The mouse was sacrificed 
and BM cells were isolated by crushing. Single cell suspensions were generated from different 
organs (spleen, lymph nodes, liver, thymus). Cell numbers were counted. Bloodsmears and 
cytospins were made and stained by MGG. Immunophenotypic analysis was performed as 
above. In a few cases, spleen cells were additionally stained with CD3-AF700 (clone 17A2, 
Biolegend 100216, 1:150), CD4-APC (clone RM4-5, Biolegend 100516, 1:200), and CD127-PE 
(clone A7R34, Biolegend 135010, 1:250), or CD41-PE (clone MWReg30, Biolegend 133906, 
1:100) and CD16/32-PeCy7 (clone 93, eBioscience 25-0161-82, 1:75) .
Transduction and transplantation of purified hematopoietic cells
LTHSCs, STHSCs, MPPs, and myeloid progenitors were FACS purified as explained above, 
and pre-stimulated for 24h in StemSpan with supplements. CLPs were pre-stimulated in 
StemSpan supplemented with 10% FBS, 100ng/mL SCF, 50ng/mL Flt3, 5ng/mL IL7 and 
P/S. 24h after pre-stimulation cells were transferred to retronectin-coated wells and virus-
supernatant produced in StemSpan was added. GFP+ cells were sorted 24h later.
Single GFP+ cells were seeded into liquid cultures as described in 23. 14 days later, wells were 
scored for the presence of a clone and the clone size was assessed. Colony size-1 represents 
colonies containing 1-30 cells, 2 31-100 cells, 3 101-1000 cells, 4 ~5000 cells, 5 ~15000 cells, 




750 transduced CD45.1+ GFP+ cells were transplanted in CD45.2 recipients plus 0.75x10^6 
CD45.2+ fresh BM cells. 12 months later BM from mice that showed >1% chimerism was 
analyzed.
Immunoprecipitation
Immunprecipitation using M2 Flag-agarose beads (Sigma) were done according to standard 
protocol in IP150 buffer (50 mM Tris-HCl at pH7.5, 150 mM NaCl, 5% glycerol, 0.2% Igepal, 
protein inhibitor cocktail (Roche)) in a myeloid celline (32D).
Chromatin-immunoprecipitation assays (ChIP) of transduced HSPCs were in essence 
performed as described 48. Flag-ChIP using M2 Flag-agarose beads was performed in IP150 
buffer and complexes were washed 4x in 500mM wash buffer (1% Triton X-100, 0.1% 
SDS, 500mM NaCl, 2mM EDTA pH8.0, 20mM Tris-HCl pH8.0) and the final wash step was 
performed in TE buffer. All other ChIPs were performed in IP buffer (66.7mM Tris-HCl, 
100mM NaCl, 5mM EDTA, 0.2% NaN3, 1.67% Triton-X-100, 0.33% SDS) and complexes 
were washed in 500mM wash buffer followed by LiCl buffer (20mM Tris-HCl pH8.0, 1mM 
EDTA, 250mM LiCl, 0.5% NP40, 0.5% Na-deoxycholate) and a final wash step in TE. 1ug of 
rabbit-anti-CBX8 (LAST) 49, rabbit-anti-Cbx7 (Millipore, 07-981) and rabbit-anti-H3K27me3 
(Upstate, 07-449) or IgG from rabbit serum (Sigma, I8140) were used per IP. Prot A and 
Prot G fast-flow sepharose (GE Healthcare) were used for pull down. Primer sequences are 
available upon request.
Western blotting
SDS-PAGE was performed according to standard protocols. Membranes were incubated 
with rabbit-anti-Cbx2 (1:1000, Abcam, ab80044), rabbit-anti-CBX8 (1:1000, LAST), rabbit-
anti-Cbx7 (1:100, Santa Cruz, P-15), rabbit-anti-Ring1b (1:1000, NAST) 50, goat-anti-Mel18 
(1:250, Abcam, ab5267), mouse-anti-Bmi1 51 (1:1000, AF27), mouse-anti-H3 (Cell Signaling 
3638, 1:300), rabbit-anti-actin (Cell Signaling 4970, 1:5000)
ChIP-sequencing
DNA samples obtained from the ChIP assays were adaptor-ligated and amplified (NEB, E6040) 
and analyzed by Illumina Genome Analyzer II. Duplicate reads were removed to avoid PCR 
bias. Using Bowtie alignment algorithm for Illumina sequence format (version 1.1.2) on the 
Galaxy server 52-54, the sequence datasets were mapped to the mouse genome (NCBI37/mm9). 
Peak detection was performed using MACS1.0.1 55-56 (Genome size 1.87e+9, tag size 36bp, 
cutoff peak detection 1e-5). Chromosomal positions were annotated to the RefSeq/ENSEMBL 
database. To define the distribution of peaks across the genome, we used Bioconductor 
(version 2.9) package ChIPpeakAnno 57 and the build in data set “TSS.mouse.NCBI37”. For 
other features a custom annotation set was created by BioConductor/R package BiomaRt 58.




Enriched genomic regions for Cbx7 and Cbx8 were determined using the empty vector 
(control) ChIP-signal as negative control. In addition, a cross comparison was performed 
were Cbx7 signal served as control for Cbx8 peak calling, and the other way around. This 
comparative analysis determines regions where the ChIP signals are enriched relative to 
control ChIP (empty vector), or to the alternative Cbx protein, by a conditional binomial 
model (75-bp window, 0.1 FDR cut-off). All statistics and plotting were performed in R.
Gene network analysis
Gene expression network analysis of Cbx7 and Cbx8 targets was performed as described 
previously 33 using gene expression data of 4 primary cell subsets (LSK, L-S-K+, Gr1+, Ter119+). 
Probes were defined as differentially expressed during differentiation if (Vmax-Vmin)/
stdev≥4 (p<0.05), assuming normal distribution (3σ). Only transcripts that show significant 
differential expression were subjected to relevance network analysis as described by Voy et 
al. 32. Pearson correlation (r) between each pair of transcripts was measured and transcripts 
with -0.8<r>0.8 were marked as connected. Networks were visualized in Gephi software 
(version 0.8beta) 59 and spatially arranged by built-in Yifan-Hu and Fruchterman-Reingold 
algorithms. A build-in modularity function was used to partition the network into significant 
tight connected communities (‘modules’). Significant differential clustering between Cbx7 
and Cbx8 targets was tested using binomial distribution.
Statistical analysis
Statistical significant differences of growth curves was assessed using ‘compareGrowthCurves’ 
of the statmod software package (R). CAFCs by limiting dilution were calculated by maximum 
likelyhood as described in 60. Other statistical analyses were performed by two-tailed t-tests 
assuming equal variances by SPSS or Excel.
RESULTS
Distinct expression of Cbx family members during hematopoietic differentiation
First, we assessed the expression of Cbx family members in purified hematopoietic subpopulations. 
Cbx7 is highly expressed in long-term HSCs (LT-HSCs), and its transcript levels gradually decreases 
upon lineage commitment (Fig 1a,b). However, Cbx7 is also highly expressed in differentiated 
lymphoid lineages (Fig 1a, Fig S2). The Cbx8 transcript is equally expressed in various primitive 
hematopoietic cells. However, at the protein level, Cbx8 levels increase on lineage commitment, 
indicating a possible role for post-transcriptional regulation 10, 23 . Cbx4 is abundant in most 
hematopoietic cell populations while Cbx2 is rather marginally but ubiquitously expressed (Fig 
1a,b, Fig S2). Notably, of all Cbx family members, the Cbx7 transcript is most abundantly expressed 
in LT-HSCs. These data suggest that the PRC1 complex in HSCs preferentially contains Cbx7.
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Figure 1. Enforced expression of Cbx genes reveals distinct effects on in vitro progenitor and HSC 
potential. A Gene expression of Cbx family members in different hematopoietic cell populations. 
Bars represent mean of 2-3 technical replicates. See Table S7 for raw data. B Protein abundance of 
Cbx2, Cbx7 and Cbx8 in Lin- Sca1+ cKit+ (LSK), Lin- Sca- cKit+ (prog), and Gr1+ cells. C Mean number 
of population doublings (± s.e.m.) for HSPCs overexpressing either control (n=4), Cbx2 (n=3), Cbx4 
(n=3), Cbx7 (n=4) or Cbx8 (n=4). n represents independent experiments, *p≤0.05. See Table S7 for raw 
data. D Mean colony-forming ability (±s.e.m) of Control and Cbx-overexpressed HSPCs (CFU=colony 
forming unit, Control n=15, Cbx2 n=6, Cbx4 n=6, Cbx7 n=18, Cbx8 n=13. n represents independent 
experiments. t-test *p<0.05, #p=0.06). E Secondary colony formation upon replation of individual 
primary colonies (n=50 primary replated colonies per sample) F Mean day-35 CAFC frequencies (±s.d.) 
of Control and Cbx-overexpressed HSPCs (Control (n=10), Cbx2 (n=6), Cbx4 (n=6), Cbx7 (n=13) and 
Cbx8 (n=8). n represents independent experiments. t-test *p<0.05. Uncropped images of blots are 
shown in Supplementary Figure 9a.










Cbx family members affect in vitro self-renewal potential
Since Cbx orthologues compete for integration into PRC1 12-13, overexpression of individual 
Cbx family members can change the composition of PRC1 complexes in favour of inclusion 
of the overexpressed Cbx protein. We overexpressed individual Cbx family members in post-
5FU-treated bone marrow (hereafter referred to as hematopoietic stem and progenitors cells 
(HSPCs)). In cytokine-driven cultures, Cbx7 overexpression results in a strong proliferative 
advantage (Fig 1c) and substantially increases the fraction of cells in the S-G2/M phase, 
without affecting apoptosis (Fig S3a,b). In contrast, Cbx4 or Cbx8 overexpression leads to 
decreased proliferation (Fig 1c, Fig S3a,b), while Cbx2 overexpression does not lead to any 
detectable changes in proliferation (Fig 1c). In liquid cultures, Cbx7 overexpressing HSPCs 
retain an immature blast-like morphology (Fig S3c), whereas the majority of Cbx8 cells 
differentiate into myeloid cells within 10 days (Fig S3c).
To measure self-renewal, cells were plated in methylcellulose-based colony assays, followed 
by whole-dish or single colony replating. Overexpression of Cbx7 substantially increases the 
colony-forming ability. This effect is even more pronounced after replating (Fig 1d). Most 
single Cbx7 colonies have a high replating potential; 15% of the primary colonies can form 
more than 200 secondary colonies (Fig 1e). In contrast, overexpression of Cbx2, Cbx4, and 
Cbx8 results in lower numbers of secondary colonies (Fig 1d,e), indicating diminished self-
renewal.
The effect of Cbx overexpression was further studied in the cobblestone-area-forming-cell 
(CAFC) assay (Fig 1f). Strikingly, Cbx7 overexpression leads to a strong increase (~100-fold) in 
day-35 CAFC activity, which reflects the activity of the most primitive hematopoietic cells. In 
contrast, overexpression of Cbx4 or Cbx8 results in significantly reduced number of CAFCs.
In summary, overexpression of individual Cbx proteins causes distinct effects on self-renewal 
in vitro. Cbx7 is unique among the Cbx members in its ability to stimulate self-renewal in 
vitro.
Cbx family members affect in vivo HSC repopulating potential
Next, we tested the repopulating ability of HSPCs overexpressing Cbx2, Cbx4, Cbx7 or 
Cbx8 in a competitive transplantation setting. Mice transplanted with Cbx2-overexpressing 
HSPCs only showed B-cell reconstitution (Fig S4a), suggesting that Cbx2 has a role in 
lymphopoiesis, but not myelopoiesis. However, HSPCs that overexpress Cbx2, Cbx4 or 
Cbx8 all fail to contribute to long-term hematopoietic reconstitution (Fig 2a), suggesting a 
rapid exhaustion of progenitors and HSCs. In contrast, cells that overexpress Cbx7 have a 
prominent competitive advantage over non-transduced cells, as revealed by high chimerism 
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Figure 2. Cbx7 induces distinct types of leukemia, whereas Cbx2, Cbx4 and Cbx8 induce a competitive 
disadvantage in vivo. Post-5FU treated bone marrow cells from CD45.1 mice were isolated and 
transduced with Control or Cbx-overexpressing retroviral vectors. 4.5-7.5x10^6 freshly transduced 
cells were then transplanted into lethally irradiated CD45.2 mice, without prior sorting for GFP. A 
Post-transplantation chimerism levels of individual mice as measured by the absolute number of GFP+ 
CD45.1+ donor cells in peripheral blood at week 16 (control n=17, Cbx2 n=8, Cbx4 n=7, Cbx8 n=12, 
or at the day of sacrifice (Cbx7 n=22). Line represents average chimerism levels. t-test *p<0.05). B 
Kaplan-Meier survival curve for mice transplanted with control, Cbx2, Cbx4, Cbx7 or Cbx8 transduced 
bone marrow cells (control n=17, Cbx2 n=8, Cbx4 n=7, Cbx7 n=22, Cbx8 n=12). C Spleen and lymph 
nodes from control, and Cbx7-induced leukemic mice. D Representative FACS plots of GFP+ spleen cells 
showing distinct dominant cell populations in Cbx7-induced leukemias. Data from two independent 
transplantation experiment are combined. Gr1/Mac1: mixture of Gr1 and Mac1 antibodies with the 
same fluorochrome.







Out of 22 mice, 20 reconstituted with Cbx7-overexpressing HSPCs developed lethal leukemias 
with variable latencies (Fig 2b-d). Twelve mice were diagnosed with T-cell leukemia. These 
mice showed increased white blood cell (WBC) counts (Fig S4d, Table S1), enlarged lymph 
nodes and splenomegaly (Fig 2c, Fig S4d). Thymus and liver were variably affected (Table 
S1). Cells were CD3ɛ+ (Fig 2d), CD4+, and CD127+, (Fig S4b, Table S1). Interestingly, Cbx7 
protein was found to be elevated in human lymphoid tumors 24. Previously, overexpression 
of Cbx7 in collaboration with c-Myc, in the lymphoid compartment has been shown to cause 
T-cell lymphomas 24. Here, we neither observed upregulation of c-Myc nor of other major 
oncogenes involved in lymphomagenesis (Fig S5).
The second type of leukemia developed with a short latency (~4 weeks for 3 out of 4 mice) 
and was classified as an immature leukemia. Malignant cells did not express any of the 
lineage markers used for analysis (Fig 2d, Fig S4c, Table S1). Peripheral WBC counts were 
increased (Fig S4d, Table S1) and cells showed a blast-like morphology (Fig S4d). Finally, 2 
out of 22 mice developed erythroid leukemias. Spleens were mildly enlarged and one mouse 
showed hemorrhagic lesions in lymph nodes (Fig 2c). Peripheral WBCs and erythrocytes 
were decreased (Fig S4d, Table S1), whereas the number of reticulocytes was increased 
(Fig S4d). In addition, bone marrow and spleen samples revealed numerous erythroid 
precursors at variable stages of maturation (Fig S4d). Malignant GFP+ cells expressed Ter119 
(Fig 2d, Table S1). For two mice it was not possible to determine the leukemia subtype (mice 
number 2 and 20 in Supplementary Table S1).
These results show that Cbx7 has a strong oncogenic potential in vivo, whereas Cbx2, Cbx4 
and Cbx8 all induce HSC exhaustion.
Cbx7 induces self-renewal in multipotent cells, but not in restricted progenitors
As post-5FU bone marrow contains a heterogeneous pool of primitive cells, we investigated 
which specific cell population is responsible for Cbx7-induced self-renewal. We overexpressed 
Cbx7 and Cbx8 in purified LT-HSCs, short-term HSCs (ST-HSCs), multipotent progenitors 
(MPPs), or myeloid progenitors, and compared their effect on the proliferative response 
in these purified populations at the clonal level. Single transduced cells were seeded in 
stromal-free cytokine-supplemented cultures, and colony-forming ability was scored 14 
days later (Fig 3a). Overexpression of Cbx7 enhanced the proliferative capacity of LT-HSCs, 
ST-HSCs and MPPs, but not of myeloid progenitors (Fig 3a). Morphological analysis (Fig 3b) 
showed that many of the Cbx7 colonies consisted of undifferentiated cells. In contrast, Cbx8 
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Figure 3. Cbx7 increases the proliferative capacity of purified multipotent hematopoietic subsets.
A Clonal analysis of the proliferative capacity of indicated purified hematopoietic cells transduced with 
Control, Cbx7 or Cbx8 retrovirus. Single transduced cells were seeded in cytokine rich media and the 
colony size that these cells could produce was scored 14 days later. The figure represents the variability 
in colony forming ability of single cells, scoring 92 cells (n) per independent experiment. Two or three 
independent experiments (m) performed per sample. B The cell type of which the colonies consisted 
at day 14 was assessed using microscopical analysis of the colony itself and MGG-staining of cytospins 
from cells of these colonies. Scale bar, 10μM.
In the FBMD-stromal co-cultures, day35+ CAFC activity is restricted entirely to the most 
primitive LSK CD48- CD150+ cells 25-26. (Fig 4a). However, Cbx7 overexpression induced late 
cobblestone-forming activity also in ST-HSCs and MPPs, but not in myeloid progenitors (Fig 
4a). Cbx8 overexpression in ST-HSC and MPPs fails to induce such an effect.
We transplanted 750 Cbx7-overexpressing LT-HSCs in lethally irradiated recipients. Bone 
marrow analysis 12 months post-transplantation shows a significant increase in the frequency 
of GFP+ ST-HSCs and MPPs, while the absolute number of lineage restricted progenitors 
(common lymphoid progenitors (CLPs) and common myeloid progenitors (CMPs)) and fully 
differentiated cells is reduced (Fig 4b). In contrast, when Cbx8 is overexpressed, lower 
numbers of all GFP+ hematopoietic cell subsets are observed, which indicates exhaustion of 
progenitors and HSCs in vivo (Fig 4b). Importantly, when Cbx7 is overexpressed in myeloid 
progenitors or lymphoid progenitors, these cells do not contribute to hematopoietic 
reconstitution (Fig 4c).
Collectively, these results suggests that Cbx7 overexpression induces self-renewal of LT-
HSCs, ST-HSCs and MPPs, and restricts their differentiation.
Loss of Cbx7 function reduces HSC self-renewal
To address whether the activity of HSCs and progenitors is dependent on Cbx7, we 
downregulated Cbx7 in HSPCs (Fig 5a). Knockdown of Cbx7 results in a proliferative 
disadvantage in liquid culture (Fig 5b), a reduction in their colony forming ability (Fig 5c), 
and a reduced frequency of CAFCs (data not shown). Cbx7 is therefore required for HSC and 
progenitor activity in vitro and other Cbx family members cannot compensate for its loss.
Next, we assessed whether the effect of Cbx7 overexpression on HSCs is dependent on 
its integration into PRC1. A mutant Cbx7 allele was generated in which the Pc-box was 
deleted 27. This abrogates binding to Ring1b and Bmi1 (Fig S6b), and integration into PRC1 
can therefore not occur. However, this mutant is still able to bind chromatin, although less 
efficiently (Fig S6c). In contrast to Cbx7WT, overexpression of Cbx7ΔPc in HSPCs neither results 
in increased proliferative capacity in liquid culture (Fig S6a), nor to increased self-renewal as 
measured by the number of colony forming units (CFUs) (Fig 6a). Furthermore, Cbx7ΔPc does 
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not lead to an increased frequency of day-35 CAFC activity (Fig 6b) and transplanted Cbx7ΔPc 
HSPCs fail to contribute to hematopoietic regeneration (Fig 6c). We reason that Cbx7ΔPc acts 
in a dominant-negative manner by binding to target loci independently of PRC1, thereby 
blocking binding of endogenous PRC1 complexes.
Cbx proteins target PRC1 to chromatin by their chromodomain which recognizes H3K9/27me3 
14-17. To study whether Cbx7-induced self-renewal is dependent on recognizing this histone 
mark, a chromodomain-mutant (Cbx7AA) was generated 27. This amino-acid substitution 
abrogates binding to chromatin (Fig S6c), but it retains the ability to bind PRC1 components 
Bmi1 and Ring1b (Fig S6b). It therefore competes with endogenous Cbx proteins. Cbx7AA, 
like Cbx7ΔPc, acts in a dominant-negative manner because its overexpression results in a 
severe impairment of in vitro clonogenicity (Fig 6a), self-renewal (Fig 6b), as well as in vivo 
repopulating ability (Fig 6c).
We verified whether perturbations of Cbx gene expression change the molecular 
composition of the PRC1 complex. Using Flag immunoprecipitation, we show that the core 
PRC1 component, Ring1b, interacts with both overexpressed Flag-Cbx7 and Flag-Cbx8 (Fig 
6d). Both Pcgf family members, Bmi1 and Mel18, bind equally to Cbx7 and Cbx8 (Fig 4d), 
suggesting equal capabilities of overexpressed Cbx7 and Cbx8 to integrate into endogenous 
PRC1. As expected, binding between Cbx7 and Cbx8 was not detected. (Fig 6d). In addition, 
chromatin immunoprecipitation (ChIP) data show dissociation of endogenous Cbx8 from 
the Ink4b-Ink4a-Arf locus upon overexpression of Cbx7, and vice versa (Fig S7a-b).
These data support the notion that Cbx7 is required for self-renewal and that the 
contrasting phenotypes after overexpression of Cbx proteins are caused by compositional 
rearrangements of PRC1.
Cbx7 and Cbx8 functional targets
As Cbx7 was the only Cbx family member inducing self-renewal, we hypothesized that Cbx7 
and Cbx8 bind to different genomic loci. Cbx8 was selected because its protein expression is 
reciprocal to Cbx7 and its overexpression showed a striking contrasting phenotype.
We evaluated whether Cbx7 and Cbx8 affect Ink4b-Ink4a-Arf, because studies have 
implicated that phenotypes of Bmi1 are, partially, dependent on this locus 28-29. We show 
that both Cbx7 and Cbx8 bind throughout this locus (Fig 7a,b, Fig S7a,b,d) which is enriched 
for H3K27me3 as evidenced by ChIP experiments (Fig S7c-d). No changes in expression 
of p15, p16 and p19 were observed (Fig S7e). Therefore, the contrasting HSC phenotypes 
induced by Cbx7 and Cbx8 are not explained by differential capabilities to repress this locus.
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Figure 4. Cbx7 induces self-renewal of LT-HSCs, ST-HSCs and MPPs, but not of lineage restricted 
progenitors. A CAFC frequencies of purified LTHSCs, STHSCs, MPPs or myeloid progenitors, transduced 
with indicated vectors. Cells were plated in limiting dilution (1,3 and 10 cells/well), after which 
the average number of CAFC (± 95 per cent confidence interval) is calculated as described in 59. B 
Phenotypical analysis of the bone marrow compartment of mice that were transplanted 12 months 
earlier with LT-HSCs that overexpress either Control (n=5), Cbx7 (n=5) or Cbx8 (n=3). Fig represents 
average (±s.e.m.) number of absolute GFP+ cells in the bone marrow of the indicated phenotype. 
n represents individual mice. t-test *p<0.05, #p<0.10. See Table S7 for raw data. C Chimerism levels 
as indicated by the percentage of GFP+ cells in the peripheral blood 24-weeks post transplantation. 
Mice were transplanted with either 750 Cbx7-overexpressing (GFP+) LT-HSCs (LSK, CD48-, CD150+), 
myeloid progenitors (LSK-,) or CLPs (Lin- Scamid cKitmid CD127+). Symbols represent chimerism levels 
of individual mice.
ChIP-sequencing (ChIP-seq) of Flag-precipitated DNA was used to identify genome-wide 
Cbx7- and Cbx8-binding sites in primary HSPCs. Analysis of Cbx8 ChIP-seq relative to 
empty vector (control) revealed a total of 7649 peaks, of which 7091 peak positions could 
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sequencing depth was comparable (31.9x106 reads for Cbx7 versus 29x106 reads for Cbx8), 
substantially fewer peaks were identified for Cbx7; 3621 peaks were called, of which 3225 
could be annotated, mapping to 2768 genes (Supplementary Information). Cbx7- and Cbx8-
enriched regions are predominantly found at the transcription start site (Fig 7c,d).
Figure 5. Cbx7 is required for HSPC self-renewal. A RT-qPCR analyses of Cbx7 mRNA expression in 
HSPCs transduced with Scrambled (Scr) and Cbx7 short hairpin (shCbx7) lentivirus. Expression was 
normalized to Hprt (n=3 independent experiments, mean±s.d.). Insert: Western blot analysis of 
HSPCs transduced with control and shCbx7 lentivirus. Actin was used as loading control. B Number 
of population doublings for HSPCs in which Cbx7 was downregulated (shCbx7) or HSPCs transduced 
with Scr lentiviral vector (n=3 independent experiments, mean±s.d., t-test p=0.08) C Colony-forming 
ability of Control (Scr) and Cbx7-downregulating HSPCs (CFU=colony forming unit, n=3 independent 
experiments, mean±s.d., t-test *p<0.05). See Table S7 for raw data.
Most identified targets were common for Cbx7 and Cbx8 (Fig 7e). Cross-comparison of Cbx8 with 
Cbx7 (using Cbx7 ChIP-seq signal as the background for Cbx8 peak calling), showed that of the 
5590 Cbx8 target genes, only 291 genes were not bound by Cbx7, and thus are unique for Cbx8 
(Fig 7e). Only 29 unique Cbx7 target genes were identified (Fig 7e). 
We assessed the quantitative differences of Cbx binding by counting the number of tags per peak 
on shared Cbx7 and Cbx8 loci (Fig 7e) (Supplementary Information). As we used the same antibody 
for ChIP-seq and the total read counts were comparable between Cbx7 and Cbx8, we reason that 
the number of tags per peak reflects the strength of occupancy on a particular genomic location, 
although we cannot exclude some extent of technical noise. For most overlapping loci, the number 
of tags per peak was consistently twice as high for Cbx8 as for Cbx7, suggesting that Cbx8 has a 
stronger overall affinity towards chromatin binding. This notion is further supported by the fact that 
Cbx8 has more targets than Cbx7 (5590 vs. 2768 respectively). However, on some genomic positions 
(Fig 7e), corresponding to 186 genes, the number of tags per peak was significantly higher for Cbx7.



































































Figure 6. Cbx7-induced self-renewal requires PRC1 integration and H3K27me3 binding. A Primary 
and secondary colony forming ability of (post 5-FU) HSPCs transduced with control, Cbx7WT, Cbx7 
chromodomain-mutant (Cbx7AA), and Cbx7 Pc-box deletion (Cbx7ΔPc) vectors (n=4 independent 
experiments, mean±s.e.m., t-test *p<0.05). See Table S7 for raw data. B Day-35 CAFC frequencies 
of control, Cbx7WT, Cbx7AA and Cbx7ΔPc bone marrow cells. n=4 independent experiments, 
mean±s.e.m., t-test *p<0.05. See Table S7 for raw data. C Post-transplantation chimerism levels as 
measured by the absolute number of GFP+ CD45.1+ donor cells in peripheral blood at week 12. Symbols 
represent chimerism levels of individual mice (Control n=7, Cbx7WT n=7, Cbx7AA n=5, Cbx7ΔPc n=2), 
line represents average chimerism levels. t-test *p<0.01, #p<0.06). D Endogenous Polycomb proteins 
bind ectopically expressed flag-Cbx7 and flag-Cbx8. Five percent of input was used as loading control. 
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Collectively, Cbx7 and Cbx8 share most of their targets. Only 291 unique Cbx8 targets 
and 29 unique Cbx7 targets were identified. Together with the 186 targets that showed 
quantitatively stronger binding by Cbx7, these genes are likely to account for the opposite 
phenotypes observed on HSCs (Fig 7e, Table S2, Fig S9a,b). Differential Cbx7 and Cbx8 targets 
contain oncogenes, differentiation-specific genes, cell-cycle regulators and transcription 
factors (Table S3).
Cbx7 and Cbx8 targets are co-regulated during HSC differentiation
PcG-induced cell specification in the hematopoietic system is more likely orchestrated by 
changes in gene networks composed of signaling molecules, chromatin modifying complexes 
and transcription factors, rather than by changes in the expression of a few individual genes. 
Therefore, we investigated whether any of the Cbx7 and Cbx8 targets exhibit correlated 
expression changes along HSC differentiation.
Expression data for the 215 Cbx7 and 291 Cbx8 targets were extracted from published 
transcriptome data in which four distinct hematopoietic cell stages (HSCs, progenitors, 
erythroid precursors and granulocytes) in two genetically distinct strains of mice were 
profiled (23 different micro-arrays, n=5/6 for each cell population) 30. From these data gene 
networks were constructed 31 consisting of 33 Cbx7 and 85 Cbx8 targets that collectively 
showed correlated expression along hematopoietic differentiation (Fig 7f, Table S4).
Three highly connected subnetworks (modules) were identified. (Fig 7f). In module 1, most 
genes that are coordinately repressed in HSC and become up-regulated in progenitors are 
Cbx7 targets (Fig 7g, Table S4). This is in agreement with the transcriptional repressive 
function of highly expressed Cbx7-PRC1 complexes in HSCs. Among them, NPM1 is a regulator 
of the ARF/p53 pathway, and loss-of-function mutations, deletions and translocations have 
been associated with acute myeloid leukemia 32-33. Within the same module, genes that 
show reciprocal expression changes during differentiation are mostly Cbx8 targets. These 
targets become repressed upon the transition from HSCs into progenitors. Bcl11a and Rlf 
show many connections with other genes in this module, and are therefore putative major 
regulators. Bcl11a expression is found to be down-regulated during differentiation, and its 
overexpression has been associated with leukaemogenesis 34-35.
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Figure 7. Cbx7 and Cbx8 targets are coordinately regulated during HSC differentiation and show 
reciprocal expression patterns. A Schematic representation of the mouse Ink4b-Ink4a-Arf locus 
and primer pairs used for chromatin immunoprecipitation (ChIP) analysis in (B). B Binding of Cbx7 
and Cbx8 to the Ink4b-Ink4a-Arf locus assessed by flag-ChIP. Bars represent mean of 2 independent 
experiments. See Table S7 for raw data. C Diagram illustrating the overall distribution of Cbx7 and Cbx8 
binding sites on TSS (±1 kb), promoter (-1 to -5 kb), miRNA, exon+UTR, intron and intergenic regions. 
D Localization of Cbx7 and Cbx8 ChiP-seq peaks relative to nearest TSS. E Schematic representation 
illustrating data analysis of flag ChiP-sequencing. F Graphic representation of the gene network of 
Cbx7 and Cbx8 targets that show correlated gene expression changes during HSC differentiation. 
Expression of the 215 Cbx7 and 291 Cbx8 target genes was extracted from transcriptome data of four 
distinct hematopoietic cell populations (HSCs (L-S+K+), progenitors (L-S-K+), erythroid cells (Ter119+) and 
granulocytes (Gr1+). Green nodes represent Cbx7 targets, grey nodes represent Cbx8 targets. Node 
size corresponds to the number of significant correlations of gene expression of a particular gene 
with other genes. Lines between nodes represent positive (red) or negative (blue) correlations of 
gene expression during hematopoietic differentiation. G Module 1 within the network represents one 
of the strongest connections within the total network. Right panels: Genes (represented by nodes) 
are clustered on basis of similarities in gene expression profiles and plotted in two graphs that show 
an inverse expression pattern along hematopoietic differentiation (L-S+K+ HSCs, L-S-K+ progenitors, 
erythroid cells (Ter119+), granulocytes (Gr+)). Green lines represent expression changes of Cbx7 targets, 
grey dotted lines of Cbx8 targets. Raw expression data can be found in Table S4.
Module 2 represents a sub-network (Fig S8c) of genes specific for myeloid differentiation 
that almost exclusively consists of Cbx8 targets. These genes show repression upon the 
transition from HSCs into progenitors and become highly up-regulated during myeloid 
differentiation (Fig S8c, Table S4). This myeloid network is negatively regulated by a single 
Cbx8 target; Gfi1b. Gfi1b is a well-known transcription factor and plays a critical role in the 
control of erythropoiesis and megakaryopoiesis 36-38. Strikingly, two Cbx7 targets, Sfpq and 
Ube3c, also negatively regulate the Cbx8 myeloid specific gene network and show reciprocal 
gene expression patterns (Fig S8c).
Finally, module 3 contains genes differentially expressed in erythroid cells. Genes that 
become down-regulated during differentiation from stem to progenitor to erythroid cells 
represent predominantly Cbx8 targets, whereas genes with a reciprocal expression pattern 
are enriched for Cbx7 targets (Fig S8d, Table S4).
Our approach shows that Cbx7 and Cbx8 targets are negatively co-regulated during HSC 
specification. Generally, genes bound only by Cbx8 are higher expressed in HSCs and become 
repressed during differentiation into progenitors, indicating that Cbx8 selectively targets 
HSC-specific genes. In turn, Cbx7 targets show the opposite expression pattern. Therefore, 
Cbx7 might induce HSC self-renewal by repressing progenitor-specific genes.





During evolution, the number of genes encoding Polycomb proteins have expanded, which 
has resulted in structural and functional diversification of PRCs. Here, we studied the role 
of different PRC1-associated Cbx family members in HSC regulation. Cbx family members 
show distinct hematopoietic cell-stage-specific expression patterns, which allows for the 
formation of variant PRC1 complexes during hematopoietic differentiation. As Cbx7 is 
highest expressed in the most immature hematopoietic populations, the PRC1 complex in 
HSCs preferentially contains Cbx7. PRC1 complexes containing Cbx7 induce self-renewal 
of HSCs by repressing the expression of progenitor-specific genes. Other Cbx proteins can 
compete with Cbx7, resulting in Cbx2-, Cbx4-, or Cbx8-containing PRC1 complexes that 
target HSC-specific genes and thereby induce entrance into the differentiation pathway. We 
suggest that stoichiometric fluctuations between PRC1 complexes containing different Cbx 
family members play a key role in balancing self-renewal and differentiation of HSCs (Fig S1).
Diversification of Polycomb genes might also account for tissue-specific stem cell functioning. 
Whereas we show that Cbx7 is the most important Cbx family member in HSCs, in epidermal 
stem cells Cbx4 plays this essential role 39. It remains to be determined which of the Cbx 
family members are required for other types of adult stem cells. Recently, Cbx7 has been 
identified as an embryonic stem cell (ESC) pluripotency factor 8,10. So far, genes that have 
been associated with ESC pluripotency, including Oct4 and Nanog, have been very distinct 
from genes required for self-renewal in adult stem cells. To our knowledge Cbx7 is the first 
gene important for self-renewal in both ESC and adult stem cells, which indicates that the 
molecular mechanism by which it exerts its activity might be conserved during ontogenesis.
In search for such a mechanism, we compared targets that we identified in HSCs with Cbx7 
targets previously identified in ESCs 8. This ESC-HSC cross-comparison revealed 600 common 
targets which represent approximately 25% of all Cbx7 targets in ESCs (2349) 8 and HSCs 
(2768) (Table S5). Interestingly, we identified 133 transcription factors, many of which 
are members of the same family (e.g. 12 Fox genes, 14 Hox genes and 3 Sox genes) (Table 
1, Table S6). In addition, Cbx7 ECS-HSC targets include Fgf and Eph receptors and genes 
involved in Wnt signaling. We hypothesize that Cbx7-regulated control of these genes is a 
core element of self-renewal.
Our data support the notion that the balance between self-renewal and differentiation, 
which constitutes a key hallmark of HSCs, is regulated by the molecular composition of 
the PRC1 complex. Therefore, genetic or pharmacologic perturbation of the composition 




Table 1: GO-analysis of genes targeted by Cbx7 in both ESCs and HSCs
* numbers in parentheses represent the number of identified gene family members
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SUPPLEMENTARY FIGURES
Figure S1. PRC1-Cbx control of HSC fate decisions. Model summarizing the findings in this paper. 
Polycomb Cbx orthologs compete for PRC1 integration and balance HSC self-renewal and differentiation. 
Cbx7-containing PRC1 complexes induce self-renewal of HSCs by repressing the expression of 
progenitor-specific genes. Other Cbx proteins can outcompete Cbx7 from PRC1, resulting in Cbx2-, 
Cbx4-, or Cbx8-containing PRC1 complexes that target HSC-specific genes and thereby induce entrance 
































Figure S2. Protein abundance of Cbx orthologs in differentiated hematopoietic cells. Western blot 
analysis of protein abundance of Cbx2, Cbx7 and Cbx8 in granulocytes (Gr1+), B cells (B220+) and T- 
cells (CD3e+). Actin was used as loading control. Also see Figure S9.
Figure S3. Effect of Cbx7 and Cbx8 overexpression on the cell-cycle. Post 5FU treated bone marrow 
cells were transduced with Control or Cbx-overexpressing retroviral vectors. GFP+ HSPCs were plated 
in cytokine-supplemented media and at day 10 cells were used for apoptosis assays, cell-cycle analysis 
and cytospins. A Apoptotic frequency of control, Cbx7 and Cbx8 bone marrow cells using FACS analysis 
of annexin-V and 7AAD positive cells. One representative FACS plots is shown from 3 independent 
experiments. B Cell cycle analysis by measurement of DNA content in control, Cbx7 and Cbx8 HSPCs (n=2 
independent experiments, mean±s.d.). C May-Grünwald Giemsa staining of control, Cbx7 and Cbx8 cells. 
One representative image is shown. Scale bar 10μM. Also see Table S7 for raw data.
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Figure S4. Cbx7-induced leukemia subtypes. A Analysis of lineage contribution of transplanted HSPCs 
transduced with Control, Cbx2, Cbx4 and Cbx8 retrovirus, 16 weeks post-transplantation. n=7-9 individual 
mice, mean±s.e.m. B FACS plot example of spleen cells from a mouse (mouse9 suppl table 1) with (CD3+, 
CD4+, CD127+) T-cell leukemia. Cells within CD45.1+, GFP+ fraction are shown. C Staining of spleen cells 
of mouse 14 (suppl table 1) with an immature leukemia type with CD3, CD127, CD71 and CD16/32. 
Cells within CD45.1+, GFP+ fraction are shown. D May-Grunwald-Giemsa staining of cells in peripheral 
blood, bone marrow, and spleen of control mice and Cbx7 mice with indicated leukemia subtypes. One 
representative image is shown for every condition. Scale bar 10μM.
Figure S5. Oncogene expression in Cbx7-induced lymphoid leukemias. Relative gene expression of Cbx7, 
c-Myc, Evi-1, Lmo2 in spleen cells from individual Control (n=3) and T-cell leukemic mice (n=5). Gapdh was 
used for normalization.





















































































Figure S6. Cbx7-induced HSC self-renewal is Polycomb dependent. A Population doublings of HSPCs 
overexpressing Cbx7WT, flag-Cbx7AA, and flag-Cbx7ΔPc . Bars represent mean from 2 independent 
experiments. B Flag-immunoprecipitation of Ring1b and Bmi1 with flag-Cbx7WT,
flag-Cbx7AA, and flag-Cbx7ΔPc in 32D cells. One representative experiment is shown from two 
independent experiments. Also see Figure S9. C Binding of Cbx7WT, flag-Cbx7AA, and flag-Cbx7ΔPc 
to the transcription start site of Ink4a. HSPCs were transduced with indicated vectors. Chromatin-
immunoprecipitation was then performed using Flag-M2 agarose beads and H3K27me3 antibodies 
coupled to sepharose beads. IgG was used as negative control. Pulled down DNA was purified and 
binding to Ink4a was assessed using qPCR. Bars represent mean from 2 independent experiments. 































































































































Figure S7. Cbx7 and Cbx8 bind the senescence locus. A-D Post-5FU treated bone marrow cells transduced 
with Control or Cbx-overexpressing retroviral vectors were sorted based on GFP expression and cultured 
for 7 days in cytokine-supplemented media. Next, ChIP was performed in control, Cbx7 and Cbx8 bone 
marrow cells using indicated antibodies. Numbers correspond to the Ink4b-Ink4a-Arf primer pairs used 
for qPCR, as shown in Figure 4a. Bars represent mean from 2 independent experiments. E Relative 
expression of p15, p16 and p19 after Cbx7 and Cbx8 overexpression in bone marrow compared to control, 
as determined by rt-PCR. Expression was calculated according to ddCT of Gapdh. Bars represent mean 
from 2 independent experiments. Also see Table S7 for raw data.
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Figure S8. Cbx7 and Cbx8 targets and gene network. A Representative examples of ChIP-seq results 
in Control, Cbx7-overexpressed and Cbx8-overexpressed bone marrow cells. The y-axis of the binding 
profiles indicates tag counts. B Validation of ChIP-seq targets by flag-ChIP, Cbx7-ChIP and Cbx8-ChIP 
followed by qpcr. Flag-ChIP and Cbx-ChIPs represent independent experiments. Npm1 and Sfpq are Cbx7 
targets (either not bound by Cbx8, or stronger bound by Cbx7 than by Cbx8), Sp3 and Ptprc are specific 
Cbx8 targets. Actin was used as a negative control locus. Also see Supplementary Table 7 for raw data. 
C Module 2 represents a myeloidspecific sub-network within the network. D) Module 3 represents an 
erythroid specific sub-network. Right panels of C and D: Genes (represented by nodes) are clustered on 
basis of similarities in gene expression profiles and plotted in two graphs that show an inverse expression 
pattern along hematopoietic differentiation (L-S+K+ HSCs, L-S-K+ progenitors, erythroid cells (Ter119+), 
granulocytes (Gr+)). Green lines represent expression changes of Cbx7 targets, grey dotted lines of Cbx8 
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ABSTRACT
Our current understanding of the dynamics of tumor development and heterogeneity is still 
very limited, although this is highly relevant for existing and future therapeutic interventions. 
Although currently under debate, tumors were long thought to evolve in a linear fashion, 
as a single cell acquired progressive mutations that advanced its proliferative rate. In this 
study, using a barcoding tool combined with overexpression of a novel (proto-) oncogene, 
Cbx7, we show that the origin and nature of leukemias is more complex than previously 
anticipated. Different clones with distinct leukemic properties can coexist in a single mouse, 
resulting in oligoclonal leukemias. We document the existence of dormant clones with 
leukemic potential. These dormant LSCs can progress to full-blown leukemia at ‘relapse’, 
after serial transplantations. In addition, we show that some LSC clones retain multilineage 
differentiation capacities, where one LSC clone can induce multiple phenotypically distinct 
leukemias at ‘relapse’. Thus, phenotypically distinct leukemias can have similar clonal 
origins. Clinically, the existence of multiple leukemic clones, with distinct biological behavior, 
suggests that combination therapy, rather than single-agents will be required to eradicate 
both dominant and dormant clones that otherwise may emerge at relapse.
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INTRODUCTION
Leukemias are clonal proliferative diseases that arise from HSCs or progenitors that failed to obey 
normal regulatory signals which should restrict their self-renewal. Sequential ‘linear’ acquisition of 
mutations in tumor suppressor genes or oncogenes has long been thought to drive leukemogenesis, 
as postulated in the original clonal evolution hypothesis 1-3. However, the use of advanced genomic 
techniques to investigate clonal diversity and evolution, now shows that tumors might be organized 
in a non-linear, branching hierarchy 4-8.
Only a subfraction of cells within the leukemic cell population, termed leukemic stem cells (LSCs), 
or leukemia-initiating cells (LICs), possesses the ability to initiate and sustain disease 9-10. The 
first publications demonstrating heterogeneity within the LSC population utilized the detection 
of viral integration sites after transduction of acute myeloid leukemia (AML) cells, and showed 
that LSCs differ in their self-renewal capacities after transplantation in immunodeficient mice 
11. More recently, Anderson et al., employed fluorescence in situ hybridization (FISH) to monitor 
translocations and copy number alterations to investigate genetic heterogeneity within pediatric 
acute lymphoblastic leukemia (ALL) 6. By assembling a putative ancestral evolutionary tree, 
encompassing the frequencies of genetic abnormalities found in a patient sample, they concluded 
that clones displayed variegated genetic abnormalities, which are likely to be inherited in a non-
linear branching manner 6. Although the resolution of this FISH-based method to identify subclonal 
heterogeneity remained limited, it clearly provided a paradigmatic proof-of-principle. Deep 
sequencing genomic DNA or RNA (exome sequencing) of malignant cells from patients, provides 
the highest possible resolution for identification of mutations or other genetic abnormalities 
within a tumor. Such attempts have been made to assess clonal heterogeneity in leukemic 
patients 12-14. Although potentially very powerful, these large datasets require the establishment of 
mathematical models and complex statistics to define subclones within populations of cells. Such 
mathematical models require the assumption of genetic stability of mutations and translocations, 
while genomes of cancers are generally instable. In addition, it remains difficult to distinguish 
which genetic abnormalities are causal to disease progression and which are irrelevant passenger 
mutations. Indeed, many mutations that may be used to identify subclones, have been suggested 
to be irrelevant for disease-progression 15. Although these studies all highlight a potential complex 
genetic architecture of leukemia, unambiguous detection of leukemic clones remains difficult to 
achieve.
One of the most important questions in understanding leukemic progression remains the nature 
and number of different LSCs, and their subclones within an individual cancer. Next, it remains 
unknown to what extent different subclones can contribute to disease progression and potential 
relapse. It has been shown that some LSCs might be quiescent 11, while these formerly quiescent 
cells can become active at relapse. It is now generally believed that distinct leukemic clones exhibit 
The dynamic behavior and cellular evolution of multilineage leukemias induced by the Polycomb group protein Cbx7
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a distinct response to therapeutic interventions, reinforcing the relevance to assess the functional 
consequences of clonal heterogeneity within a leukemia. In order to approach this question, 
distinct subclones must be distinguished during disease development with (ultra-)high resolution. A 
recently described method, which would potentially accomplish exactly this, is the marking of cells 
by the introduction of a unique, heritable mark that can be detected in its offspring experimentally 
16-21. These methods rely on the viral integration of a random “barcode” sequence of fixed length 
in the genome of target cells. After transplantation of barcoded cells, the population and their 
offspring can be traced by quantifying the abundance of unique barcodes using deep sequencing.
Very recently, we have shown that retroviral overexpression of the Polycomb PRC1 member Cbx7 
in bone marrow cells causes leukemia 22. While typically a single oncogene causes one specific 
tumor type, the epigenetic modifier Cbx7 causes a wide spectrum of leukemias including T-ALL, 
erythroid and undifferentiated leukemias. By implementation of a barcoded Cbx7 overexpression 
vector, we have now generated a mouse model in which Cbx7 serves as the initial leukemic ‘hit’ and 
every pre-LSCs is uniquely labelled. We show how our approach allows for the identification of LSC-
derived clones in the transplanted primary and secondary recipients. We describe clonal dynamics 
in mice that will succumb to leukemia. In addition, we document that minor clones with different 
leukemic potential can co-exist in a relatively clonal leukemia and that clonally-related leukemic 
cells can show lineage conversion. Both phenomena can result in variegated disease. Beyond a 
detailed insight into Cbx7-driven leukemic biology, our model will be highly relevant for the study 
of tumor dynamics and clonal evolution.
METHODS
Mice
C57Bl/6 (CD45.2) were purchased from Harlan. C57Bl/6.SJL (CD45.1) mice were bred, and all 
animals were housed at the Central Animal Facility of the University of Groningen. All animal 
experiments were approved by the Groningen University Animal Care Committee.
Construction of barcoded vector libraries
The SF91 vector was kindly provided by Prof C. Baum (Hannover Medical 
School, Hannover, Germany). The barcode linker was created by annealing two 













Primers were dissolved in 0.5× ligation buffer (Fermentas) at a concentration of 100μM. 
After heating the mixture for 5 minutes at 95°C, primers were allowed to anneal at gradually 
decreasing temperature. The annealed barcode linker was ligated into the BsrGI-BamHI 
site of the SF91-empty vector (Figure 1A), or the Cla1-BsrGI or in BamHI-BstBI site of the 
SF91-Cbx7 vector at equimolar ratio. The resulting vector was transformed into 10-beta 
competent Escherichia coli cells (New England Biolabs) and grown overnight on LB plates 
supplemented with 50 μg/mL ampicillin (Sigma-Aldrich). Colonies were pooled by flushing 
plates with LB supplemented with 50 μg/mL ampicillin. After overnight culture, plasmid 
DNA was extracted with the use of the GenElute HP Plasmid Midiprep Kit (Sigma-Aldrich).
Figure 1. Construction and validation of barcoded vector library. A Insertion of the barcode linker 
into retroviral vectors SF91 and MIEV. The linker contains a variable sequence part that consists of 
pairs of degenerate nucleotides (N or S) flanked by fixed triplets. The crude PCR sequence trace of the 
resulting vector batch suggests the random insertion of nucleotides at N and S positions.  B The vector 
library, created by combining approximately 800 bacterial clones, was retransformed into Escherichia 
coli. By combining the sequence traces of the 88 resulting clones, the crude PCR sequence trace could 
be reconstructed.























Validation of barcode vector library
Random sequence tags or ‘barcodes’ were generated by annealing 2 synthetic 
oligonucleotides consisting of sets of random nucleotides separated by fixed triplets 19. 
The resulting double-stranded linker was then ligated into the retroviral vector (Figure 
1A). Although in theory more than 4 million possible linker variants could be generated, in 
practice the number of variants was restricted to the number of bacterial clones generated 
on transformation. From each resulting vector library, barcode sequences were amplified 
with primers directed against internal vector sequences, after which the resulting mixture 
of equal-sized PCR products was sequenced. The resulting crude sequence traces suggested 
that a largely random mixture of sequence tags was generated, because N and S positions 
were found to be essentially equal in all 4 (A, T, C, and G) or 2 channels (C and G), respectively 
(Figure 1A). To validate the complexity of the prepared barcode libraries, we transformed 
a high complexity vector batch (created by combining 800 bacterial clones) back into E. 
coli and performed monoclonal sequence analysis. Of 88 sequencing trials, 78 represented 
unique barcodes. By combining in silico the sequence traces of all 88 trials the crude 
PCR sequence trace could be reconstructed (Figure 1B), confirming that the insertion of 
nucleotides at each variable position was close to random. Together, these data confirmed 
that the generated vector libraries are indeed composed of vectors marked with randomly 
generated barcodes.
Retroviral transduction of bone marrow cells
Post 5FU primary BM cells were transduced as previously described 19, 22-23. Briefly, Phoenix 
ecotropic packaging cells were cultered (75cm2 filter flasks, Greiner Bio-One) and transfected 
in 3.5-cm wells with 1 μg of barcoded vectors containing about 200-300 barcodes. Virus-
containing supernatant harvested 24 and 48 hours later was used to transduce 7.5 × 105 
BM cells per 3.5-cm well. Transduction efficiencies were determined by flow cytometry (BD, 
LSR-II) and varied between different experiments.
Bone marrow transplantation
Freshly transduced HSPCs (4.5-7.5 x10^6; CD45.1) were transplanted into lethally irradiated 
(9.0 Gy) CD45.2 mice, without prior GFP sorting. The relative contribution of transduced 
cells (GFP+) to different hematopoietic lineages in the blood, was determined by blood 
withdrawal from the retro-orbital plexus at indicated time points, as described previously 22.
At clear signs of morbidity, blood was taken from the orbital plexus. Sick mice, were 
euthanized and bone marrow cells were isolated by crushing femurs, tibiae and pelvic 
bones. Single-cell suspensions were prepared from the spleen. Blood, bone marrow and 
spleen cells were analyzed as described previously 22. For serial transplantation experiments, 




Barcode recovery and identification
Genomic DNA was extracted from purified blood, bone marrow and spleen cells with the use 
of the REDExtract-N-Amp Tissue PCR Kit (Sigma-Aldrich) followed by a clean-up step using 
the Nucleospin Plasma XS kit (BioKe, Macherey-Nagel). Individual samples were amplified 
using unique multiplexing primers, containing a sample tag, directed against the internal 
EGFP vector sequence (eGFP forward) in combination with a uniform SF91 WPRE reverse 
primer (5’-CCCTAAAAATGTAAATGATTGCCCCACC-3’). 35-cycle amplification was performed 
using DreamTaq Green mastermix (Fermentas). Each barcode sample was amplified in 
duplicate and the mixture of equal-sized PCR products was pooled and purified (Roche, High 
Pure PCR Cleanup Micro Kit). Next, products were phosphorylated using polynucleotide 
kinase (Fermentas) at 37C for 30 minutes, after which an additional round of purification 
was performed. Sequencing was performed using an Illumina HiSeq2000 sequencer in the 
sequencing facility of University Medical Centre Groningen (using FASTQ format Illumina 1.3+).
In addition to deep sequencing, barcodes from gDNA from selected samples 
were amplified using eGFP forward 5’-CTGCCCGACAACCACTACCTG-3’; and 
SF91 WPRE reverse, 5’-CCCTAAAAATGTAAATGATTGCCCCACC-3’) or LTR reverse 
5’-GCCTTGCAAAATGGCGTTACTGC-3’, individually purified, subcloned into pCR4-TOPO-TA 
(Invitrogen) and transformed into 10-beta competent E coli cells (New England Biolabs).
Analyses of barcodes were performed using Sanger sequencing.
Deep sequencing data processing and noise filtering
Different sequence runs comprised up to approximately 200 samples per batch. Raw FASTQ 
sequence data underwent multiple rounds of filtering to remove low quality reads using 
custom-written scripts in Perl (v5.14.2), Bioconductor (2.11) in conjunction with R (2.15). 
Scripts are available upon request. All high quality sequences were compressed into a set 
of unique sequences, where frequencies of all unique sequences were counted. Sequences 
occurring only once (singletons) were removed.
Within the remaining reads, all identical reads were pooled and their frequencies were 
counted. Unique reads were split on the basis of exact match to 8-9nt of the sample tag of 
the forward primer and its 5’ flanking sequence (13 nt total), resulting in a list of all reads 
that belong to one experimental sample (sample sets). Within each sample set the data were 
sorted in descending order on the basis of frequencies. Barcode sequences were extracted 
by calculating the position of the sample tag, primer length, and remaining distance to the 
first variable barcode position, using Python. This included the full length variable region 
of the barcode, plus the 5 base-long flanking sequences from both ends of the barcode. 
In each data set, barcodes were pairwise compared (in descending frequency order) for 
similarity using Levenshtein distance algorithm (Python-Levenshtein 0.10.2 package). 
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5
120
Infrequently occurring barcodes with a distance 0 or 1 were considered as sequence errors 
and not considered for analysis 21, 24. In addition, samples for which in total less than 125 
reads were recovered, were considered as failed and removed.
The top 100 unique sequences from each sample set were used to create a combined set 
(tables) of experimental data for each transplantation experiment. Within each experimental 
set sequences were checked for presence of barcode sequence, and only those that carried 
a recognizable barcode structure were taken into consideration. In each experimental 
dataset a 1% cut-off for cumulative barcode frequency was used: all barcodes exceeding 
this 1% threshold were taken for further analysis. The barcode that was most frequently 
found among all samples from one transplantation experiment was numbered barcode #1, 
the second most frequently appearing barcode was numbered barcode #2, etc.
Statistics
In case of multiple vector integration, a clone can be composed of multiple barcodes. 
In that case, two or more barcodes will be found in approximate equal ratios (‘linked 
barcodes’) in all analyzed samples within a specific transplantation experiment. The 
presence of linked barcodes due to multiple vectors integrating in a single cell was tested 
using a custom script in Python employing the Bray-Curtis spatial distance metric from Scipy 
(http://docs.scipy.org/doc/scipy/reference/spatial.distance.html). We tested whether 
fluctuations of barcodes in different samples from the same transplantation experiment 
occured by random using Monte Carlo modelling with maximal 30% fluctuations and an 
average dataset of 12. The expected frequency of multiple hits was calculated using Poisson 
distribution and provided as p-values. All linked barcodes with p<0.05 were considered as 
coming from the same clone.
RESULTS
Overexpression of Cbx7 in bone marrow induces different types of leukemia
Overexpression of the Polycomb member Cbx7 in post-5FU bone marrow cells (which include 
hematopoietic stem and progenitor cells; HSPCs) has been shown to induce multiple leukemia 
subtypes 22. These leukemias were characterized by morphological and immunophenotypic 
analyses of cells isolated from various hematopoietic tissues such as blood, bone marrow, spleen 
and lymph nodes.
The majority of mice transplanted with Cbx7-overexpressing bone marrow cells developed a T-cell 
leukemia (Figure 2). In these mice, extensive extramedullary hematopoiesis was observed; white 




Some mice showed hepatomegaly and thymic enlargement as well. FACS analysis showed that a 
large proportion of cells in these tissues expressed CD3ε, CD4, and CD127 22.
A second type of leukemia was classified as an immature leukemia (Figure 2), since malignant cells 
did not express any of the lineage markers used for analysis (CD3ε, CD3, CD4, CD127, Ter119, Gr1, 
Mac1, B220, CD16/32, CD41). Extramedullary hematopoiesis was observed in the spleen, but not 
in lymph nodes. Peripheral white blood cell counts were increased, and cells in blood, bone marrow 
and spleen showed a primitive blast-like morphology 22.
Figure 2. Cbx7-induced leukemia phenotypes. Post-5FU-treated bone marrow cells from CD45.1 mice were 
isolated and transduced with control or Cbx-overexpressing retroviral vectors. Freshly transduced cells were 
then transplanted into lethally irradiated CD45.2 mice, without prior sorting for GFP. Mice developed different 
types of leukemia, indicated by the color of the bar, at indicated timepoints (x-axis).
Finally, two mice developed an erythroid leukemia (Figure 2). In contrast to spleens of mice 
that developed an immature or T-cell leukemia, spleens of erythroid leukemic mice were only 
mildly enlarged and were colored dark red, instead of red with white patches reflecting areas 
of extramedullary hematopoiesis of white blood cells. Lymph nodes were not enlarged, but one 
mouse showed hemorrhagic lesions in lymph nodes. Peripheral white blood cell counts were 
decreased, and increased numbers of reticulocytes and decreased numbers of mature erythrocytes 




























were detected. In addition, microscopic evaluation of bone marrow and spleen samples revealed 
numerous erythroid precursors at variable stages of maturation. Malignant cells expressed Ter119 
22. Together, overexpression of Cbx7 induces leukemias with a high penetrance but with variable 
phenotypes. Thus, Cbx7 has a strong, but dynamic oncogenic potential.
In this study, HSPCs were transduced with a Cbx7 vector library (or control vector library) 
composed of 200-300 unique barcoded vectors. After transduction, 4.5-7.5x106 non-sorted cells 
were transplanted in irradiated recipients. At selected timepoints after transplantation, cells were 
isolated from different hematopoietic tissues, analyzed and/or purified by flowcytometry, and 
barcodes were retrieved from genomic DNA using deep sequencing. In this model, overexpression 
of Cbx7 serves as the initial leukemic ‘hit’ and every pre-LSCs is uniquely labelled. This allows for 
the identification of single LSC–derived clones in the transplant recipient. Clonal waves of HSC 
contributions to the blood and emergence and persistence of clonal dominance was analyzed 
by regular blood sampling (week 4,8,16 and 24) (Figure 3, 1). The clonal composition in blood, 
bone marrow and spleen was analyzed after leukemia had developed in mice (Figure 3, 2). In 
several instances, bone marrow cells were isolated from leukemic mice and serially transplanted in 
secondary recipients (Figure 3, 3).
Figure 3. Schematic representation of experimental set-up. HSPCs were transduced with a barcoded Cbx7 
vector library and transplanted in irradiated recipients. 1 Clonal contributions of HSCs to the blood was analyzed 
by regular blood sampling (week 4,8,16 and 24). 2 The clonal composition in blood, bone marrow and spleen 
was analyzed after leukemia development in mice. 3 Bone marrow cells were isolated from leukemic mice 
and serially transplanted in secondary recipients. For clonal analysis, cells were analyzed and/or purified by 































Cbx7-induced leukemias are not obligatory monoclonal
We analyzed contributions of major and minor clones in different hematopoietic tissues in every 
individual control or leukemic mouse. To this end, we retrieved barcodes from blood, bone 
marrow and spleen samples taken at the time of sacrifice. In some cases, multiple vectors may 
have integrated in a single cell. In these cases, one barcode does not reflect one single clone, but 
a clone can be composed of multiple barcodes. Indeed, using Bray-Curtis distance algorithm (see 
Methods), we have found dominant but also minor clones with multiple vector integrations in 
some leukemic mice (for example, Figure 4d mouse 4: barcode 1a, 1b, and 1c, represent clone #1, 
Figure 4f mouse 16: barcode 1a-1d represent clone #1, mouse 17, barcode 1a-1d represent clone 
#1, Supplementary Figure S2a-b). These mice were transplanted with bone marrow cells where 
a 40% transduction efficiency was reached. Since the random occurrence of 3-4 integration sites 
under these conditions is still small (~2% of cells. Poisson, p<0.05, 24), this indicates that Cbx7 gene 
dosage due to multiple vector integrations might have a positive effect on cell proliferation and 
clone selection.
As expected, all hematopoietic lineages in control, non-leukemic mice were repopulated by bone 
marrow cells transduced with barcoded retroviral vectors (Figure 4a). The hematopoietic system of 
most of these mice was repopulated by 13-26 different clones (Figure 4b, mouse 1 and 2, Figure S1 
mouse 4 and 5). Typically, 2-3 major clones were found to predominate in all different hematopoietic 
tissues (blood, bone marrow and spleen) and made up approximately 30%-60% of all cells. One 
mouse displayed a biclonal hematopoietic system (blood, bone marrow and spleen) (Figure 4b, 
mouse 3), but this did not evolve in malignancy. We suspect that this mouse was transplanted with 
a low number of stem cells.
In Figure 4c-f we display the cell lineages and extent of clonality in various hematopoietic tissues 
(blood, bone marrow and spleen) of mice transplanted with bone marrow cells transduced with 
barcoded Cbx7-expression vectors that all developed leukemia. In general, the hematopoietic 
system of Cbx7-induced leukemic mice (Figure 4c-f, Figure S2a-b) was composed of relatively 
fewer clones compared to healthy controls (Figure 4b, Figure S1). However, surprisingly, in many 
cases the leukemic hematopoietic system did not show monoclonality (Figure 4c-f, Figure S2a-b). 
Although some T-cell leukemias were clearly monoclonal (Figure 4c, Figure S2a) and in these cases 
one clone constituted 80-100% of all cells in the blood, bone marrow and spleen, other mice, with 
a phenotypically identical disease, displayed oligoclonal T-cell leukemias (Figure 4d, Figure S2a). In 
these mice, two to four LSC clones simultaneously contributed to malignant outgrowth of T-cells 
in the blood, bone marrow and spleen, resulting in increased white blood cell counts and splenic 
enlargement.
Mouse 3 (Figure 4d), presented with a large number of CD3ε+ T-cells, but also the number of 
Ter119+ erythroid precursors and immature hematopoietic cells (Lin-) was excessive in blood, bone 
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Figure 4. Clonality in control and Cbx7-induced leukemic mic. A Average cell counts and percentage of 
different celltypes in blood, bone marrow and spleen of control mice (n=5, also see figure S1). B Control mice 
were transplanted with barcoded control vector transduced cells. The number of clones and their relative 
contribution to blood, bone marrow and spleen was analyzed. C-F Mice were transplanted with bone marrow 
cells transduced with barcoded Cbx7-expression vectors. The absolute contribution of different cell lineages in 
blood, bone marrow and spleen (left) and the contribution of different clones to the blood, bone marrow and 
spleen (right) in T-cell leukemic mice C-D, erythroid leukemic mice E and mice with an immature leukemia F. G 
Different clones in different hematopoietic lineages from the blood and the spleen. Different major and minor 
(as illustrated by the size of the pie) hematopoietic cell populations (Gr1+ granulocytes and CD3ε+ T-cell) were 
FACS-purified on basis of marker expression, gDNA was isolated and barcodes were extracted. Similar but also 
different barcodes contribute to different lineages. The size of the pie illustrates the percentage of cells in the 
indicated tissue.
Different clones in individual mice are indicated by different colors and their corresponding number. In all Cbx7 
mice, the barcode that was most frequently found among all samples from one transplantation experiment 
was numbered barcode 1 (blue), the second most frequently appearing barcode was numbered barcode 2 
(green) etc. Note that the clone numbering and coloring relates only to clones found in an individual mouse; 
similarly colored and numbered clones in separate mice refer to distinct clones.
marrow and spleen. Three distinct clones (blue clone 1 (with three vector integrations: barcodes 
a,b,c), green clone 2, and yellow clone 3) were likely collectively responsible for this malignancy. 
There are two explanations for such oligoclonal contributions to phenotypically distinct expanded 
hematopoietic celltypes. First, LSCs may have retained the ability to (an extent of) multilineage 
differentiation. Second, if instead LSCs have only unilineage differentiaton capacities, different 
LSC clones must have contributed to the expansion of different lineages. We cannot formally 
discriminate between these possibilities, since not all distinct cell populations have been separately 
analyzed for their clonal composition. However, since all three LSC clones contributed to malignant 
Cd3ε+ T-cells (Figure 4g), and since the prevalence of these clones together is ~95% in the spleen, 
these very same clones most likely contributed to expanded erythroid and immature cells as well. 
This suggests multilineage differentiaton capacities of LSCs.
Mouse 4 and 5 (Figure 4c) both showed an oligoclonal T-cell leukemia. In mouse 4, the expansion 
of malignant CD3ε+ cells is most profound in the spleen. In this mouse, clone 2 and 3 together 
constitute ~85% of cells in the spleen and the same clones are predominant in sorted CD3ε+ 
cells (Figure 4g). In mouse 5, three clones (clone 1, 4 and 6) are responsible for the expansion of 
malignant CD3ε+ cells (Figure 4c, Figure 5 mouse 5). In this mouse, but also in mouse 11 (Figure 
S2a), malignant clones predominated the blood and spleen, but not the bone marrow, in which 
no signs of leukemia were detected. This might suggest migration of malignant LSCs and/or their 
progeny to the blood and spleen, after which relatively normal hematopoiesis persisted in the bone 
marrow by the activity of other HSC clones.
The hematopoietic system of the two mice that developed an erythroid leukemia (mouse 13 and 14, 
Figure 4e) showed oligoclonality in blood, bone marrow and spleen. In contrast, the hematopoietic 
system of mice that developed an immature leukemia was always monoclonal (Figure 4f, Figure 
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S2b). We also analyzed the clonal composition of different hematopoietic cell populations in 
individual mice. To this end, different cell lineages from the blood and spleen were FACS purified 
and barcodes were retrieved from genomic DNA using deep sequencing (Figure 4g, Figure S2c-d). 
We found that minor non-malignant clones could still contribute to residual normal myelopoiesis 
(Gr1+ cells) in leukemic mice. In addition, dominant barcodes could mark both malignant T-cells 
as well as non-malignant granulocytes (Figure 4g, Figure S2c-d). Thus, the cell from which the 
leukemia derived possessed both lymphoid and myeloid differentiation capacities, which suggests 
that the oncogenic origin of leukemias lies within multipotent stem cells.
Together, our data suggest a distinct degree of competition between malignant clones in different 
types of leukmia that most probably originated from multipotent cells: we show the coexistence 
of multiple collaborating, or at least equally competitive, clones in erythroid leukemias and some 
T-cell leukemias, while clones in other T-cell leukemias and all undifferentiated leukemias were 
aggressively competing and ultimately resulted in one dominant clone.
Variable onset of clonal dominance
Phenotypical analysis and deep sequencing of barcodes from blood samples taken during the 
course of the transplantation experiment, allowed us to assess the timing of clonal dominance and 
leukemia development.
At early time points after transplantation, only a few clones (2-8 clones) contributed to blood 
cell regeneration of mice transplanted with Cbx7-overexpressing bone marrow cells (Figure 5, 
Figure S3). Some clones were already contributing to hematopoietic reconstitution early after 
transplantation, and showed multilineage differentiation capacities (for example Figure 5, mouse 
1 clone 1, mouse 15 clone 1). These clones then expanded over time, to ultimately dominate the 
hematopoietic system (Figure 5, mouse 1 clone 1, mouse 15 clone 1, Figure S3 mouse 8 clone 1, 
mouse 14 clone 1). Although these clones initially showed multilineage differentiation capacities 
in the pre-leukemic period, at the timepoint of leukemia development, they showed malignant 
proliferation towards preferentially one hematopoietic cell type.
However, we also found cases in which minor clones, which remained undetectable in the blood at 
earlier timepoints, became dominant and contributed to leukemia development (Figure 5, mouse 
5 clone 6, mouse 18 clone 1, Figure S3 mouse 11 clone 1). Together, our data reveal a highly variable 
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Figure 5. Onset of clonal dominance in Cbx7-induced leukemic mice. Left: percentage of different donor-
derived GFP+ hematopoietic cell types in blood on indicated timepoints, as analysed by FACS. Right: The 
contribution of different clones to the blood on indicated timepoints. The final timepoint is the day of sacrifice 
at clear signs of morbidity. Different clones in individual mice are indicated by different colors and their 
corresponding number. In all mice, the barcode that was most frequently found among all samples from one 
transplantation experiment was numbered barcode 1 (blue), the second most frequently appearing barcode 
was numbered barcode 2 (green) etc. Note that the clone numbering and coloring relates only to clones found 
in an individual mouse; similarly colored and numbered clones in separate mice refer to distinct clones.






























































































































































Clonal dynamics after serial transplantation
Heritability of clonal dominance and leukemia phenotype
Next, we tested whether Cbx7-induced leukemias were transplantable and whether 
the leukemic types as assessed by organ involvement, tissue morphology, and immune-
phenotype were similar in the original donor and in secondary recipients. For this purpose, 
we serially transplanted bone marrow cells from five leukemic mice into 3 to 5 secondary 
recipients. Barcode analysis allowed us to determine whether the clonal origin of leukemia 
in secondary recipient mice was identical to the disease-causing clone in the original donor 
mouse.
In the first serial transplantation experiment, we observed a very stable pattern of disease 
phenotype and clonal dominance (Figure 6). Three secondary recipient mice transplanted 
with bone marrow cells from a primary recipient with a monoclonal T-cell leukemia, all 
developed T-cell leukemias as well. Recipients, like the donor, showed enlarged spleens with 
white patches (illustrating areas of extramedullary hematopoieis), enlarged lymph nodes 
(data not shown), and expansion of CD3e+ cells (Figure 6). Barcode analyses revealed that 
the disease-causing clone was identical in the donor mouse and all individual recipients 
(Figure 6, mouse 4 donor, and recipient 1-3, clone 1).
Activation of dormant LCS clones
Second, we observed the appearance of different leukemic phenotypes, coinciding with the 
emergence of new dominant clones after serial transplantation (Figure 7a,b). Bone marrow 
cells from donor mouse 2, with an oligoclonal T-cell leukemia were serially transplanted in 3 
recipient mice, of which recipient 1 and recipient 2 also developed a T-cell leukemia (Figure 
7a, recipient 1 and 2). In contrast, recipient 3 developed an immature leukemia (Figure 7a, 
recipient 3). In this mouse, malignant GFP+ cells in the blood, bone marrow and spleen did 
not express any of the lineage markers used for immunophenotyping, while the large majority 
of cells in mice which succumbed to a T-cell leukemia expressed CD3ɛ+. To understand the 
clonal dynamics associated with the appearance of different leukemic phenotypes after 
serial transplantation, different cell populations were FACS-purified from the blood and 
spleen of secondary recipients, and the contribution of each clone to different cell lineages 
was determined. Clone 2 and 3 were identified as the malignant clones present in the donor 
mouse, since these cells contributed to the expansion of CD3ɛ+ cells primarily in the spleen 
(Figure 7a, Figure 4g mouse 2). The same two clones were also highly dominant in expanded 
CD3ɛ+ cells in blood (68% and 95% of total cells) and spleen (91% and 95% of total cells) from 
recipient 1 and 2 that developed T-cell leukemia, similar to the donor. However, the immature 
leukemia in recipient 3 appeared to be of different clonal origin. Different clones (clone 1 and 
clone 4) were responsible for the expansion of immature cells in recipient 3, which composed 
5
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96% of cells in the blood and 98% of cells in the spleen. Interestingly, clone 1 and clone 4 also 
contributed to a modest expansion of immature cells in the spleen of recipient 1 (30% of total 
cells). These clones were barely detectable in the hematopoietic system of the donor mouse 
at leukemia diagnosis, and thus previously dormant.
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Figure 6. Heritability of clonal dominance and disease phenotype. Serial transplantation of bone 
marrow cells isolated from a mouse with a T-cell leukemia into 3 secondary recipients. A Absolute 
number of indicated cell types in blood, bone marrow and spleen (upper panel), and the clonal 
composition of blood, bone marrow and spleen (lower panel) in the donor. B Left panel: absolute 
number of indicated cell types in blood, bone marrow and spleen of secondary recipients transplanted 
with bone marrow cells from mouse 1. Right panel: The contribution of different clones to the blood, 
bone marrow and spleen of secondary recipients. Different colors represent different clones and are 
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Figure 7. Activation of dormant LCS clones after serial transplantation
A Serial transplantation of bone marrow cells from a mouse with a T-cell leukemia into 3 secondary 
recipients. Recipients developed either a T-cell leukemia or a leukemia with an immature phenotype.
Left: absolute number of indicated cell types in blood, bone marrow and spleen (upper panel), and 
the contribution of different clones in the blood, bone marrow and spleen (lower panel) in the donor.
Right: Left panels: absolute number of indicated cell types in blood, bone marrow and spleen of 
recipients. Right panel: clonal composition of blood and spleen of recipients in sorted hematopoietic 
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pies reflect the percentage of cells in the indicated tissue. Different colors represent different clones 
and are indicated by different numbers. B Serial transplantation of bone marrow cells from a mouse 
with a T-cell leukemia into 4 secondary recipients. Recipients develop either a T-cell leukemia or an 
erythroid leukemia. Left: absolute number of indicated cell types in blood, bone marrow and spleen 
(upper panel), and the contribution of different clones to the blood, bone marrow and spleen (lower 
panel) in the donor.
A similar pattern of activation of minor clones was observed in the third serial transplantation 
experiment (Figure 7b). While in the donor mouse, clone 1, 4 and 6 drove T-cell malignancy 
predominantly in the blood and spleen (Figure 7b, figure 3c mouse 3), in recipient mice 
different novel clones were contributing to leukemia (Figure 7b). Only recipient 2 inherited 
the same dominant clone (clone 1, blue) as one of the disease causing clones in the donor, 
driving a similar disease phenotype (T-ALL). Clone 3 (yellow), which was relatively minor in the 
donor mouse, became highly dominant after serial transplantation, causing T-cell leukemia 
in recipient 1 and 3. Although clone 2 (green) was highly prevalent in the bone marrow of 
the donor mouse, at the time of sacrifice it was not yet malignant since it did not contribute 
to the expansion of T-cells in blood and spleen. However, this clone developed into a T-cell 
leukemia in recipient 4. Surprisingly, the very same clone caused development of an erythroid 
leukemia in recipient 5. In another experiment (data not shown), serial transplantation of bone 
marrow cell from a mouse with a T-cell leukemia also resulted in development of an erythroid 
leukemia in one of the secondary recipients. While all recipients with a T-cell leukemia showed 
enlarged spleens with white patches, containing areas of extramedullary hematopoiesis of 
white blood cells, enlarged lymph nodes, and expression of CD3ε+ on GFP+ cells, the spleen of 
recipient 5 was colored dark red, lymph nodes were not enlarged, and cells expressed Ter119+ 
(Figure 7b, Figure S4). The observation that a single clone can induce two morphologically 
and immunophenotypically distinct types of leukemia documents that this particular clone 
retained multilineage differentiation capacities.
In these two serial transplantation experiments, we document the existence of minor or 
dormant clones with leukemic potential in the donor mouse. Upon serial transplantation of 
bone marrow cells, these clones can cause leukemia in secondary recipients with a similar or 
different disease-phenotype.
Differentiation of LSC clones after serial transplantation
Third, we observed evolution of leukemic clones from an immature phenotype to the 
lymphoid lineage. Bone marrow cells from a mouse with an immature leukemia, which 
did not express any of the immunophenotypic lineage markers (mouse 15, Figure 8), were 
serially transplanted into three recipient mice. Strikingly, all three recipients (recipient 1, 2, 
3) developed a similar CD3ε+ T-cell leukemia. Barcode analysis of the blood, bone marrow 
and spleen showed that a single clone (clone 1) is highly dominant in the donor as well as 
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in all recipients. Thus, leukemias in the recipients originate from the same LSC clone as the 
leukemia in the donor. However, differentiation of the LSC clone into the lymphoid lineage 
after serial transplantation, resulted in a phenotypically distinct leukemia type in all recipients. 
Thus, phenotypically distinct leukemias might have similar clonal origins.
Altogether, these observations show that different clones with different leukemic properties 
can coexist in a single mouse. Minor LSC clones with similar or different differentiation 
potential can be relatively dormant in the bone marrow of a leukemic mouse and progress 
to full-blown leukemia only after serial transplantation. In addition, some LSCs clones retain 
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In early conceptual tumor models, malignant cells were thought to descend from a single common 
ancestor whose offspring sequentially acquired multiple mutations or other genetic abnormalities 
in time 1-3. This model implies that all cells in a tumor are linearly related to each other and are 
homogenous in their mutational landscape and behavior. In contrast, more recent studies suggest 
that at least some tumors display substantial phenotypic and genetic heterogeneity, whereby 
cellular evolution can result in a branched model of tumor development 5-6, 12-15, 25, 26.
Although emerging evidence suggests that leukemias (and other tumors for that matter) are 
comprised of a multitude of different subclones, our understanding of the dynamics of tumor 
clonality remain very limited. Also, preclinical mouse models of leukemia have so far not employed 
in vivo tracking of clonal progression and leukemia transformation. In the current study, we 
pioneered a novel barcoding tool combined with overexpression of Cbx7, an epigenetic modifier 
capable of inducing self-renewal of HSCs 22, to discern patterns of clonality in highly variable 
leukemic subtypes. We delineate leukemic heterogeneity with unprecedented resolution, and 
document the coexistence of (sometimes quiescent) LSCs with different leukemic properties in 
one tumor.
Our analysis revealed three general patterns of clonal evolution (figure 9). First, some leukemic 
clones are highly stable and dominant. These clones rapidly and strongly dominate the 
hematopoietic system of the primary donor mouse, and upon serial transplantation cause a similar 
type of leukemia in secondary recipients. A second pattern consists of minor clones in primary 
donors that become activated and highly dominant after serial transplantation. Leukemias in 
these recipient mice are thus of different clonal origin than the disease-causing dominant clone 
in the original donor mouse. As a consequence, the leukemic type (lymphoid, erythroid, or 
immature) in the recipients can be either similar or different as observed in the primary donor. 
Third, we have observed evolution (or differentiation) of leukemic clones from immature to the 
lymphoid lineage. In these cases, the leukemias in the donor and the recipients are of the same 
clonal origin, but in the recipients the leukemia manifests as a different clinical subtype. In all 
three cases we show that clonal dominance is not a prerequisite for end-stage leukemia. 
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Figure 8. Differentiation of LSC clones. Serial transplantation of bone marrow cells from a mouse with 
an immature leukemia into 3 recipients. Recipients all developed a T-cell leukemia. A Absolute number 
of indicated cell types in blood, bone marrow and spleen (upper panel), and the clonal composition of 
blood, bone marrow and spleen (lower panel) in the donor. B Left panel: absolute number of indicated 
cell types in blood, bone marrow and spleen of recipients. Right panel: The contribution of different 
clones to the blood, bone marrow and spleen. Different colors represent different clones and are 
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Figure 9. A model of clonal contributions to leukemia development and relapse. Our study indicates 
that after a first (epigenetic) hit, normal hematopoietic stem cells can evolve in pre-LSCs resulting in 
clones with different properties. LSC clones can either agressively compete and induce monoclonal 
leukemias, or rather coexist and produce oligoclonal leukemias, as depicted in this figure. Distinct LSC 
clones can have different properties, resulting in different disease phenotypes at relapse. Quiescent 
LSCs can become activated, resulting in phenotypically different disease at relapse (clone ‘2’). If 
leukemia arises from a LSC with multilineage potential (clone ‘3’), a relapsed leukemia can be of similar 
or different phenotype. Secondary epigenetic or genetic mutations can potentially further drive tumor 
heterogeneity.
Several severely diseased mice displayed an oligoclonal leukemia, but in addition, minor 
clones can be present in the bone marrow of a leukemic mouse and progress to leukemia 
only after serial transplantation. Secondary epigenetic or genetic mutations can potentially 
drive clonal evolution and tumor heterogeneity.
The heterogeneity in differentiation capacities of LSC clones supports the hypothesis that 
in our model the origin of LSCs resides within multipotent stem cells. First, we show that 
LSC clones in a single mouse can contribute to malignant proliferation of cells of different 
lineages (e.g. mouse 3 Figure 4). Second, we found that dominant barcodes can mark both 
malignant T-cells as well as healthy granulocytes. Third, cells belonging to a single clone can 
display different leukemic phenotypes upon serial transplantation. Togvether, this indicates 
that the leukemia-initiating stem cell has retained multilineage differentiation capacities. 
Our data do not allow to directly estimate the frequency with which LSCs occur in leukemic 
mice. However, the observation that ample disease heterogeneity was induced among 
secondary recpients, suggests that LSCs within these grafts were present at limiting dilution.
We show that Cbx7 can induce different types of leukemia 22. It remains to be determined 
how one apparent genetic abnormality (Cbx7 overexpression) can induce three distinct 
disease phenotypes. Since Cbx7 is an epigenetic modifier, it is tempting to speculate 
that overexpression of Cbx7 generates an altered chromatin structure that is susceptible 
to stochastic epigenetic or genetic secondary ‘hits’, which ultimately shape the disease 
phenotype. There is precedent in cancer biology for a single genetic abnormality to cause 
different diseases, for example, a recurrent mutation in Jak2 (V617F) can cause three 
types of chronic leukemias, known as Essential Thrombocythemia, Polycythemia Vera and 
Myelofibrosis 27-29.
The dynamic clonal behavior, and conversion of leukemic phenotype that we observed 
in our mouse model shows resemblance with patients presenting with leukemic relapse 
after treatment. First, if remissions in relapsed patients are treated similarly as the original 
leukemia, the response is often different, indicating that emerging clones have novel 




reported recurrently. A conversion from ALL to AML is most common, particular in pediatric 
patients 33-39. Conversions from AML to ALL occur less frequently, but have been reported for 
both children and adults 39-46. Case reports of other types of leukemic conversions, such as 
erythroleukemia into ALL have also been published 47. In leukemic patients showing a relapse 
of a different lineage (so-called ‘lineage switch’), leukemic clones often have a different 
morphology, cell size, amount of cytoplasm, presence of Auer rods and new phenotypic 
lineage markers 47 37. These clinical data are highly reminiscent to our current findings. By 
identifying the cell of origin of the initial leukemia (in the donor) and the secondary (relapsed) 
leukemia (in the recipient), we show that phenotypically distinct secondary leukemias can 
originate both from the same LSC clone that retained multilineage differentiation capacities, 
or from a different LSC clone with different leukemic properties.
Overall, we conclude that the clonal make-up of leukemias can be more complex than 
previously anticipated. We provide direct evidence for the quiescent nature of LSCs and 
show lineage conversion at the clonal level. Leukemias can be oligoclonal, with clone-
dependent variability in multiple biological traits. As not all clones are equal, therapies 
should focus on eliminating all clones with variable behaviors, including quiescent LSCs. As 
such, the finding of clonal heterogeneity at diagnosis argues in favor of adopting combination 
rather than single-agent sequential therapies with the goal to eradicate dominant as well 
as minor clones that may emerge at relapse. The barcoding approach that we advocate 
in the current study has been shown to be very powerful in delineating the behavior of 
normal hematopoietic stem cells 19, 24, and will also be of benefit to the study of preclinical 
leukemic clonality models. Finally, we advocate to implement novel methodology in the 
clinic that allows to monitor the extent of leukemic clonality during disease progression and 
after treatment.
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SUPPLEMENTARY FIGURES
Figure S1. Clonality in control transplanted mice. Control mice were transplanted with barcoded control 
vector transduced cells. The number of clones and their relative contribution to blood, bone marrow 
and spleen was analyzed. Different clones in individual mice are indicated by different colors and their 
corresponding number. Note that the clone numbering and coloring relates only to clones found in an 
individual mouse; similarly colored and numbered clones in separate mice refer to distinct clones.
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Figure S2. Clonality in Cbx7-induced leukemic mice. Ppercentage of different donor-derived GFP+ 
hematopoietic cell types in blood, bone marrow and spleen (left), and the contribution of different clones 
to blood, bone marrow and spleen (right) at the day of sacrifice at clear signs of morbidity, in A T-cell 
leukemic mice and in B in immature leukemias. C-D Different clones in different hematopoietic lineages 
from the spleen from T-cell leukemic mice C and from blood from mice with an immature leukemia (D). 
Different major and minor (as illustrated by the size of the pie) hematopoietic cell populations (Gr1+ 
granulocytes, CD3ε+ T-cell, and other (Lin-)) were FACS-purified on basis of marker expression, gDNA 
was isolated and barcodes were extracted. Similar but also different barcodes contribute to different 
lineages. The size of the pie illustrates the percentage of cells in the indicated tissueDifferent clones in 
individual mice are indicated by different colors and their corresponding number. In all mice, the barcode 
that was most frequently found among all samples from one transplantation experiment was numbered 
barcode 1 (blue), the second most frequently appearing barcode was numbered barcode 2 (green) etc. 
Note that the clone numbering and coloring relates only to clones found in an individual mouse; similarly 
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Cbx7 mouse 11: T-cell leukemia

























































Cbx7 mouse 14: erythroid leukemia










































































































Figure S3. Onset of clonal dominance in Cbx7-induced leukemic mice. Left: percentage of different donor-
derived GFP+ hematopoietic cell types in blood on indicated timepoints, as analysed by FACS. Right: The 
contribution of different clones to the blood on indicated timepoints. The final timepoint is the day of sacrifice 
at clear signs of morbidity. Different clones in individual mice are indicated by different colors and their 
corresponding number. In all mice, the barcode that was most frequently found among all samples from one 
transplantation experiment was numbered barcode 1 (blue), the second most frequently appearing barcode 
was numbered barcode 2 (green) etc. Note that the clone numbering and coloring relates only to clones found 

















Figure S4. Appearance of a phentypically distinct leukemia after serial transplantation. Pictures 
of spleen and lymph nodes are depicted from a control mouse and leukemic mice from figure 7b. 
After serial transplantation of bone marrow cells from a mouse with a T-cell leukemia, recipient mice 
developed either a T-cell leukemia, or an erythroid leukemia (recipient 5).
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SUMMARY
Adult stem cells that reside within different organs and tissues are critical actors for the 
maintenance of tissue structure and function, also referred to as ‘tissue homeostasis’. By 
their potential to undergo self-renewal divisions, as well as to differentiate into the mature 
cells of their surrounding tissue, they can sustain homeostasis throughout life by replacing 
aged cells and repairing damaged tissue. For example, blood cells in the circulation have a 
limited lifespan, and are continuously replenished by hematopoietic stem cells (HSCs) that 
reside in the bone marrow. Although self-renewal of HSCs is essential to maintain the HSC 
pool throughout life, excessive self-renewal is a key characteristic of leukemic cells. Therefore, 
insight into the process that balances self-renewal and differentiation will provide relevant 
information on cellular and organismal aging, as well as on cancer (leukemia) development.
Epigenetic mechanisms help to maintain the characteristic gene expression profile of 
stem cells, or to drive changes in gene expression that accompany the transition from 
hematopoietic stem cells to terminally differentiated blood cells. In true self-renewal 
divisions, daughter cells have to inherit the same epigenetic status as the parental cell 
from which they derive, to maintain a unique HSC cell signature. Thus, for a cell division 
to be truly self-renewing, besides accurate duplication of genomic DNA, the chromatin 
structure also needs to be copied and transmitted to the daughter cells. In contrast, during 
a differentiation division, chromatin modifications need not to be faithfully copied, leading 
to differential gene expression profiles and a distinct (i.e. non-stem cell) identity of daughter 
cells.
In this thesis, our overall aim was to further our fundamental understanding of the 
epigenetic machinery that distinguishes hematopoietic stem cell self-renewal divisions from 
differentiation divisions.
In Chapter 1, as an introduction, we describe a specific class of epigenetic modifiers, known 
as the Polycomb Group (PcG) proteins. PcGs can either maintain or modify the chromatin 
structure by maintaining or establishing specific histone modifications, such as H3K27me3 
and H2AK119Ub. According to the ‘histone code’ these modifications result in compaction 
of chromatin and inhibition of transcription by blocking the movement of RNA Polymerase 
along the DNA. PcGs reside within two main multimeric complexes termed Polycomb 
Repressive Complex 1 and 2. Genes encoding for Polycomb group proteins have expanded 
during evolution, resulting in a variety of PRC1 and PRC2 subcomplexes in mammals. The 
effects of single PcGs by either downregulating or upregulating their expression, has revealed 
the importance of PcGs such as Ezh2 and Bmi1 in hematopoietic stem cells. It is generally 
believed that Polycomb proteins repress the transcription of lineage-specific genes in HSCs. 




and be recruited to stem cell-specific self-renewal genes, to promote differentiation and 
suppress unlimited proliferation. However, due to the evolutionary diversification of PcG 
genes and proteins, a wide array of combinatorially distinct PRCs exist. To date, the role of 
different family members has remained unknown. Are PRC subcomplexes cell type specific? 
Do PRC subcomplexes have different enzymatic activities and molecular functions? Do PRC 
subcomplexes target different sets of genes for histone modifications?
Accumulating evidence indeed indicates that the activity of PRC1 and PRC2 is highly dependent 
on its exact molecular composition. In addition, data suggests that family members such 
as Ezh1 and Ezh2, and Bmi1 and Mel18 have distinct functions in hematopoietic cells. We 
therefore hypothesize that the diversity of PRC subcomplexes may regulate the dynamic 
equilibrium between HSC self-renewal and differentiation. Compositional rearrangements, 
either due to misexpression of PcG genes or due to mutations in PcG genes, may constitute 
oncogenic events by improper PRC enzymatic activity and target selectivity. This may result 
in various types of hematological malignancies, which have been reviewed in detail in this 
chapter.
In Chapter 2, we review the role of Polycomb group proteins in cellular aging and cellular 
transformation, and postulate that these can actually be viewed as two sides of the same 
coin. We speculate that PcG proteins are important in regulating the balance between aging 
(limited stem cell self-renewal) and the risk of developing cancer (excessive self-renewal). 
Both hematopoietic stem cell aging and development of hematopoietic malignancies are 
accompanied by the perturbance of a variety of cellular processes, including senescence, 
DNA repair and cell fate decisions (self-renewal vs. differentiation). While impaired self-
renewal activity, skewing of myeloid differentiation, and derepression of the ‘senescence’ 
INK4a-ARF locus, are common hallmarks of normal HSC aging, malignant transformation 
of HSCs is generally associated with the acquisition of excessive self-renewal properties. 
Because of the unique self-renewal characteristics of stem cells, these cells are traditionally 
thought to be immortal and exempt from aging. However, this would render them very 
vulnerable to malignant transformation due to the potential accumulation of genetic 
or epigenetic lesions. The induction of HSC senescence provides a potential protective 
mechanism, explaining why the self-renewal potential of HSCs declines with age. The 
balance between self-renewal and senescence must therefore be carefully controlled. We 
postulate that PcG proteins are key players in this process.
As already suggested in Chapter 1, evolutionary diversification of Polycomb-encoding genes 
argues for the existence of cell-type- and differentiation-stage-specific PRC1 and PRC2 
subcomplexes with unique molecular functions. In Chapter 3 we studied the role of different 
PRC1-associated Cbx family members in HSC regulation. We show that Cbx family members 
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have distinct cell stage-specific expression patterns, which allows for the formation of 
variant PRC1 complexes during hematopoietic differentiation. As Cbx7 is highest expressed 
in the most immature hematopoietic populations, the PRC1 complex in HSCs preferentially 
contains Cbx7. By overexpressing individual Cbx genes in hematopoietic stem and 
progenitor cells, we show that Cbx7-containing PRC1 complexes can induce self-renewal of 
multipotent hematopoietic cells by repressing the expression of progenitor-specific genes. 
Due to the excessive self-renewal of Cbx7-overexpressed cells, mice transplanted with 
Cbx7-overexpressing hematopoietic stem and progenitor cells all develop leukemias. Cbx7 
can be outcompeted by other Cbx7 family members, resulting in Cbx2-, Cbx4-, or Cbx8-
containing PRC1 complexes. We show that these complexes inhibit HSC self-renewal by 
inducing entrance into the differentiation pathway by repressing HSC-specific genes. Our 
data support the notion that in HSCs PRC1 complexes composed of different Cbx subunits 
regulate the balance between self-renewal and differentiation.
In Chapter 4 we used the Cbx7 mouse model, developed in Chapter 3, to study the behavior 
of leukemic stem cells (LSCs) in vivo. Our current understanding of the dynamics of tumor 
development and heterogeneity is still very limited, although this is highly relevant for 
existing and future therapeutic interventions. We used a previously developed barcoding 
tool, in which cells are marked by the introduction of a unique, heritable DNA ‘barcode’ 
in the retroviral vector. After transduction and transplantation, offspring of individual cells 
(clones), can be traced by sequencing and quantifying the abundance of unique barcodes. 
In Chapter 3, we showed that Cbx7 overexpression resulted in three different types of 
leukemia; immature, erythroid and T-cell leukemias. By implementation of this barcoding 
tool, we have generated a mouse model in which Cbx7 served as the initial leukemic ‘hit’ 
and every pre-LSCs is uniquely labelled. This approach allowed for the identification of LSC-
derived clones in the transplanted primary and secondary recipients.
Although all cells of a tumor were thought to be clonally related, our model documents 
the coexistence of (sometimes quiescent) LSC clones with different leukemic properties 
in one tumor. LSC clones can aggressively compete, resulting in monoclonal leukemias, or 
collaborate (or at least being equally competitive) resulting in oligoclonal leukemias. Within 
(oligoclonal) leukemias, LSC clones can have different properties resulting in different 
disease phenotypes at relapse, illustrated in our model by serial transplantation studies. 
Quiescent LSCs can become activated resulting in phenotypically different disease at relapse. 
In addition, some LSC clones retain multilineage differentiation capacities and one LSC clone 





Polycomb Cbx family members in hematopoietic stem cells
Our data, as well as previous reports 1-5, show that PRC1 complexes can be constitutionally 
distinct and functionally more complex than previously anticipated. Cbx proteins are 
mutually exclusive for PRC1, and one report showed that they specifically assemble in PRC1 
complexes containing either Bmi1 or Mel18, but not in PRC1 complexes containing other 
Pcgf orthologs 2. Like Cbx proteins, Bmi1 and Mel18 also show non-redundant functions in 
HSCs. While Bmi1 is required for long-term HSC self-renewal 6-7, Mel18 has negative effects 
on self-renewal 8-9. Biochemically, Bmi1 and Mel18 also have different properties. Whereas 
Bmi1 is able to stimulate the E3 ubiquitin ligase activity of Ring1b, Mel18 does not exert this 
activity 10. We show that, in a myeloid celline, Cbx7 and Cbx8 can assemble in both Bmi1 
and Mel18-containing PRC1 complexes. Thus, Cbx7-Mel18, Cbx7-Bmi1, Cbx8-Mel18, Cbx8-
Bmi1 complexes might all coexist in HSCs, but whether they have different molecular and 
biological functions remains to be determined. In addition, Reinberg et al. showed that non-
canonical PRC1 complexes also exist 2 (reviewed in Chapter 1). These complexes lack Cbx, 
but instead contain either Rybp or Yaf2 and can bind PcG target sites independently of PRC2 
and the H3K27me3 mark 11. In embryonic stem cells, Cbx7-containing and Rybp-containing 
PRC1 complexes define overlapping but also different biological functions. Both PRC1 
subcomplexes target many common genes, but while RYBP-PRC1 complexes also specifically 
target genes involved in metabolism and the cell-cycle, Cbx7-PRC1 complexes target genes 
involved in lineage commitment 12. Whether these non-canonical PRC1 complexes also exist 
in hematopoietic cells and whether they are required for HSC regulation is subject to further 
study.
We identified Cbx7 as an important hematopoietic stem cell gene. By studying genome-
wide binding sites of Cbx7, we showed that Cbx7 might aid to maintain progenitor-specific 
genes in a repressed state, thereby preventing HSCs from entering differentiation. However, 
the ChIP-seq experiments were performed with heterogeneous cell populations (although 
enriched for stem and progenitors cells), in which either Cbx7 or Cbx8 was overexpressed. In 
addition, since the protein levels are very high after overexpression (+1000-fold), this might 
potentially result in the identification of false positive targets. To reduce this possibility, we 
employed a very stringent protocol of identifying specific Cbx7 and Cbx8 targets. Next to 
using a empty vector control as a blank dataset, the sequencing profile of the data set of the 
alternative Cbx ChIP-seq data was used to extract specific targets. Since both Cbx7 and Cbx8 
were overexpressed, and we do not focus on common targets, this should have reduced 
identification of false positive targets. Ideally, however, one would not use overexpression 
conditions to search for targets of a specific protein, but rather do ChIP-seq using antibodies 
against the endogenous protein. We are currently optimizing ChIP seq experiments for low 
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cell numbers, which would make it possible to study binding sites of different (endogenous) 
Cbx-containing PRC1 complexes in different rare hematopoietic cell subsets, including long-
term HSCs (approximately 20.000 cells can be isolated from one mouse). This would give 
insight into the dynamics of Polycomb PRC1 targets during normal HSC differentiation.
It has been reported previously that Cbx7, but also other PcG proteins, can recruit DNA 
methyltransferases (Dnmt) to chromatin 13. DNA methylation might thus induce another 
dimension of gene repression, specifically for loci bound by Cbx7-PRC1 complexes. Dnmt3a 
is one of the de novo methyltransferases that can actively initiate DNA methylation of 
unmethylated DNA, which will generally result in gene repression. Different isoforms are 
known to occur for Dnmt3a. Preliminary data in our lab showed that overexpression of Cbx, 
but not Cbx8, resulted in enhanced expression of the longer isoform (≈130 kD) of Dnmt3a, 
but repression of the shorter isoform (≈78 kD). Expression of the longer isoform of Dnmt3a 
is also found to be specific for primitive hematopoietic subpopulations, defined by L-S+K+. 
These results implicate a possible unique function of the long Dnmt3a isoform in HSCs. It 
might be of interest to study whether Cbx7 requires the long Dnmt3a isoform for stable 
repression of its targets in HSC, to induce HSC self-renewal.
In chapter 1, we described that due to the evolutionary diversification of PcG genes and 
proteins, a wide array of combinatorially distinct PRCs exist. This diversification of PRC 
complexes might account for tissue-specific stem cell functioning. Whereas we show that 
Cbx7 is the most important Cbx family member in HSCs, in epidermal stem cells Cbx4 showed 
to be most important 14. However, this role seems not to be PRC1-dependent. Cbx4 exerts 
SUMOylation activity independent of its chromodomain to suppress terminal differentiation 
of epidermal cells. Instead, we show that Cbx7 requires an intact chromodomain and 
integration into PRC1 to induce HSC self-renewal. It remains to be determined which of the 
Cbx orthologs are required for other types of adult stem cells.
Cbx7 and Cbx8 knock-out mice
Tan et al. showed that Cbx8 deficient mice display no apparent hematopoietic phenotype 
15. The number of hematopoietic stem cells and progenitors in the bone marrow is normal, 
and they are functionally equivalent to their wildtype counterparts in reconstitution of 
the hematopoietic compartment after transplantation into irradiated recipients. However, 
the PRC1 complex composition in Cbx8-/- hematopoietic stem cells has not been studied. 
According to our results, Cbx2 and/or Cbx4 might be functionally redundant to Cbx8. In 
that case, Cbx2 and Cbx4 might substitute for Cbx8 and incorporate into PRC1 complexes, 
without any functional consequences.




mice would have reduced number of hematopoietic stem cells and potentially suffer from 
bone marrow failure. This has not been reported. However, during early development, full 
conventional knock-out mice might develop unexpected compensatory mechanisms which 
might obscure the study of a particular gene. Cbx7 is shown to be essential for ESCs 4-5, which 
makes it surprising that Cbx7-null mice are viable. This suggests that such compensatory 
effects to rescue the adverse effects of loss of Cbx7 during development might indeed have 
occurred. Conditional Cbx7 knock-out mice have been generated in the RIKEN Reseach 
Institute (dr. Koseki, RIKEN, Japan), and it might be worth studying HSCs of these mice, for 
example in a transplantation setting.
While no obvious hematological phenotype has been reported in adult Cbx7-null mice, 
these mice do developed liver and lung adenomas and carcinomas. The authors suggest 
that Cbx7 might have tumor suppressive functions by inhibiting cell cycle progression. This is 
supported by several other reports that showed that loss of CBX7 expression correlates with 
a poor prognosis in several types of cancer, such as thyroid cancer, pancreatic cancer and 
colon carcinoma 17-21. On the contrary, our data suggest that Cbx7 functions as an oncogene, 
since its expression causes several types of lethal leukemias in mice and its protein level 
was found to be elevated in human lymphoid tumors 22. This apparent discrepancy between 
tumor suppressive and oncogenic functions of Cbx7 might be explained by tissue-specific 
functions of Cbx-containing PRC1 complexes, as argued before. As discussed in Chapter 1, 
depending on the cell context and interacting partners, individual PcG genes may display 
either tumor suppressor or oncogenic functions, even within the same tissue. For example, 
loss or gain of Ezh2 activity (either by altered expression or by mutations) can both contribute 
to leukemogenesis in patients 23-24.
Extrapolation to the clinic
Regenerative medicine is expected to transition from a research promise to clinical reality 
in the upcoming years. However, the use of regenerative medicine relies on a proper 
understanding of pathways involved in stem cell specification. Modulation of the expression 
of genes that induce differentiation or self-renewal of HSCs by gene-therapy may be 
required to fully exploit the use of stem cells in future regenerative therapies. However, 
the introduction of new genetic material is undesired in clinical protocols since it is still 
under debate whether insertional mutagenesis from the vectors used to transfer genetic 
material can trigger clonal expansion of HSCs itself 25-26. Therefore, small molecules that 
target key genes or pathways, including those found in this study, might be of use in ex vivo 
manipulation and perturbation of the function of stem cells. We are currently planning to 
explore the design of small molecules that could potentially interfer with PRC1 complex 
compositions. We now have several in vitro but also in vivo platforms to screen the effect 
of such small molecules. Potent small molecules that can ‘remove’ Cbx7 from the complex 
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are predicted to induce terminal differentiation of leukemic cells, and might therefore 
cure Cbx7-induced leukemias in mice. If so, molecules that interfer with PRC1 complexes 
might be used in a clinical trial setting. Such a strategy has been successful in the past for 
bromodomain-containing proteins 27. 
However, the above-mentioned strategy will take multiple years to develop. In the meantime, 
it might be of interest to investigate the prognostic value of our findings in clinical settings. 
The expression of, and mutations in some Polycomb genes, is already used as a prognosis 
factor. We expect that Polycomb complex composition might be a more relevant predictive 
factor. A first step would be to screen Polycomb complex compositions in samples from 
patients that suffered from leukemia, such as acute myeloid leukemia, acute lymphoid 
leukemias and chronic myeloid and lymphoid leukemias.
Using our barcoded Cbx7-induced leukemia mouse model, we show that the clonal make-
up of leukemias can be more complex than previously anticipated. We provide evidence 
that different LSC clones have different leukemic properties, which can become prevalent 
at leukemia relapse. Secondary epigenetic or genetic mutations can potentially drive tumor 
heterogeneity and clonal progression after relapse. It would be of interest to combine our 
barcoding approach to define LSC clones, together with genome sequencing to precisely 
identify the occurence of secondary hits. Using this method, potential tumor ‘driver’ 
mutations could be identified with higher resolution and precision than with genome 
sequencing alone. Our finding of leukemic LSC heterogeneity might explain why patients 
with relapsed leukemias who are treated similarly as when the leukemia first occurred, might 
show a different response to therapy 28-30. Second, it might explain why relapsed leukemias 
might display different phenotypes, which has been reported recurrently 31-45. We argue 
that therapies should focus on eliminating all clones within a tumor, including quiescent 
LSCs. As such, the finding of clonal heterogeneity at diagnosis argues in favor of adopting 
combination, rather than single-agent therapies with the goal to eradicate dominant as well 
as minor clones that may emerge at relapse.
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DUTCH SUMMARY / NEDERLANDSE SAMENVATTING (VOOR NIET-INGEWIjDEN)
Introductie
We zijn allemaal ontstaan uit één enkele cel, gevormd door de samensmelting van de 
zaadcel van onze vader en de eicel van onze moeder. We erven dan ook de helft van ons 
genetisch materiaal (DNA) van de vader en de helft van de moeder. In het DNA liggen onze 
erfelijke eigenschappen verborgen, in zogenaamde genen (kleine stukjes DNA). Genen 
in het DNA (+/- 30.000 in de mens) bevatten de code voor de opbouw van eiwitten, de 
werkpaarden van een cel die specifieke functies uitoefenen. Sommige eiwitten bepalen 
bijvoorbeeld de kleur van onze ogen, terwijl andere eiwitten zorgen voor het omzetten van 
suiker in energie. In principe heeft Iedere cel in ons lichaam hetzelfde DNA en dus dezelfde 
genetische informatie. Echter, als we nu naar onszelf kijken zien we dat ons lichaam bestaat 
uit verschillende organen en weefsels die weer zijn opgebouwd uit verschillende celtypes 
die er allemaal heel verschillend uitzien. Bijvoorbeeld, huidcellen beschermen ons zodat 
schadelijke bacteriën en virussen ons lichaam niet kunnen binnendringen, terwijl levercellen 
enzymen aanmaken zodat we ons voedsel kunnen verteren en daar energie uit kunnen 
opnemen. Maar hoe kan het dat dezelfde genetische informatie leidt tot deze verschillen? 
Alle cellen bezitten hetzelfde DNA, en dit codeert immers voor dezelfde eiwitten. Dit komt 
omdat, afhankelijk van het celtype, bepaalde genen in de cel ‘uit’ staan, en andere ‘aan’. Een 
voorbeeld is hemoglobine. In principe draagt iedere cel het gen voor hemoglobine, maar 
alleen in de rode bloedcellen staat deze ook daadwerkelijk ‘aan’ en wordt dit eiwit gemaakt 
dat zorgt voor zuurstofbinding. Niet alle eiwitten worden dus in iedere cel gemaakt. Het 
proces dat hiervoor zorgt heet ‘epigenetica’. Epigenetische mechanismes bepalen hoe het 
DNA is opgevouwen in de cel, en welke stukken DNA, met daarin genen, bloot komen te 
liggen en kunnen worden gebruikt om eiwitten te maken, en welke daarentegen worden 
verborgen. De manier waarop het DNA is gevouwen bepaalt dus welke genetische informatie 
in het DNA wordt gebruikt voor de functie van de cel.
Zoals hierboven uitgelegd bestaan verschillende organen uit verschillende celtypes. Maar 
het is nog complexer. Ook ieder orgaan zelf bevat verschillende celtypes, die individueel 
allemaal een specifieke taak hebben maar tezamen de functie van het orgaan uitoefenen. 
In bijna ieder orgaan zijn stamcellen ontdekt. Stamcellen hebben de unieke eigenschap om, 
relatief ongelimiteerd, zichzelf te vernieuwen, waardoor vanuit één stamcel twee stamcellen 
ontstaan. Hierdoor blijven er gedurende ons hele leven stamcellen behouden. Tevens 
kunnen stamcellen uitrijpen tot alle verschillende celtypes waaruit het orgaan bestaat. Dit is 
noodzakelijk omdat rijpe cellen in een orgaan maar een kort leven beschoren is. Ze moeten 
continu vervangen worden om de functie van het orgaan te behouden . Bloedstamcellen 
zijn de best bestudeerde stamcellen. Deze stamcellen zitten in het beenmerg, omdat hier 
het bloed wordt aangemaakt. Naast dat ze zichzelf kunnen vernieuwen, kunnen ze uitrijpen 
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tot allerlei verschillende typen bloedcellen, zoals witte bloedcellen, rode bloedcellen en 
bloedplaatjes.
Ook bij deze stamceldelingen zijn epigenetische processen belangrijk. Tijdens een deling 
van een stamcel waarbij een nieuwe stamcel wordt gevormd moet de functie van de cel 
behouden blijven. Dit betekent dus concreet dat naast het erfelijke materiaal -het DNA- ook 
de manier waarop het DNA verpakt zit in de cel moet worden gekopieerd. Daarentegen, 
wanneer een stamcel moet uitrijpen tot bijvoorbeeld een rode bloedcel, zijn weer andere 
eiwitten in de cel nodig om de functie van de rode bloedcel te vervullen. Dit betekent dat 
de manier waarop het DNA zit verpakt in de cel moet veranderen. Hierdoor verandert het 
pakket aan eiwitten waardoor de rode bloedcel zijn specifieke taak kan uitoefenen: zuurstof 
transport.
Eiwitschakelaar bepaalt of stamcel zichzelf vernieuwt of gaat specialiseren
In dit proefschrift zijn Polycomb eiwitten bestudeerd. Polycomb eiwitten kunnen de wijze 
waarop het DNA is gevouwen in de cel veranderen. Ze bepalen dus mede welke genetische 
informatie in het DNA wordt gebruikt voor de functie van de cel. Polycomb eiwitten zijn 
belangrijk voor bloedstamcel delingen, wat in dit proefschrift is aangetoond. Ze kunnen 
bepalen of een stamcel zichzelf vernieuwt of dat het zal uitrijpen tot een bloedcel. Dit 
mechanisme is vrij ingewikkeld want verschillende Polycomb eiwitten functioneren tezamen 
in een groot eiwitcomplex. Voor iedere positie in dit complex concurreren verschillende 
Polycomb eiwitten met elkaar.
In dit proefschrift is aangetoond dat de samenstelling van dit eiwitcomplex werkt als een 
schakelaar die bepaalt of stamcellen uitrijpen tot rijpe bloedcellen met een specifieke 
functie in het lichaam, of zorgen voor de productie van nieuwe stamcellen. Het eiwitcomplex 
varieert in samenstelling doordat vier verschillende eiwitten al dan niet aanwezig zijn. Een 
van de vier eiwitten, Cbx7, moet aanwezig zijn om stamcelvernieuwing te bevorderen. 
Als Cbx7 ontbreekt, en één van de andere drie familieleden (Cbx2, 4 of 8) in het complex 
zit, wordt de aanmaak van nieuwe stamcellen geremd en specialiseren de cellen juist tot 
uitgerijpte bloedcellen.
Door beenmergtransplantaties uit te voeren in muizen heeft dit onderzoek ook aangetoond 
dat als er teveel van het Cbx7 eiwit in de stamcel aanwezig is, leukemie ontstaat. De 
verhouding tussen verschillende eiwitcomplexen is dan dermate verstoord dat er teveel 
vernieuwing van stamcellen plaatsvindt. Hierdoor ontstaat ongeremde en ongecontroleerde 
celgroei; kanker. Leukemie is dan ook bloedkanker die zich kenmerkt door ongecontroleerde 
celdelingen en een blokkade in uitrijping van stamcellen. Dus, zorgt de schakelaar voor te 













kan ook bloedceltekort ontstaan, denk aan bloedarmoede. Tijdens veroudering neemt de 
incidentie van dit soort ziektes toe, omdat ‘oude’ stamcellen minder goed gereguleerd 
zijn. Dit komt door opstapeling van foutjes in het DNA of door fouten in de regulatie 
van epigenetische processen o.a. door Polycomb eiwitten. Dit onderzoek geeft daarmee 
‘fundamenteel inzicht in de rol van stamcellen in de subtiele balans tussen ziekte en 
gezondheid’ (persbericht UMCG, 28 maart 2013).
Er zijn in de afgelopen jaren veel studies gedaan om kennis te vergaren over het mechanisme 
van stamcel delingen. De studie in dit proefschrift heeft daar aan bijgedragen. Het is echter 
nog een grote stap om de bevindingen te vertalen naar de kliniek. Hypothetisch gezien zou 
het veranderen van de samenstelling van het Polycomb eiwitcomplex in het laboratorium 
kunnen leiden tot een vermeerdering van stamcellen voor een beenmergtransplantatie. 
Hoe meer stamcellen kunnen worden getransplanteerd, hoe beter dit is voor de patiënt. 
Eén methode om dit te doen is door bepaalde stofjes die aangrijpen op dit eiwitcomplex 
toe te voegen aan het medium waarin de cellen groeien. Een andere methode is om 
stamcellen genetisch te manipuleren door het inbrengen van extra stukjes DNA van genen 
die coderen voor eiwitten in het complex. Echter, niet van alle manipulatiestrategieën die in 
het laboratorium worden toegepast zijn de lange termijn effecten bekend en daarom wordt 
het nog niet veilig bevonden voor toepassing in de kliniek. Er is dus nog een lange weg te 
gaan voordat nieuw bevonden kennis en toepassingen in het laboratorium van nut zijn voor 
patiënten. Een goede samenwerking tussen wetenschappers in het laboratorium en artsen 
in de kliniek is dus essentieel en zal uiteindelijk resulteren in een verbeterde zorg voor de 
patiënt.
Niet alle cellen in een kanker zijn hetzelfde
Dit onderzoek heeft ook bijgedragen aan de kennis van het ontstaan en de ontwikkeling van 
leukemie in het bloedvormend systeem. Hiervoor is een zogeheten ‘DNA barcode’ gebruikt. 
In dit onderzoek zijn extra kopieën van het Cbx7 gen in het DNA van muizenstamcellen 
gebracht, maar daarnaast ook een uniek variabel stukje DNA, een ‘barcode’. Iedere 
individuele stamcel draagt dus een unieke ‘barcode’. Deze barcode wordt bij iedere celdeling 
gekopieerd en geërfd door de dochtercellen. Hierdoor is het mogelijk om te zien welke 
bloedcellen door de stamcel worden geproduceerd. Een groep cellen die wordt gevormd uit 
één stamcel heet een ‘kloon’. Alle cellen van dezelfde kloon hebben dus dezelfde ‘barcode’.
Stamcellen kunnen, nadat ze een foutje in de DNA code hebben opgelopen, of een fout 
in de manier waarop het DNA verpakt zit in de cel, ongeremde en ongecontroleerde groei 
laten zien en klonen vormen die bijdragen aan leukemie ontwikkeling. Deze studie laat 
zien dat een leukemie niet altijd bestaat uit cellen die allemaal identiek zijn. De leukemie 
kan bestaan uit meerdere klonen en dit maakt het gedrag van de leukemie complex. 
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Verschillende leukemieklonen kunnen verschillende eigenschappen hebben met betrekking 
tot groei en uitrijping (type leukemie), en verschillend reageren op stress (zoals bijvoorbeeld 
chemotherapie). In deze studie is dit aangetoond door leukemiecellen van een muis met 
een leukemie (donor), door te transplanteren in andere ontvangermuizen. In sommige 
ontvangermuizen resulteerde dit in een andere uitrijping van de cellen en verandering in het 
type leukemie (bijvoorbeeld rode bloedcel leukemie), in vergelijking tot het type leukemie 
dat oorspronkelijk aanwezig was in de donor muis (bijvoorbeeld witte bloedcel leukemie).
Als we deze bevindingen vertalen naar de kliniek betekent het dat leukemie bij mensen 
complexer kan zijn dan eerder werd gedacht. Als er meerdere klonen aanwezig zijn in een 
patiënt, kunnen deze verschillend reageren op chemotherapie. Deze studie laat zien dat 
sommige klonen heel klein kunnen zijn en blijven ‘slapen’ in het beenmerg na stress. Bij een 
patiënt kan dit betekenen dat deze kloon niet reageert op de chemobehandeling, terwijl 
andere klonen wel worden uitgeroeid. Deze ‘slapende’ leukemie klonen kunnen mogelijk 
jaren later leiden tot een tweede leukemie met andere eigenschappen. Aangezien leukemie 
dus kan bestaan uit meerdere klonen met verschillende eigenschappen, benadrukt deze 
studie het nut en de mogelijke noodzaak van combinatie-therapie bij de behandeling van 
leukemie. Hierbij worden verschillende medicijnen tegelijk gebruikt. Dit heeft als doel het 















Het is zover. De lange weg van experimenten doen in het lab, data analyseren en artikelen 
schrijven voor mijn PhD project ligt achter mij. Straks mag ik mezelf doctor in de medische 
wetenschappen noemen, ter ere van al dat zwoegen. Maar dit was nooit gelukt zonder de 
praktische hulp en morele steun van velen. Graag wijd ik dan ook de laatste bladzijden van 
dit proefschrift aan het bedanken van deze mensen.
Allereerst, Gerald. Ik wil je graag bedanken voor de fijne tijd die je mij hebt gegeven in jouw 
lab. Ik loop natuurlijk nog niet zo lang mee in het professionele veld, maar naar mijn mening 
mag ik mezelf gelukkig prijzen met zo’n baas en promotor. Ik heb heel veel van je geleerd, 
natuurlijk allereerst op wetenschappelijk gebied. Je deur stond altijd open om nieuwe 
resultaten of nieuwe ideeën te bespreken. Je wist altijd een goed evenwicht te vinden in 
het geven van zowel vrijheid als sturing in mijn project. Ik heb dit als zeer prettig ervaren, en 
hopelijk heb ik dit ook laten blijken. Door jouw steun, vertrouwen en de kansen die je mij gaf 
heb je zeer zeker ook bijgedragen aan mijn persoonlijke professionele ontwikkeling. Bedankt 
dat je me de kans geeft mij nog verder te ontwikkelen in jouw lab als post-doc onderzoeker. 
Hoe we dit ook zullen gaan invullen, ik heb het gevoel dat je mij steunt in al mijn keuzes en 
dat je mijn mentor wilt zijn in mijn carrière. Wat kan een AIO zich nog meer wensen?
Lenja, mijn co-promotor, het is onmogelijk in woorden te bevatten hoeveel ik van je heb 
geleerd. Het leggen van onverwachte verbanden, het ‘out of the box’ denken, kritisch zijn, 
en creativiteit. Dit is allemaal belangrijk om succesvol wetenschap te kunnen doen, en deze 
eigenschappen heb ik altijd in je bewonderd. In deze zaken zal ik nog zeker verder moeten 
groeien maar met jou als leermeester ben ik hopelijk al een eindje op weg. Ook heb je mij 
altijd bijgestaan in niet-lab gerelateerde zaken. BEDANKT!
I would also like to take the opportunity to thank the members of the reading committee, 
Prof. E. Vellenga, Prof. M. van Lohuizen and Prof. A. Iwama.
Collega’s zijn allesbepalend voor het hebben van plezier in je werk. En als AIO heb je ook nog 
eens periodes dat je je collega’s vaker ziet dan de persoon waarmee je samenwoont (sorry 
Maarten..)! Ik liep (hoop ik) vaak met een lach op mijn gezicht op het werk rond, en dat komt 
door alle fijne collega’s met wie ik heb mogen werken. Daarom wil ik graag uitgebreid alle 
huidige maar ook oud-collega’s van de stamcelbiologie bedanken. Allereerst Ronald, met 
je grappen en grollen. Naast dat je me altijd hebt bijgestaan met wetenschappelijk raad-
en-daad, heb ik vaak met je gelachen. We hebben een aantal jaren een kantoor gedeeld, 
en ik vond dat erg gezellig. De andere (ex) post-docs die ik graag zou willen bedanken zijn 
Hein, Sophia, en Brad. Hein, bedankt voor je kritische blikken tijdens werkbesprekingen en 
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PhD meetings. Sophia, je hebt me ontzettend geholpen tijdens de laatste fase van het NCB 
manuscript. Bedankt voor de cursus ‘het schrijven van goede rebuttal letters’ :) en bedankt 
voor je morele steun tijdens stressvolle momenten. We hebben ook veel persoonlijke 
gesprekken gehad tijdens de korte tijd dat we nu collega’s zijn. Ik bewonder je wijsheid en 
je kalmte.
Brad, you left the lab and we have not been much in contact since. Science is a busy life, 
but I am sure we will meet soon at conferences. You are a real hardcore cell-biologist, and 
thought me a lot with your critical view. Your door was always open to discuss plans, data, 
and FACS-protocols. We also had a good time together at the ISEH conference in Melbourne, 
and our short “sunny” trip afterwards. Good luck with your carreer!
Een lab kan niet zonder goede analisten, ze zorgen voor het dagelijks reilen-en-zeilen en 
hebben veel (vaak meer dan AIO’s!) ervaring met lab-technieken. Gerald, je hebt een 
geweldig analisten-team samengesteld, dat mede verantwoordelijk is voor de successen in 
het lab.
Ellen, zonder jouw gouden handen hadden we nooit genoeg experimenten bij elkaar 
kunnen pipetteren voor de NCB publicatie. Samen met jou experimenten doen heb ik altijd 
erg gezellig gevonden. Ik vind je eerlijkheid heel prettig, daardoor weet ik altijd precies waar 
ik aan toe ben. We werken nu voor het zesde jaar samen, en ik hoop dat deze samenwerking 
de komende jaren net zo prettig zal zijn. Mathilde, wat een geluk dat jij in mijn derde 
jaar kwam als nieuwe analist in ons lab (bedankt voor het ‘ koppelen’ Sandra O!). Ik heb 
je natuurlijk niet voor niets gevraagd om mijn paranimf te zijn (nee, je hoeft geen rokje 
aan!). Je bent een harde werker en net als Ellen, heb jij gouden handen. Inmiddels ben 
je zo ongeveer onmisbaar geworden voor het lab, wat soms misschien wel wat zwaar op 
je schouders drukt. Maar zie het als compliment. Naast dat je een collega bent, zie ik je 
toch ook wel als vriendin. De avonturen die we samen hebben meegemaakt zal ik met een 
lach op mijn gezicht blijven herinneren. Denk aan je autocross wedstrijd, ons bezoekje aan 
meneer Hulzebosch, het stappen in Kopenhagen, ons snelweg-avontuur, etc... Er zullen vast 
nog meer avonturen volgen! Martha R., met jou en Ronald deelde ik het kantoor op de 
vijfde en we hebben veel gezellige(oa over UFO’s) en ook persoonlijke gesprekken gehad. 
Jij hebt me altijd geholpen met alle muizen-experimenten, en ik ben je daar heel dankbaar 
voor. Het is niet altijd prettig wat we de diertjes aan moeten doen, maar je deed het altijd 
met zoveel mogelijk liefde en zachtaardigheid. Dit is heel bewonderenswaardig. Je bent en 
blijft een grote dierenvriend. Bertien, hetzelfde geldt eigenlijk voor jou. Jij bent ook geweldig 
in het doen van in vivo experimenten, maar je regelt ook alle organisatie daaromheen. Ik 
ben blij dat je dit ons allen uit handen neemt. Ook in het lab ruim je vaak zonder gemopper 













waardering daarvoor uitspreken. Daarnaast ben je een hele fijne collega, waar ik altijd op 
kan bouwen. Erik, als enige kerel tussen al die vrouwen heb je het vast niet altijd gemakkelijk 
;) Of misschien vind je het stiekem toch eigenlijk wel leuk. Ik word vaak al duizelig als ik naar 
jouw computerscherm kijk, bio-informatica blijft voor mij abacadabra. Ik ben blij dat jij dat 
een leuk vak vindt, en dat je hiermee ons lab bent komen versterken. We hebben samen, en 
met Lenja, grote datasets weten te veranderen in begrijpelijke figuren en conclusies. Ik kom 
ook graag even bij je bureau langs om een praatje maken, met een kopje koffie erbij. Dus, 
bedankt voor je hulp en gezelligheid!
En dan zijn er nog drie analisten die inmiddels niet meer op de stamcel afdeling werkzaam 
zijn maar die ik toch graag zou willen bedanken. Bert, jij ging al bijna met pensioen toen ik 
net als AIO begon. Ik heb van jou nog geleerd hoe je CFU-GMs moest inzetten en scoren 
en ik heb als eerst met jou meegekeken hoe je beenmergcellen moet isoleren. Bedankt! Ik 
hoop dat je volop geniet van je vrijheid en pensioen! Sandra O, we hebben te kort mogen 
genieten van jouw harde werken. Jij kwam ons lab versterken toen ik net in mijn tweede jaar 
(?) zat. Je hebt me heel veel geholpen met cobblestones scoren (uiteraard!), maar ook met 
alle analyses die gedaan moesten worden op de cellen van de zieke muizen. Bedankt! We 
hebben ook veel lol gehad, en zelfs nog een korte tijd samen gesport (fitness en squash). 
En toen ging je verhuizen, terug naar je ‘roots’. Ik vind het leuk dat we af en toe nog contact 
hebben. Jaring, je kwam als uitmuntende student van Brad bij ons op het lab, en daarna heb 
je ongeveer een jaar bij ons als analist gewerkt. Je hebt ons allemaal veel geleerd van FACS, 
bedankt! Je protocollen worden nog steeds veelvuldig gebruikt, evenals de Jaring-assay.
And of course, I would like to thank all my current colleague PhD students in the stem cell 
biology department. Evgenia, I enjoyed working with you and discussing about scientific but 
also non-scientific topics. Our trip with Maarten, Alice and Brad to a ‘sunny’ desert island in 
the Whitsundays of Australia was quite an experience and this will stay a living memory for 
me (with good pictures!). You are about to finish, so I wish you all the best in this final phase 
of your PhD. Višnja, we have worked a lot together on your ‘Dnmt project’ and my ‘Cbx 
project’ and we also wrote a review together. I appreciate all your help and efforts in the 
lab. I hope to see your thesis soon! Edyta, you are relatively new in the lab, but you already 
have generated a large set of data. You are a very hard worker, and I am confident that you 
will finish your PhD successfully. Sara, you smart girl. Still a long way to go before you will 
finish your PhD, but time will fly! We started a project together, and I sincerely hope that it 
will result in a nice paper. I also wish you all the best with the histone-content-during-aging 
project. This was your own idea which you brought into the lab when you started. Also many 
thanks for your moral support which you and Sophia gave me during the stressful revision 
period of the NCB paper.
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Other PhD students already finished and left the stem cell biology department to start a new 
path in their career. Marta, we started our PhD about the same period. We did not work 
much together, but I remember hearing in my office when you were having a good laugh in 
the lab on the 5th floor while doing experiments. Having fun doing science is important :). 
Thank you! Alice, we hebben redelijk veel samengewerkt tijdens onze AIO periode, en we 
zetten dat nu voort in een andere setting (de MPN Stichting). Ik vind het leuk om je af en toe 
nog te spreken en te zien. We hebben allebei veel meegemaakt, en dat verbindt toch wel. 
Sandra R. we shared the office for a short period of time. You were about the finish your 
PhD when I started, and I remember that you were working day and night on your computer 
to make the deadlines of your papers. Thanks for the chats and laughs we had. Leonie, 
we hebben eigenlijk nooit samengewerkt, maar je hebt zoveel sporen nagelaten in het lab 
dat het eigenlijk toch wel zo voelt. We hebben elkaar redelijk goed leren kennen tijdens 
congressen en daar veel plezier gehad. Sommige collega’s noemen mij de ‘tweede Leonie’. 
Jij en ik zijn er samen nog niet uit of dat nu positief of negatief is bedoeld, of wel? Bedankt 
voor al de tips die je mij hebt gegeven gedurende mijn PhD (je weet waar ik het over heb…;)
During my PhD, I also had the honor to guide several Bachelor, Master and Topmaster 
students during their internships. You have all contributed to the research in this thesis, 
thank you. I enjoyed supervising you very much, it gave me much pleasure in the day-to-
day lab-life. Thanks to (in order of appearance): Hedy van Wijngaarden, Anne-Bart Seinen, 
Femke Feringa, Karina Wakker, Reinier Bron, Klaas van der Laan, Violeta Stojanovska 
and Marta Vilà González. I hope I have contributed, in some extent, to your professional 
development, and I wish you all good luck in your (scientific) carreers!
Graag zou ik ook het secretariaat en het ERIBA-management willen bedankt voor hun 
support. Allereerst Annet, toen we nog op de vijfde verdieping zaten stond je altijd klaar 
om te helpen met financiële en organisatorische zaken. Bedankt! Ik ben blij dat je bent mee 
verhuisd naar het ERIBA. Sylvia en Maria zijn in het ERIBA het team komen versterken, en 
ik heb ook al mogen kennis maken met hun vriendelijkheid en behulpzaamheid. Bedankt! 
Ook zou ik graag de receptionisten van het ERIBA, joke en Kim willen bedanken. Het is altijd 
prettig om een vriendelijk gezicht te zien en een kort praatje te maken als je het gebouw 
binnenloopt om aan je werkdag te beginnen. Ook wil ik graag het management bedanken. 
Op de vijfde verdieping was dat Gerrie Hoogenberg en in het ERIBA Henk Heidekamp en 
Helena Rico.
Our lab also collaborates intensively with other labs, for example with the Experimental 
Hematology Department headed by prof. E. Vellenga and prof. j.j. Schuringa. I enjoyed 
the early Monday-morning meetings, and learned a lot from the more clinical-oriented 













to thank some members of this department personally. jan-jacob en Edo, bedankt voor 
jullie kritische blikken en vragen, deze waren heel verhelderend. Bart-jan, ook bedankt voor 
je kritische vragen en hulp bij sommige moleculair biologische vragen in mijn beginjaren. 
Vincent, je hebt nog een tijdje bij de SCB gewerkt. Ik herinner me jou vooral in je blauwe trui 
in de koude kamer :). Alweer een aantal jaren geleden ben je verhuisd naar de hematologie. 
Bedankt voor de discussie die we hadden.
I would also like to thank all previous and current members from the departments from 
prof. Kampinga, prof. Sibon and prof. Coppes of the fifth floor. Een paar mensen zou ik graag 
in het bijzonder willen bedanken. Ody, ik ben als student van de celbiologie cursus als eerste 
bij jouw afdeling op de vijfde verdieping terecht gekomen. Ik had toen samen met Nynke 
(nu post-doc bij Rob, het wereldje is klein..) het geluk om door Willy wegwijs gemaakt te 
worden op het lab. Wat een energie! Ik heb veel geleerd, en ook veel gelachen. Willy en Ody, 
bedankt voor deze eerste kennismaking met de wetenschap. Harrie, ik ben vervolgens stage 
gaan lopen bij jou en Michel. Ik heb een ontzettend leuke en leerzame tijd bij jullie op het lab 
gehad. Tijdens mijn stage op de afdeling heb ik veel leuke momenten gehad en uitstapjes met 
o.a. Floris, Maria, Michel, jurre en Erwin, bedankt! Mede door deze positieve ervaring ben 
ik, dan wel bij een andere afdeling, weer op de vijfde terug gekomen als AIO bij Gerald. Het 
contact tussen mij en de mensen in jullie labs is altijd goed en gezellig gebleven. jeannette, 
Bart, Hette en Maria, ik ken jullie nu al zoveel jaren, bedankt voor al jullie behulpzaamheid 
en gezelligheid. Marianne Z, naast een vriendin en een vriendin-van-vrienden, ben jij toch 
ook enkele jaren mijn collega-aan-de-andere-kant-van-de- gang geweest. Bedankt voor de 
gezellige koffie pauzes en kletsmomentjes in de gang. Most members of the department of 
R. Coppes I still see quite often during our Thursday meetings, but we have also shared the 
lab for a few years. Thanks for the collaboration and fun, Rob, Marianne van der Zwaag, 
Miriam, Yamini, Martti and Sarah, and from the radiotherapy ‘division’ Ghazale and Sonja.
In the new ERIBA building, we now share the lab and open office with the members from the 
departments from prof. Lansdorp and dr. Foyer. I would also thank all these lab members 
for the nice atmosphere at work. Sandra H, bedankt voor onze gezellige koffiepauzes die zijn 
begonnen op Schiermonnikoog! Niek en Evert-jan, jullie hebben nog een tijd bij ons op de 
vijfde op het lab gewerkt, bedankt voor de gezelligheid! Nancy, bedankt voor je gezelligheid. 
Petra, ik heb als derdejaars studente nog een paar weken bij jou een practicum gedaan 
(‘jullie studenten kunnen echt nog helemaal niets!”). Leuk om jou weer zoveel te zien!
I also had the opportunity to work as a guest-researcher for a short period of time during 
my PhD in the department of Kristian Helin, in Copenhagen, Denmark. There I learned all 
in’s and out’s (well, as much as you can learn in a few months) about immune-precipitation 
from Xudong Wu, a very experienced post-doc. Xudong, you are a great teacher with a lot of 
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patience! In just a few weeks I did so many experiments, it resulted in about two full figures 
of the NCB paper. This would have never been possible without your help and guidance 
in the lab, but also your scientific view was indispensable. I am really happy we are still 
in contact! Susanne, bedankt voor je gezelligheid en gastvrijheid tijdens mijn bezoek aan 
jullie lab. Je stond altijd klaar om vragen die ik had over de technieken te beantwoorden, of 
je hielp me met zoeken als ik weer eens iets niet kon vinden. Ik heb de etentjes bij jou en 
Ingmar thuis erg gezellig gevonden. Kristian, our short meetings during my stay were very 
valuable to me. I appreciate that you welcomed me in your lab, and I learned a lot.
Ik heb ook veel uren doorgebracht in het cytometrie-centrum. Ik heb altijd veel leuke 
gesprekken gehad tijdens het sorteren met Geert, Henk, Roelof-jan en in het verleden 
ook Harold. Ook ontzettend bedankt voor alle keren dat jullie langer bleven omdat ik 
toch nog een paar minuutjes langer wilde door sorteren. Dat getuigt van betrokkenheid, 
en het wordt erg gewaardeerd! Geert, jouw kennis van FACS is echt onuitputtelijk. Mede 
hierdoor is hoogstaand onderzoek waarbij FACS komt kijken mogelijk. Roelof-Jan, bedankt 
voor die avond dat we, op speciaal verzoek, in de avonduren tot wel middernacht hebben 
gesorteerd, met pizza nootjes en (geen) bier! Henk, ik zal de volgende keer mijn zweepje 
proberen thuis te laten ;) alhoewel het erop lijkt dat je mijn figuurlijke slagen stiekem toch 
wel kan waarderen.
Alhoewel niet allemaal succesvol, heb ik ook nog veel experimenten gedaan in samenwerking 
met de Genetica afdeling. Pieter van der Vlies, Bahram en jelkje, bedankt voor jullie hulp 
en geduld! Ook wil ik graag alle mensen van het CDP bedanken, voor alle goede zorgen voor 
mijn muizen.
En last-but-not-least, zou ik graag mijn familie en vrienden willen bedanken. Allereerst mijn 
lieve vriendinnetjes Seda en Patrizia. Seda, je zit momenteel veeeel te ver weg. Je bent 
ontzettend reislustig waardoor ik je de laatste tijd wel erg veel moet missen. We zijn vaak 
na het werk wat gaan eten, en wezen stappen. Hierdoor kon ik me weer opladen voor het 
werk. Graag had ik de traditie om ieder jaar samen een lang weekend weg te gaan naar een 
leuke stad in ere gehouden, maar dat gaat nu natuurlijk even niet lukken. Je hebt vaak een 
andere kijk op dingen dan de meeste mensen, en daarom ben je ook zo belangrijk voor mij. 
BEDANKT! Patrizia, ik heb niet voor niets jou gevraagd om mijn paranimf te zijn. Samen met 
Richard heb je me altijd in alles ontzettend gesteund. Het wetenschaps-wereldje kennen 
jullie helemaal niet, maar jullie zijn altijd vol belangstelling. Ik vind het altijd erg fijn om na 
een lange dag hard werken bij jullie gezin (met de liefste kleine meisjes!!!) bij de eettafel 
te kunnen aanschuiven. Als ik bij jullie ben, voel ik me thuis, en kan ik alles (ook het werk) 
even vergeten. BEDANKT! Ook wil ik mijn andere goede vriendinnen bedanken voor alle 













Mijn dank gaat ook uit naar mijn schoonfamilie, die altijd vol belangstelling is. Ton en Willy, 
Aris en Inge, Susanne en Ard, bedankt! Ook bedankt voor al het begrip voor de keren dat ik 
het te druk had met mijn werk om op bezoek te komen met Maarten.
Mijn grote dank gaat ook uit naar mijn familie. Mijn lieve grote zus Dina en mijn zwager 
Lammert, en hun schattige kleine meid Lenthe die zoveel vreugde in al onze levens heeft 
gebracht. Bedankt voor jullie steun in mijn keuzes. Onvoorwaardelijke steun heb ik ook 
altijd van mijn ouders gekregen. Lieve pap en mam, door de kansen die jullie mij hebben 
gegeven sta ik nu hier en ben ik wie ik ben. Lieve mam, jij staat altijd voor mij klaar. Je zou 
me alle moeilijke momenten en nare klussen wel uit handen willen nemen, om het mij 
gemakkelijker te maken, maar dat is gewoon onmogelijk. Je hebt me altijd geholpen als ik 
daarom vroeg, en ik ben je daar ontzettend dankbaar voor. 
Lieve pap, ik vind het heel spijtig dat je de grote ceremoniële dag niet mee kan maken. 
Je was altijd vol interesse, en kwam vaak met allerlei (kranten)artikelen aanzetten over 
stamcellen en hematologie. Maar mijn promotietraject duurde lang, te lang voor jou. Mijn 
onderzoek heeft raakvlakken met de ziekte die jij hebt gehad, en daardoor zijn sommige 
aspecten van mijn werk soms erg confronterend, maar toch ook mooi. Ik ben met de neus 
op de feiten gedrukt van het belang van onderzoek over bloed stamcellen en leukemie. Door 
wat we hebben meegemaakt zet ik me nu ook vrijwillig in voor andere patiënten door mijn 
werk voor de MPN Stichting. Bedankt voor alle fijne jaren, en alle steun en hulp die ik van je 
heb gekregen. Ik hoop dat je kleine ‘puk’ je een beetje trots heeft gemaakt.
Lieve Maarten, waar moet ik beginnen om jou te bedanken? Bij de keren dat je de tijd die 
we samen zouden hebben weer moest opofferen omdat mijn experimenten toch weer voor 
moesten gaan? Bij de keren dat je ’s avonds laat (zelfs op kerstavond!) mee bent gegaan 
omdat ik weer een zieke muis had? Bij de wetenschappelijke discussies die we hebben 
gevoerd waardoor er weer nieuwe ideeën voor experimenten ontstonden? Bij de leuke 
vakanties en uitjes die we hebben gemaakt waardoor ik alle rompslomp op het werk kon 
vergeten? Bij de steun en liefde die ik van je heb gekregen? Maarten, ik probeer het samen 
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